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ABSTRACT
The objective of this study was to isolate a cDNA probe corresponding to a constitutive 
diabetes-inducible and insulin-reversible cytochrome P450 (RLM6). This cDNA would then 
be used in conjunction with a polyclonal monospecific antibody to RLM6 to study the 
regulation of this enzyme at the mRNA and protein level. The polyclonal, monospecific 
antibody to RLM6 was used to screen a male rat liver cDNA library in the phage vector Xgtll. 
Six recombinant phage harbouring RLM6 cDNA inserts were isolated from the expression 
library. Three of these were plaque purified and their cDNA inserts examined. The largest 
insert (approximately 1.1Kb, and termed RLM6-1) was subcloned into the plasmid vector pUC 
19 and characterised. Restriction endonuclease mapping and nucleotide sequencing revealed 
that when the RLM6 cDNA was compared to that of the ethanol-inducible P450 HEl, the two 
cDNAs were identical, the RLM6-1 cDNA corresponding to nucleotides 310 to 1402 of the 
P450 HEl sequence.
The RLM6-1 cDNA was subsequently used as a molecular probe to study the 
regulation of this gene in pathophysiological conditions. Northern blot and dot blot 
hybridisation analyses demonstrated that both streptozotocin-induced diabetes and fasting 
significantly elevated the steady state levels of RLM6 mRNA in male rat liver. The increased 
RLM6 mRNA level in the diabetic rat resulted in increased RLM6 apoprotein synthesis when 
the polysomal RNA was used in a cell-free, protein synthesising system, indicating the 
elevated RLM6 level observed in diabetic rats correlated with the increased RLM6 mRNA 
concentration.
Daily insulin treatment of diabetic rats reversed the diabetes-dependent increase in 
RLM6 mRNA in a time-dependent manner, returning to control values after approximately 2 
weeks of continuous insulin treatment. This insulin-dependent reduction of the RLM6 mRNA 
level was paralleled by a similar time-dependent decrease in serum acetone concentration.
Testosterone treatment of the diabetic rat also resulted in a decrease in both RLM6 mRNA and 
in vitro translated apoprotein.
Preliminary studies investigating the effects of endotoxaemia on P450 expression 
would indicate that in obstructive jaundice there is a marked suppression of RLM6 mRNA. 
and P450 specific content. In vitro studies indicated that Kupffer cells may be indirectly 
involved in the suppression of P450s. Finally arachidonic acid was found not to be a substrate 
for RLM6.
Taken collectively, the data presented reveal that the diabetes-inducible cytochrome 
P450 RLM6 is probably the same gene as P450 DEI and appears to be under a complex mode 
of regulation, both by dietary factors and by the hormonal status of the animal.
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Amp Ampicillin
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35S Sulphur 35
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SSC Standard saline citrate buffer
TCA Trichloroacetic acid
TE Tris/EDTA buffer
TEMED N,N,N,N’-tetramethylethylenedi amine
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Tween Polyoxyethylene-sorbitan monolaurate
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Throughout this thesis gene refers to either cDNA or genomic DNA depending
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CHAPTER 1
INTRODUCTION
There is currently a wealth of reviews available on the cytochrome P450 superfamily, which 
covers many aspects of both the biochemical and molecular characteristics of this large family 
of proteins (Ryan and Levin, 1990, Okey, 1990 and Gonzalez, 1990). As the subject matter of 
the present investigation is primarily involved with a single P450 isozyme and its regulation at 
the molecular level, I have concentrated in my introduction on those topics that are directly 
relevant to these studies.
Thus, following a brief summary of the early historical work on cytochrome P450, the 
evolution of the nomenclature and the general reactions that the enzyme catalyses, an attempt 
has been made to review our current knowledge on the effects of pathophysiological conditions 
(particularly diabetes) and their modulation of specific P450 forms. In addition, hormonal 
imbalances that occur during abnormal physiological conditions such as diabetes have been 
considered, as well as the similarities between the diabetes-inducible cytochrome P450 and 
P450j, an ethanol-inducible P450.
1.1 CYTOCHROME P450
The term cytochrome is derived from Greek and literally means “coloured substance in the 
cell”. This colour derives from the properties of the outer electrons of iron in the 
haemoprotein, and “P450” denotes a reddish pigment that when reduced and bound to carbon 
monoxide has the unusual property of giving a major optical absorption peak (soret maximum) 
at 450nm. The first reported evidence, for the presence of this carbon monoxide binding 
pigment came when scientists began to study liver microsomes. This observation was made 
independently by two groups in the same year (Klingenberg, 1958 and Garfinkel, 1958).
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Subsequently, Omura and Sato in 1964 identified the haemoprotein nature of this microsomal 
pigment (classifying it as a b type) and provisionally gave it the name cytochrome P450. The 
role of P450 in the microsomal mixed function monooxygenase system was also established at 
this time (Cooper et al, 1965), and over the next 2.5 decades it has become evident that 
multiple forms of P450 exist throughout the animal and plant kingdom.
1.1.1 N om enclature
Omura and Sato, (1964) had intended that the name “P450” would be provisional, until more 
knowledge about the substance had been elucidated. However as more P450s were discovered 
primarily through protein purification research, it became clear that many P450 forms had 
broad and overlapping substrate specificities which precluded establishing a nomenclature 
system based upon distinct catalytic functions and the terminology based on the spectral 
properties persisted. But in the last 10 years the isolation and sequencing of P450 proteins, 
genes and cDNAs have facilitated the development of a P450 classification system based on 
primary amino acid sequence alignment data (Nebert et al, 1987). The basis of this system is 
outlined in Table 1.1.
AMINO ACID 
RESEMBLANCE
DESIGNATION
<25-40% Different families
40-70% Different subfamilies within a family
70-100% Different members within a subfamily
Table 1.1: The classification of cytochromes P450
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Throughout this thesis where possible I have used the new nomenclature as proposed by 
Nebert and in Figure 1.1,1 have chosen P450 HEl to illustrate how the system (shown in 
Table 1.1) operates for a given P450 isozyme, which is particularly relevant to this work.
1.1.2 Cytochrome P450-catalysed reactions
Cytochromes P450 are the terminal oxidases in a wide variety of biotransformation systems, 
and have two broadly defined roles:
i) PHYSIOLOGICAL ROLE: Where they are involved in the biosynthesis and 
metabolism of endogenous substrates such as cholesterol, bile acids, steroid hormones, 
vitamin D and prostaglandins (Parke, 1980).
ii) DETOXIFICATION ROLE: Which constitutes a protective system against the 
accumulation and deleterious effects of xenobiotic chemicals (Gillette #  al, 1972). However 
this is often a double edge sword by activating xenobiotics producing mutagenic and 
carcinogenic metabolites (Conney, 1982). These two roles are illustrated for mammalian 
P450s in Figure 1.2.
This group of proteins functions by converting hydrophobic substances into more 
hydrophilic derivatives, that can be more readily eliminated from the body. This is brought 
about by the ability of almost all P450s to insert an atom of molecular oxygen into C-H bonds 
as shown in the equation below:
R-H + O2 + NADPH + H+ ->  ROH + NADP+ + H20
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Figure 1.2: The function of mammalian P450s
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1.1.3 The P450 gene superfamily
«
It has been estimated that P450s were present over 1.4 billion years ago (Nelson and Strobel, 
1987). Presently, the gene family consists of over 100 protein sequences, which have been 
characterised in 15 eukaryotic and 4 prokaryotic species. This is shown diagramatically in 
Figure 1.3. However this research field is moving very quickly with new genes and families 
of genes seemingly being identified on a monthly basis. Just recently the first plant P450 
cDNA has been isolated from avocado (Bozak et al, 1990). These workers found it to share 
<40% predicted amino acid sequence similarity when compared to other known P450s and 
they suggested that it should go into a separate gene family (cyp P450 71).
As well as the widespread distribution throughout the animal and plant kingdom, one 
also finds within the mammalian population a marked tissue distribution. For example, the 
highest drug metabolising activity is normally associated with the liver but it is also found in 
many extrahepatic tissues, including the small intestine, colon, kidney and lung (DeWaziers et 
al, 1990) and more recently in the olfactory neuroepithelium (Nef et al, 1990).
A number of P450 isozymes are present at significant levels in untreated animals and 
these are commonly known as constitutive forms. It has also been established that certain 
chemicals can selectively induce individual isozymes, for example P450IA1 and P450 HB l are 
elevated in the rat following treatment with 3-methylcholanthrene and phénobarbital 
respectively (Botelho et al, 1979). In addition both hormonal stimuli and pathophysiological 
conditions alter P450 levels and it is these which I will concentrate on in the next section of this 
introduction.
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Figure 1.3: The Cytochrome P450 gene superfamily
(taken from Gonzalez and Nebert, 1990)
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1.2 MODULATION OF DRUG METABOLISM BY DIABETES MELLITUS
Diabetes Mellitus is one of the most characterised and studied diseases known to man. It kills 
thousands yearly and the symptoms include hypoglycaemia, hypolipidaemia, ketosis, vascular 
lesions and renal failure. The cause of clinical diabetes is always insulin deficiency, which 
maybe relative rather than absolute. Thus diabetes occurs when the pancreatic islets are 
damaged so that the amount of insulin that is secreted is reduced, or when the effect of insulin 
on tissues is reduced and the compensatory increase in insulin secretion is inadequate. There 
are two common types of spontaneous diabetes in humans:
Maturity onset diabetes: This usually develops after the age of 40 and is associated with normal 
(3 cell morphology and insulin content. Most patients are obese and have a reduced number of 
insulin receptors on their adipose tissue cells. This disease state is also referred to as non- 
insulin-dependent diabetes mellitus (type II diabetes).
Juvenile onset diabetes: This disease usually develops before the age of 40, is not associated 
with obesity and is often complicated by ketosis and acidosis. Plasma insulin levels are low or 
undetectable and there are often pathological changes in the p cells. This disease state is also 
refered to as insulin-dependent diabetes mellitus (type I diabetes).
To study the disease, animal models have been used, and these include the spontaneous 
diabetic rat (type II diabetes) and animals which have been treated with selective pancreatic p 
cell toxins such as alloxan and streptozotocin (type I diabetes) (see figure 1.4).
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Figure 1.4: Chemical inducers of diabetes mellitus
1.2.1 Early history and background information
In 1961, Dixon et al first reported a change in drug metabolising activity from an alloxan- 
treated male rat. In this short term diabetic study where the effects on metabolism were 
monitored 1-3 days after the initial alloxan treatment, it was found that the in vitro metabolism 
of hexobarbital, chloropromazine and codeine was suppressed, and the hexobarbital sleeping 
times were prolonged. In addition all of the changes noted above could be reversed to control 
levels (within 24hr) after insulin treatment of the diabetic animals. Two years later, these same 
workers (Dixon et al, 1963) using the same diabetic model, found an increased in vitro 
hydroxylation of aniline but a decrease in aminopyrine metabolism. Once again insulin 
treatment could reverse the effects on aniline metabolism but it had no effect on aminopyrine 
metabolism. They postulated at the time that these observations may be alterations in the 
physical characteristics of the enzymes involved, which had been brought on by the diabetic
state.
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Over the years, these seminal observations have been verified by a number of other 
research groups (Kato and Gillette, 1965 and Weiner et al, 1972). In 1978 Reinke et al also 
confirmed these early findings but in addition demonstrated in female streptozotocin diabetic 
rats an increase in hepatic aminopyrine N-demethylase, aniline hydroxylase and biphenyl 4- 
hydroxylase activity . This result contrasted to the diabetic male where one only observed an 
increase in biphenyl 4-hydroxylase and aniline hydroxylase activity but a decrease in 
aminopyrine N-demethylase activity. One of the recurring features of all these studies was 
that aniline hydroxylase activity and cytochrome P450 content were increased in both sexes of 
diabetic rats and that both effects could be reversed upon insulin treatment.
It was thought at this time, that the modulation of metabolism of these compounds 
(particularly aniline) in diabetes was mediated by separate cytochrome P450 isozymes. This 
hypothesis was proven correct by two reports in the early 1980s (Past and Cook, 1980, 1982). 
In the earlier report, work using the technique of SDS-PAGE suggested that the overall 
increase in the hepatic microsomal P450 content seen in diabetic animals was not due to a 
uniform increase in the haemoprotein population, but due to increases and decreases in specific 
electrophoretically separable haemoproteins. In the second report evidence was presented 
demonstrating that alloxan-induced diabetes in the male rat resulted in an increase of a unique 
hepatic microsomal P450 seen as a 52,000 Mr protein band on SDS-PAGE. They also 
showed that the distinct 52,000 Mr P450 interacted with type II compounds yielding a 2 fold 
greater absorbance change than was seen in control rats. Based on this evidence they went so 
far as to say that the 52,000 Mr P450 was the catalytic component that contributed to the 
selective increase in the metabolism of aniline observed in diabetic rats.
In the studies mentioned so far the p-cell toxins alloxan and streptozotocin had been the
accepted model of diabetes, but there was an underlying fear that it might be the chemical 
nature of the diabetic agents themselves rather than the pathophysiological condition of diabetes 
that altered drug metabolism. These fears were laid to rest when Warren et al, (1983) showed
that essentially there were no marked differences in drug metabolism between the chemically 
induced and the genetic (BB-spontaneous diabetic rats) models of diabetes.
Up to this time the assessment of hepatic drug metabolism in diabetic humans had been 
very limited. However it had been noticed in one study (Salmela et al, 1980) that hepatic P450 
levels were increased significantly in human diabetics with normal livers. In 1982 altered 
chemical metabolic activity was observed in humans (Owen et al, 1982). These workers 
investigated acetone metabolism in nine diabetic patients who had moderate to severe 
ketoacidosis. They found that plasma acetone levels were high and exceeded plasma 
acetoacetate and p-hydroxybutyrate concentrations, concluding that at high concentrations in 
body fluids, acetone either inhibited its own in vivo metabolism or that there were different 
patient populations with regard to acetone metabolism.
1.2.2 Purification and characterisation of the diabetes-inducible cytochrome 
P450
In 1987 the diabetes-inducible and insulin reversible form of cytochrome P450, was purified 
from diabetic male rat liver for the first time (Favreau et al, 1987). This protein, designated 
RLM6 was found to metabolise aniline and acetol in reconstituted systems containing 
NADPH-cytochrome P450 reductase and lipid and was thought to be similar, if not the same as 
the protein observed by Past and Cook, (1982). It was predominantly isolated as a high spin 
cytochrome and had a minimum molecular weight of 53,500. When the NH% terminal 
sequence of RLM6 was compared to other known constitutive and inducible forms of P450 
(Favreau et al, 1987) it was found to be identical at least in the first 20 amino acids to that of 
P450j, a form previously shown to be induced by the anti-tuberculosis drug isoniazid (Ryan et 
al, 1985). In addition, using a monospecific antibody raised to RLM6 they showed on SDS- 
PAGE that a cross-reacting protein of identical molecular weight was also induced by ethanol, 
acetone, fasting and by isoniazid. It was suggested by these workers (Favreau et al, 1987) that
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the structurally diverse compounds inducing RLM6 may act by mimicking endogenous 
compounds such as acetone (ketone bodies) whose concentration rises in the 
pathophysiological conditions of diabetes and starvation. A further suggestion from these 
results is that RLM6 and P450j may be the same isoenzyme of P450.
Funae et al, (1988) also purified a diabetes-inducible cytochrome P450, which they 
found to have essentially the same characteristics as the enzyme described by Favreau et al, 
(1987). The induction of RLM6 has also been observed in spontaneous diabetic rats (BB/Wor 
rat model) demonstrating that the alterations in RLM6 hepatic content was not due to the 
streptozotocin per se (Favreau and Schenkman, 1988a).
Monospecific polyclonal antibodies have been used as a very powerful tool to 
characterise individual P450 isozymes. It has been demonstrated, using antibodies to other 
specific P450 isozymes that in addition to the elevation of RLM6 there is a concomitant 
decrease in 3 male specific constitutive forms (P450 IIA2, IIC11 and IIC13) (Favreau and 
Schenkman, 1988b). This supports the earlier conclusions that Past and Cook, (1980) had 
reached (see section 1.2.1).
1.3 CYTOCHROME P450 IIE l
In section 1.2.2 several lines of evidence indicated that the diabetes-inducible cytochrome P450 
(RLM6) may be closely related to the ethanol-inducible P450. Therefore in this section I will 
review the current knowledge on this protein which has received considerable interest in the 
last 3 years.
The discovery of P450 induction by ethanol derives from the question of whether 
ethanol stimulates its own metabolism (Lieber and DeCarli, 1968). However it took a long 
time before an individual P450 isozyme could be assigned to this induction specifically (Koop 
et al, 1982). This new P450 (termed LM3a) was purified to homogeneity from hepatic 
microsomes of rabbits, which had been treated with ethanol. Since then, immunoblotting
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techniques have been used to identify immunorelated P450s to cytochrome P450 HE1 in 
different tissues and species. In 1985, Ryan et al provided the first evidence that isoniazid and 
ethanol induce the same cytochrome P450 (P450j) in rat which was orthologous to the rabbit 
form LM3a . Cytochrome P450 HLj the human orthologue of P450j/LM3a was successfully 
purified from the hepatic microsomes of an individual intoxicated with ethanol (Wrighton et al,
1986). Two other groups have confirmed these latter studies in man (Lasker et al, 1987 and 
Ekstrom et al, 1989). There is no known selective inhibitor of P450 BEI to date, but antibody 
inhibition studies have revealed that as well as structurally, the function of the human enzyme 
(HLj) has been conserved through evolution. These studies (Wrighton et al, 1986) 
demonstrated that anti-P450j inhibited human liver microsomal NDMA metabolism a known 
substrate for rat P450j (Yang et al, 1985).
Apart from these three different mammalian species P450 DEI has been characterised in 
the hamster (Ardies et al, 1987 and McCoy and Koop, 1988), the alcohol dehydrogenase 
deficient deermouse (Handler gf al, 1988) and in primary cultures of chicken embryo 
hepatocytes (Sinclair et al, 1989). This enzyme is predominantly a liver specific enzyme in all 
of the species that have been studied to date. Immunohistochemical analysis has revealed a 
30% higher concentration of DEI in the centrilobular region than the periportal region of rat 
liver (Ingelman-Sundberg et al, 1988). By contrast, Watkins et al, (1990) have shown in the 
human liver that there was no significant change in the amounts of IIEl in the individual liver 
lobes.
P450 DEI has also been found in extrahepatic tissues, and Ding et al, (1986) have 
reported that the orthologous rabbit form was detectable on immunoblots of kidney and nasal 
mucosa microsomes but not microsomes from brain, lung, adrenal, heart, intestine, ovary, 
spleen, testis or uterus from untreated or ethanol treated rabbits. Recently LM3a has also been 
identified in rabbit bone marrow (Schnier et al, 1989). The rat P450 IIEl has also been 
measured in the kidney but only barely detectable in lung, ovaries and testis (Thomas et al,
1987).
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As well as ethanol, several other volatile (and some non-volatile) chemicals have been 
shown to be both substrates and/or inducers of P450 IIEL These are summarised in figures
1.5 and 1.6 respectively and it is clear that there is no structural commonality between these 
chemicals.
However it is interesting to note from figures 1.5 and 1.6 that a number of small 
organic molecules are involved in the induction of this isozyme and that P450 IIEl plays a role 
in carcinogen metabolism. In respect to the latter it has been recently shown that P450j is 
highly effective at demethylating N-nitrosodimethylamine generating an ultimate carcinogen 
(Wrighton et al, 1986) and that ethanol or acetone treated animals potentiate the hepatotoxic 
effects of CCL4 (Reinke et al, 1988) and acetaminophen (Raucy et al, 1989).
Generally P450 induction is commonly thought of as being a response to exogenous 
chemicals but P450 DEI is an example of a system that can also respond to altered endogenous 
physiological states. For example, in the rat, fasting induces N-nitrosodimethylamine 
demethylase activity (Miller and Yang, 1984), a catalytic activity associated with cytochrome 
P450 IIEl and Banhegyi et al, (1988) have demonstrated that 4-nitrocatechol and p- 
aminophenol, which are the hydroxylated products of p-nitrophenol and aniline respectively 
accumulate in isolated mouse hepatocytes after starvation, both of which are good substrates of 
P450 IIEl (Figure 1.5). In 1987, Hong et al proved conclusively using immunoblots that 
P450j was the specific isozyme induced by starvation.
In the previous section (1.1.1) I have indicated how, over the last 30 years the diabetic 
state has been associated with an increase in the metabolism of aniline and it is clear from a 
number of reports that this activity has been attributed to P450 IIEl, in the diabetic animal. 
For example, Bellward et al, (1988) have indicated that there is both a increase in P450 DEI 
protein content (immunoblots) and an increase in aniline hydroxylation, in the livers of 
spontaneous diabetic rats.
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Obesity ranks as one of the most prevalent diseases in the western world carrying with it 
substantial increases in morbidity and mortality. While many of the negative aspects of 
obesity remain unexplained it is firmly established that the oxidative clearance of many drugs is 
increased in obese humans (Abemethy and Greenblatt, 1986). More recently, studies using 
obese rats have shown that they are more susceptible to liver damage by metabolically activated 
drugs, such as acetaminophen and anaesthetics (Salazar et al, 1988). From Figure 1.5 it can 
again be seen that these two compounds are substrates for P450 DEI and indeed these workers 
suggested that this would be the isozyme most likely to be induced in obese rats. However 
further work was required to substantiate this claim.
1.3.1 Mechanism of induction of cytochrome P450 IIEl
Molecular biology techniques have proved extremely useful in advancing our
understanding of how a number of the P450 isozymes are regulated both during development 
and in adulthood and have proved a valuable adjunct to the biochemical and immunological 
approach that I have discussed so far in the previous sections.
In the last few years orthologous cDNAs for P450 IIEl have been isolated and 
sequenced from the rat (Song et al, 1986), human (Song et al, 1986) and rabbit (Khani et al,
1987). The rat and human genes share approximately 80% sequence similarity at the 
nucleotide and amino acid levels. Figure 1.7 summarises an overview of P450 HEl regulation 
at the transcriptional and post-transcriptional levels. It can be seen from this figure that P450 
IIEl is under a complex mode of regulation. Song et al, (1986) have demonstrated
that P450 HEl mRNA and protein levels were not present in newborn rats, however within 
one week after birth, in both male and female rats there was a rapid increase in P450 HEl 
mRNA and protein.
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Figure 1.7. Scheme depicting the modes of regulation of P450 IIE l by various 
physiological and chemical signals. M= specific cytidine residues at the genes 5' end that 
are demethylated after birth. It is unknown whether starvation or the diabetic state also stabilises 
the P450 DEI protein (indicated by ?). (This diagram has been modified from Gonzalez, 1989).
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These levels remained elevated up to 12 weeks of age and nuclear run on transcriptional 
analysis confirmed that this was due to transcriptional activation of the gene. This mode of 
developmental regulation for P450 IIEl has since been correlated with specific 5' cytosine 
déméthylation (Umeno et al, 1988), a phenomenon that is associated with the developmental 
gene activation in other systems. For example, a 5* Hha I site in the rat aldolase B gene is 
hypermethylated in foetal liver and becomes demethylated in adult liver, coincident with 
expression of the gene (Daimon et al, 1986). However it was not clear to these workers 
whether the déméthylation itself caused the increase in gene activity or was simply the result of 
an activation of transcription by other factors (further work was required to elucidate this 
fully).
In contrast to transcriptional activation observed during the development of the 
immature rat, in the adult rat it was shown (Song et al, 1986) that small organic molecules such 
as acetone and ethanol only induced P450 IIEl protein levels, with no increase in mRNA 
content. In addition, Khani et al, (1987) studying the orthologous rabbit form also did not 
detect an increase in mRNA adequate to account for the induction of LM3a by imidazole. 
These results indicated that IIEl was post-transcriptionally regulated either at the level of 
translation or by stabilisation of the protein against degradation. Song et al, (1989) using 
amino acid pulse labelling in vivo, ruled out a translational increase and instead suggested that 
acetone and pyrazole stabilised the protein. But in a recent study by Kim and Novak, (1990) 
this earlier data has been challenged. The latter authors have postulated, that in the initial 
exposure to pyridine to rats, induction may proceed through enhanced translational efficiency. 
The evidence for protein stabilisation on the other hand is not in doubt. Eliasson et al, (1988) 
have suggested from work carried out in primary rat hepatocyte cell cultures, that the small 
organic molecules like ethanol which are known to induce P450 HEl act as ligands preventing 
it from degradation. These latter workers showed:
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i) A correlation between the binding affinity of the compounds to their ability to prevent 
P450 IIEl loss from culture.
ii) That P450 IIEl mRNA decreased at similar rates from both treated and untreated 
hepatocytes.
These results have been supported by Song et al, (1989) who demonstrated in the 
untreated animal that HEl protein was degraded biphasically, consisting of a rapid (1/2 life of 
7hr) and a slow (1/2 life of 37hr) component. In contrast, in rats treated with acetone, only the 
37hr component of the degradation curve was observed. In addition, there was no change in 
the turnover of total microsomal protein, indicating a specific effect on P450 IIEl. Very 
recently Eliassons group has gone one step further (Eliasson et al, 1990) and has postulated a 
mechanism for the post translational ligand dependent stabilisation of P450 DEI (Figure 1.8).
Using rat hepatocyte cultures Eliasson et al, (1990) demonstrated that glucagon or 8- 
bromoadenosine 3,,5'-cyclic monophosphate could cause an enhanced rate of P450 HEl 
degradation as well as phosphorylation of ser-129. But when substrates for the enzyme were 
present they protected the enzyme from both phosphorylation and degradation.
However to complicate matters further, Song et al, (1987) have shown that in 
spontaneously diabetic rats, or in rats made diabetic through chemical treatment, there is up to a 
10 fold increase in P450 IIEl mRNA levels with a concomitant increase in IIEl protein. 
Nuclear run on transcription assays proved that the increase in mRNA was not due to 
transcriptional activation, and they postulated that the mRNA was specifically stabilised, or the 
efficiency of pre-mRNA was markedly enhanced. In another perturbed physiological state, 
starvation, Hong et al, (1987) have also observed an increase in both P450 IIEl mRNA and 
protein. Therefore it would appear, as indicated earlier, that different modes of regulation exist 
depending on the inducing regime.
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However this may not be the case in other species. In the hamster, induction of the 
orthologous protein by ethanol or pyrazole was accompanied by an increase in specific 
translatable P450 IIEl mRNA (Kubota et al, 1988). These authors demonstrated (using in 
vitro translation and subsequent immunoprécipitation of translation products with antibody to 
P450 HEl) that ethanol and pyrazole increased hepatic P450 IIEl mRNA levels by 160% and 
45% respectively, when compared to controls. Although this contrasts with the observations 
of Song et al, (1986) one must bear in mind that different experimental procedures were used 
to measure mRNA levels.
1.4 A POSSIBLE IN  VIVO  ROLE FOR THE DIABETES AND ETHANOL- 
INDUCIBLE P450s
The biological functions of the majority of P450 constitutive isozymes, have yet to be fully 
elucidated. RLM6/P450 IIEl is no exception to this, and as I have alluded to earlier, is a 
constitutive P450 isozyme as well as one that can be induced. The fact that it is present at basal 
levels in the uninduced animal suggests that it may have a critical function for life and 
presumably a role to play in intermediary metabolism.
The ability of the enzyme to metabolise acetone and acetol (see section 1.3) has 
suggested an adaptive role for this enzyme in the pathophysiological conditions of diabetes and 
fasting. It has been well documented that in both of these disease states lipid metabolism is 
altered, with an increase in ketone body formation (Peng et al, 1983). In recent years there has 
been a lot of attention on the fate of ketone bodies and in particular acetone, in mammals. 
Argiles, (1986) suggested that mammals do not just eliminate acetone as a metabolic end 
product but may, under special conditions such as diabetes and fasting, re-use it, via the 
metabolic machinery, promoting gluconeogenesis and thus prolonging the survival of the 
animal (see Figure 1.9).
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Other work has indicated that rats fed acetone in their drinking water have higher than normal 
concentrations of 1,2-propanediol and 2,3-butanediol in blood serum (Casazza et al, 1984). 
More recently 1,3-butanediol has been shown to elevate blood concentrations of ketone bodies 
as well as inducing P450 HEl (Li et al, 1989).
However for acetone to be gluconeogenic one needs to demonstrate that there is a net 
conversion of acetone to glucose. Landau and Brunengraber, (1987) have addressed this 
question and they conflict with Argiles's earlier observations. In these studies they infused [2- 
14C] acetone into rats and followed its metabolism. Their conclusions were that at low acetone 
concentrations, such as those encountered under physiological conditions, most acetone is 
metabolised via the gluconeogenic pathway. But at higher concentrations, such as those 
encountered in diabetes and fasting the majority of metabolism occurs via acetate (see Figure 
1.9) without a net glucose production.
1.5 HORMONAL REGULATION OF CYTOCHROME P450
In recent years, studies on the expression and regulation of cytochrome P450 have indicated that 
change in hormonal levels is a major factor contributing to the altered expression of constitutive 
cytochrome P450s in rat liver (Yamazoe et al, 1989, Waxman et al, 1988 and Morgan et al,
1985).
1.5.1 Developmental regulation of P450s by growth hormone and testosterone
Yamazoe et al, 1989 have divided the P450s into two groups, neonatal and pubertal depending 
on the age of appearance in rat liver, j
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i) Neonatal: These include P450 IIB1, IIB2 and IIEl which appear in rat liver 
approximately 10 days after birth and at puberty their levels are suppressed.
ii) Pubertal: These include P450 IIC7, IIC13, IIC11 and IIC12 which are only 
expressed at approximately 20 days of age.
The latter of these two categories are P450 isozymes that are sexually differentiated and in the 
last 5 years it has become clear that gonadal and pituitary hormones play a very important role 
in their expression and regulation. In particular, growth hormone has been shown to act as 
both a stimulative and suppressive factor in regulating the pubertal cytochrome P450s (Morgan 
et al, 1985 and MacGeoch et al, 1985). Adult rats are sexually differentiated with respect to the 
temporal pattern of pituitary growth hormone . Male rats exhibit an episodic or pulsatile 
growth hormone secretion at 3-4hr intervals with low or undetectable levels between peaks, 
whereas female rats have a more continuous secretion pattern (Jansson et al, 1985) (see Figure 
1. 10).
In turn these secretory patterns are regulated by hypothalamic secretion of the positive 
effector, growth hormone releasing factor (GRF) and the negative regulator somatostatin. The 
hypothalamic regulation is determined by neonatally secreted testicular androgen, which 
appears to imprint the high amplitude growth hormone pulses characteristic of the adult male rat 
(Jansson et al, 1985).
1.5.2 Modulation of growth hormone and testosterone secretion by diabetes, 
fasting and xenobiotics
Growth hormone: In 1979, Tannenbaum et al, showed conclusively for the first time, that 
prolonged food deprivation had a marked effect on the ultradian growth hormone rhythm 
observed in the adult male rat (Figure 1.10). A 24hr starvation period resulted in a significant 
depression in the amplitude of growth hormone pulses, which declined progressively over 
48hr and 72hr, with normal periodicity not evident. In a second series of experiments, they
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Figure 1.10. Schematic presentation of the growth hormone secretory pattern of 
male and female rats
A: adult female rat. B: adult male rat. (Diagram modified from Jansson et al, 1985).
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measured somatostatin-like immunoreactivity and concluded that there was not in fact a 
decrease in growth hormone synthesis but a decrease in its release from the pituitary gland. 
This they attributed to higher circulatory levels of somatostatin. Two years later Tannenbaum, 
(1981) gave the first indication that streptozotocin-induced diabetes, also significantly 
suppressed the amplitude of growth hormone pulses. The effect was noted as early as 18hr 
post-treatment and continued over a 4 week period. Again as was seen in the fasted animal, 
they attributed the observation to higher circulatory levels of somatostatin.
Olchovsky et al, (1990) have confirmed these earlier findings proving that in the 
diabetic animal there were higher levels of somatostatin and in addition they established that the 
levels of circulatory growth hormone releasing factor were reduced by 80%.
The effects of xenobiotics, such as ethanol on growth hormone rhythms is poorly 
understood. But a recent report by Fielder et al, (1989) suggests that ethanol consumption 
during pregnancy, in female mice, has no effect on maternal or foetal serum growth hormone 
concentrations. Yet in a different study, chronic ethanol administration to immature female rats 
seemed to reduce significantly serum growth hormone levels (Dees et al, 1990).
Testosterone: Complicating matters further is that growth hormone is by no means the only 
hormonal change that accompanies the pathophysiological conditions of diabetes and fasting.
In 1981, Murray et al, investigated the pituitary-testicular axis in diabetic male rats, 
demonstrating a reduction in plasma testosterone levels. They thought that this may be due to 
Ley dig cell insensitivity, to the anterior pituitary hormone, lutenising hormone (LH). In 
addition, Schenkman et al, (1989) used a radioimmunoassay to detect plasma testosterone 
levels and found that testosterone levels declined from a normal level of approximately 
3.8ng/ml to 1.0ng/ml, 4 weeks after the initial streptozotocin treatment.
Ethanol is also known to decrease blood testosterone levels (Gordon et al, 1976). This is 
due in part to enhanced testosterone degradation and conversion to oestrogens, as well as to 
decreased testicular synthesis of steroids. Recently studies performed in the neonatal rat (Kelce
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et al, 1990) have established that acute ethanol exposure reduced plasma testosterone levels to 
30% of control values, yet in the mature animal, testosterone levels were not significantly 
lowered.
However a number of reports have recently emerged indicating that testosterone 
certainly has an indirect role, if not a direct one, to play in the modulation of cytochrome P450 
isozymes. Ohi et al, (1989) looked at the effects of administering Buserelin (a synthetic 
agonist of lutenising hormone-releasing hormone) to male Sprague-Dawley rats. As a result of 
this treatment, as one would expect, testosterone levels decrease but reduced aminopyrine N- 
demethylase, 7-propoxycoumarin O-depropylase and testosterone 2 a -  and 16|3-hydroxylase 
activities were additionally observed. Aromatase activity in cultured human genital skin 
fibroblasts (Berkowitz et al, 1990) has also been lowered upon testosterone treatment. When 
these latter workers incubated 50nM testosterone with the cultured skin fibroblasts, a dose- 
dependent and time-dependent decline in aromatase activity as compared to controls cultured in 
the absence of testosterone was observed. The human patients used in this study were 
androgen insensitive, therefore the effects observed were not mediated by androgen receptors. 
In addition, experiments with cycloheximide proved negative and thus new protein synthesis 
was also not required. But when the cells were incubated at low oxygen tension, the inhibition 
of aromatase activity by testosterone was diminished. They proposed that by incubating cells 
in the presence of testosterone it might permit the destruction of aromatase by oxygen derived 
free radicals formed during aromatisation. Another study, this time in Hen granulosa cells 
established that testosterone decreased the activity of P450 cholesterol side-chain cleavage and 
3 (3-hydroxysteroid dehydrogenase (Lee and Bahr, 1990).
In the mouse kidney, testosterone treatment (2-4mg/kg) has been demonstrated to both 
induce and repress P450 gene expression, independently of growth hormone (Henderson et al, 
1990). In the streptozotocin diabetic male rat, testosterone replacement therapy over a 2 week 
period slightly but significantly affected the suppression of P450 IIC11 and reversed the
changes in P450 IIA2, IIIA2 and IIC12, without altering the suppressed state of growth 
hormone secretion (see section 1.5.1) (Thummel and Schenkman, 1990).
1.5.3 Regulation of cytochrome P450 IIEl by hormones
Hypophysectomy is a surgical procedure which can remove the pituitary gland either totally or 
partially and has been a widely used tool to study the effects of pituitary hormones on the 
cytochrome P450 family. The first indication that growth hormone (an anterior pituitary 
hormone) influenced P450 IIEl regulation came from a study performed on 
hypophysectomised male and female Sprague-Dawley rats (Williams and Simonet, 1988). 
They demonstrated after surgical treatment, a 5 and 10 fold increase in P450 HEl protein levels 
from males and females respectively. However a corresponding elevation in associated 
enzymic activity (metabolism of N-nitrosodimethylamine) was not observed. Treatment of the 
hypophysectomised animals with a subcutaneous injection of growth hormone, twice daily for 
6 days (this mimics the adult male pulsatile growth hormone secretory pattern) significantly 
decreased P450 IIEl levels in both males and females. Interestingly the decrease was more 
pronounced in the females.
NADPH-cytochrome P450 reductase levels were also monitored in this latter study, 
and were found to be suppressed by 65% and 55% in male and females respectively, from 
growth hormone treated hypophysectomised animals. This suggested to these authors that this 
may be the reason for the low enzyme activity level that was seen. With respect to this latter 
finding, Waxman et al, (1989) again using hypophysectomised rats found a similar 
discrepancy between protein and enzyme activity levels with P450-dependent, microsomal 
steroid hydroxylase activities. They also demonstrated a 50-60% reduction in reductase 
activity but found this could be reversed upon thyroxine treatment (thyroxine is one of a 
number of hormones that are decreased in hypophysectomised animals). As well as elevating 
the reductase levels this in turn brought the microsomal steroid hydroxylase levels associated
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with the individual P450 forms to levels commensurate with their respective P450 protein 
levels.
In a study comparing hypophysectomised rats to diabetic rats (Yamazoe et al, 1989) 
similar results were obtained for P450 IIEl, to those reported by Williams and Simonet, 
(1988). They again showed that the increase in P450 IIEl seen in hypophysectomised rats 
from both sexes could be lowered when animals were supplemented with growth hormone, 
either by intermittent injection or more successfully by continuous infusion. No effect was 
observed when prolactin was given. In addition, these workers have demonstrated that P450 
IIEl mRNA is changed by hypophysectomy and/or growth hormone treatment, in parallel with 
the changes in P450 DEI protein levels. This suggested to them that the suppressive effects of 
growth hormone on P450 DEI were through a somatogenic-receptor mediated process.
In diabetic rats, P450 IIEl mRNA was also increased, to approximately the same level 
as seen in hypophysectomised animals, but the protein content was 2-3 fold higher (Yamazoe 
et al, 1989). This suggested to these authors that there was probably another stimulatory 
factor acting translationally or post-transladonally in the livers of diabetic rats, in addition to the 
reduction in serum growth hormone.
There are however many ambiguities with the animal models mentioned so far, 
primarily because of the numerous endocrine ablations that are seen in both 
hypophysectomised and diabetic rats (see Table 1.2). The use of hepatocytes circumvents 
many of these problems. In a recent report, Schuetz et al, (1990) have demonstrated, using 
adult rat hepatocytes cultured on a reconstituted basement membrane, that growth hormone acts 
specifically and selectively to suppress P450 HBl and IIB2 at the level of gene transcription, 
and no effect was observed on the rate of P450 IIEl transcription.
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HYPOPHYSECTOMISED DIABETES
4  Insulin 4  Insulin
4  Glucagon 4  Growth hormone
4  Lutenising hormone 4 Testosterone
4  Thyroxine 4  Follicle stimulating hormone
4  Growth hormone t  Glucagon
Table 1.2. A lterations in the plasma concentrations of key horm ones in 
hypophysectomised and diabetic rats: 4 = decrease in plasma concentration t = 
increase in plasma concentration.
In section 1.3.1 and 1.5, I have already considered some of the molecular biological 
approaches to the developmental regulation of P450 IIEl and its role as a neonatal P450, 
where it has been observed that during the post-suckling period, P450 IIEl declines in both 
sexes, but to a slightly lower level in males. Waxman et al, (1989) have investigated the 
regulatory events controlling these developmental changes, and have discovered, using western 
blots, that P450 HEl levels in hormonally altered rats are under gonadal control, with both 
testosterone and oestrogen suppressing P450 IIEl levels. However they suggested that the 
developmental expression of HEl was primarily under the suppressive control of growth 
hormone and that the effects of androgen and oestrogen were largely mediated by their effects 
on growth hormone secretion, (although they did not rule out the possibility of testosterone 
having a direct effect).
Thummel and Schenkman, (1990) have recently shown that the induction of P450 IIEl 
in adult diabetic female rats does not coincide with a reduction in growth hormone secretion
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and these workers suggested that induction of P450 HEl in male and female diabetic rats was 
not related to changes in growth hormone.
1.6 MODULATION OF CYTOCHROME P450 LEVELS BY ENDOTOXIN
For many years it has been known that bacterial endotoxins cause disruption of carbohydrate
metabolism in animals, particularly hypoglycaemia, depletion of glycogen and inhibition of 
gluconeogenesis. In order to further examine the endogenous regulation of cytochrome P450
IIEl and its role in metabolism, the effects of endotoxin on P450 HEl were examined in the 
rat.
1.6.1 Metabolic effects of Salmonella endotoxin
Endotoxins are soluble lipopolysaccharide (EPS) components of the outer portion of the cell 
wall of Gram-negative bacteria, that are released into body fluids, during infection by these 
organisms. Although LPS is synthesized in the cytoplasmic membrane, it is located in the 
outermost layer of the cell surface, with which the bacterial cell interacts with its environment 
(Nikaido and Nakae, 1979). A schematic structure of a Salmonella lipopolysaccharide is given 
in Figure 1.11. After entering the mammalian circulation, LPS elicits a wide variety of distinct 
biological effects such as fever, hypotension, tissue injury, plasma hypoglycaemia and 
immunomodulation (Rietschel et al, 1982). Virtually every organ is affected in the endotoxin 
poisoned animal but the majority of research has been focused on the liver and immunologic 
systems as sites of action of LPS. Here I will concentrate primarily on the liver, as cytotoxic 
lesions occur mainly in this organ and because of the numerous metabolic activities that are 
altered after endotoxin poisoning, such as depletion of carbohydrate reserves, inhibition of 
gluconeogenesis and inhibition of enzyme induction (Bradley, 1979). One of the group of 
enzymes modulated by endotoxin are the microsomal mixed function oxidases.
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In 1972, Rose et al, demonstrated that the duration of barbiturate-induced sleep was 
prolonged within a few hours after a LPS injection. Since this time a number of reports have 
confirmed that the activities of drug metabolising enzymes in rat liver are significantly 
decreased when intraperitoneal doses of endotoxin are given to animals (Renton and 
Manneiing, 1976, Gorodischer et al, 1975 and Yaffe and Sonawane, 1978).
In 1982, Sonawane et al, demonstrated that after a single 1 or 2mg/kg i.p. dose of 
endotoxin, hexobarbital sleeping time was increased in adult male rats. After 6hr, significant 
inhibition of microsomal cytochrome P450 occurred, continuing for up to 24hr after initial 
endotoxin administration. Injection of inactivated endotoxin failed to result in any significant 
decrease in P450. Experiments conducted in vitro also resulted in a decreased hepatic 
microsomal P450 content as well as aminopyrine N-demethylase activity, however this was 
only observed after preincubation of the hepatocytes with an NADPH-generating system 
supplemented with EDTA (Sonawane et al, 1982).
é - o
JL Lipid A [JO-specific chain Core
Polysaccharide Lipid u
Figure 1.11. Schematic diagram of Salmonella lipopolysaccharide
Key: Monosaccharide ^  Ethanolamine ®  Phosphate
*/vvv Long Chain (Hydroxy) Fatty Acid
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In recent years, specific P450 isozymes have been investigated in endotoxin treated animals. 
In the mouse, Stanley et aU (1988) made a detailed study on the modulation of P450s from the 
P4501, IIP, IIC and III families after endotoxin treatment. They established that high doses 
(lOOOpg/kg) caused a 39% decrease in all hepatic cytochrome P450s studied and in particular a 
strong suppression of IIC6 mRNA was observed. Yet smaller doses (80pg/kg) actually 
potentiated the expression of certain P450 forms and their related activities (IIB1, IIB2 and 
IA2). Morgan, (1990) has clearly demonstrated that the administration of purified bacterial 
LPS (30-100pg/kg) to male rats, suppressed constitutively expressed male specific cytochrome 
P450 (P450 IIC11), by approximately 35% of control values, whereas the female specific 
cytochrome P450 decreased by only 17% of control values upon LPS administration. Even 
although a general reduction in total microsomal P450 was seen, Morgan suggested that due to 
the relative percentage (25-50%) of these constitutive isozymes in the uninduced liver, that they 
must be selectively decreased over other P450s. Another interesting point from this study was 
that a substantial decrease in the amount of endotoxin was required to elicit a near-maximum 
i  suppression of P450 as compared to the dose required for the mouse (Stanley et al, 1988).
1.6.2 Role of Kupffer cells in endotoxin modulation of cytochrome P450
Recently it has become evident that the changes observed in endotoxin treated animals are 
probably not due to the endotoxin per se, but mediated by the potent cytokines released from 
macrophages and Kupffer cells, in response to stimulation by LPS. Kupffer cells represent a 
significant cellular component of the liver and together with infiltrating macrophages derived 
from the blood become "activated" during endotoxaemia releasing highly reactive and 
potentially toxic mediators. These mediators include colony stimulating factor, tumour 
necrosis factor and interleukin-1 (Laskin, 1989).
The role of Kupffer cells in the modulation of hepatic cytochrome P450 had 
previously been examined by Peterson and Renton, (1984) who demonstrated that following
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the phagocytosis of particulate matter by Kupffer cells, a factor was released which inhibited 
cytochrome P450-dependent drug transformation, in adjacent cultured hepatocytes. The 
particulate matter used was dextran sulphate, which was important as this did not induce 
interferons which are a known mediator in both cytochrome P450 loss and induction 
(Parkinson et al, 1982, Moochhala and Renton, 1989). Therefore interferon was ruled out in 
this case as a cause of P450 loss. Two years later these same workers (Peterson and Renton,
1986) supported their earlier in vitro study with an in vivo experiment. This time latex particles 
(0.46p.m diameter) were administered to mice and a similar depression in the P450 dependent 
monooxygenase system observed. When the Kupffer cells and hepatocytes were examined 
under the electron microscope it was found that the latex particles had been taken up 
exclusively by the Kupffer cells.
Morgan, (1990) has suggested that interleukins 1 and 6 are probably the most important 
cytokine mediators responsible for the suppression of P450IIC11 and EC 12, but it is not clear 
if the effect is direct or indirect. It has also been established that on administering endotoxin to 
rats, growth hormone secretion is suppressed, at least in the first 6hr (Kasting and Martin, 
1982). This observation also indicates that as in the hypophysectomised or diabetic animal 
models there are a number of changes that occur in the endotoxin treated animal which may 
govern P450 induction or suppression.
1.7 OBJECTIVES OF THE PRESENT INVESTIGATION
Since the majority of drugs are metabolised by hepatic microsomal cytochrome P450 enzyme 
systems, any alterations in the composition of the cytochrome P450 family members will have 
an effect on how drugs are metabolised. The pathophysiological states of diabetes, fasting and 
endotoxaemia are three conditions which alter the amounts of individual P450 isozymes. It is 
therefore of great importance for the formulation of drug therapy to characterise the changes in
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individual P450 isozymes under these different conditions and to assess their effects on drug 
metabolism.
To this end I have employed a molecular approach to study one cytochrome P450 
whose level is altered by these pathophysiological conditions. At the outset, an antibody 
previously raised against the diabetes-inducible protein RLM6 (Favreau et al, 1987), was used 
to screen a rat liver Xgtl 1 cDNA library, in order to isolate cDNA clones encoding the gene for 
RLM6. Several clones were isolated the largest of which I have characterised. I have 
sequenced this cDNA and used it as a probe to examine the expression of the RLM6 gene in 
different tissues and during altered physiological conditions. When my studies began it was 
assumed that the gene encoding RLM6 would be novel although, it was known from protein 
data that RLM6 and P450j were similar. However by no means was it certain they were the 
same protein, encoded by the same gene. During the period of isolation and characterisation of 
the RLM6 cDNA, the cDNA sequences for the alcohol-inducible P450j in the rat and LM3a in 
the rabbit were published. It thus became possible to compare these DNA sequences with that 
of the diabetes-inducible RLM6 cDNA. This analysis is presented, indicating that RLM6 and 
P450j (BEI) are identical. At this point attention focussed onto the regulation of IIE1 by the 
pathophysiological conditions and on the question of the hormonal control of IIE1 mRNA 
levels. It was intended that these studies should throw light on the endogenous role of BEI in 
liver metabolism and its importance in drug metabolism.
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CHAPTER 2
METHODS AND MATERIALS
2.1 MATERIALS
2.1.1 Chemicals
All chemicals purchased were of the purest grades available and unless otherwise stated were 
supplied by BDH Chemicals Ltd., Poole Dorset.
Sigma Chemical Company: Streptozotocin. citric acid (trisodium salt), sodium chloride, 3-[N- 
moipholino] propane sulphonic acid (Mops), EDTA, ethidium bromide, polyvinyl pyrrolidone, 
Tween 20, Nonidet P-40, bromophenol blue, xylene cyanol, spermidine trihydrochloride, 
bovine serum albumin (BSA) fraction V, isopropyl-p D-thiogalactosidase (IPTG), Tris and 4- 
chloro-napthol.
National Diagnostics. (Avlesburv.U.IO: 2% N,N' Methylene bisacrylamide solution, 30% 
acrylamide solution.
BRL: N,N,N',N'-tetramethylethylenediamine (Temed), agarose, low melting point (LMP) 
agarose, guanidinium thiocyanate and urea.
Oxoid Ltd: bacto-tryptone, yeast extract
Difco Laboratories U.S.A.: Bacto-Agar.
Pharmacia (TJpsalla. Sweden"): Ficoll.
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2.1.2 Radiochemicals
i) Deoxycytidine 5'- [a 32P] triphosphate, triethylammonium salt. Specific activity 
approximately 3,000Ci/mmol. 10mCi/ml. (Amersham).
ii) Deoxyadenosine 5' -[a35S] thiotriphosphate, triethyl ammonium salt. Specific activity 
l,200Ci/mmol. (NEN).
iii) L- [35S] - Methionine. Specific activity 1134Ci/mmol. (NEN).
2.1.3 Antibodies
i) The primary antibody to RLM6 was a kind gift from Dr. J. B. Schenkman, University of 
Connecticut Health Centre (Favreau et al, 1987). The antibody was raised in a 1.5kg female
‘New Zealand white rabbit, by four weekly intradermal injections of the purified RLM6 protein 
in an emulsion containing Freunds complete aduvant. Serum was collected four weeks after 
the final injection and the resulting IgG was isolated by adsorption to protein A agarose. The 
antibody was made monospecific by absorbing it to a sepharose column containing bound, 
partially purified cytochrome P450 (from which RLM6 was lacking) from untreated male rats.
ii) The primary antibody to P450 IVA1 was a kind gift from Dr. R. Sharma. (Biochemistry 
Department, University of Surrey). The IVA1 protein was purified from clofibrate induced 
rats and a polyclonal antibody raised to it, in a sheep (Sharma et al, 1988).
iii) The secondary biotinylated anti-sheep IgG and anti-rabbit IgG were obtained through 
Sigma.
iv) The tertiary streptavidin-biotinylated-horseradish peroxidase (HRP) complex was 
purchased from Sigma.
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2.1.4 cDNA probes and libraries
cDNA probes: To study the expression of cytochrome P450 IVA1 a 2.1kb cDNA insert, 
isolated from a clofibrate induced rat liver poly A+ Xgtl 1 cDNA library (Eamshaw et al, 1988) 
was kindly provided by Dr. D. Eamshaw (Department of Biochemistry, University of Surrey). 
To monitor the levels of RNA loaded onto Northern and dot blots, human actin cDNA probe 
was used. The recombinant plasmid containing the actin cDNA was kindly provided by Dr. D. 
Eamshaw (Gunning et a/,1983).
cDNA library: The RLM6 antibody (see section 2.1.3) was used to screen a Xgtll rat liver 
poly A+ cDNA library that had been made from clofibrate treated rats and kindly provided by 
Dr. D. Eamshaw.
2.1.5 Bacterial/Phage strains
Ecnli Bacterial strains Genotype
TB1 used in preparing competent cells ara hsd R. thi, str A  Alac-pro rk+
as a host for recombinant plasmids A080dlacZ M15
Y1090 host for Xgtll Alac U169 pro A+ Alon am D139
str V sup F [tryC22::TnlO] (pMC9) 
Y1089 host for Xgtl 1 lysogen formation À/ac U169 pro A+ Alon am D139
jfr A hflA150 [chr::TnlO] (pMC9)
Plasmid vector: The plasmid pUC 19 (Norrander et al, 1983) was used in a number of the 
cloning techniques to be described. A map detailing the multiple cloning site can be seen in 
Figure 2.1 .
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Phage: To immunoscreen a cDNA library the vector used was the bacteriophage Xgtll. A 
detailed restriction endonuclease map can be seen in Figure 2.2.
2.1.6 Restriction endonucleases
The enzymes shown in Table 2.1 were used in a number of different experiments throughout 
this work and unless otherwise stated all were used in accordance with the manufacturers 
instructions.
RESTRICTION ENZYMES RECOGNITION SITE
s - y
Eco R1 G'AATTC
Stu I AGG'CCT
Eco RV GATATC
Av<2 I CPyCGPuG
P stl CTGCA’G
Bam HI G'GATCC
Table 2.1: Restriction enzymes: The nomenclature for the nucleotides shown in column 2 
is as follows:- G=Guanine A=Adenine collectively known as the Purines (Pu)
T=Thymine C=Cytidine collectively known as the Pyrimidines (Py)
The slash (') indicates where the enzyme recognises the DNA and cuts it.
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1£coRl 
/  397
Multiple Cloning 
Site
Hind m  
448
pUC19
2686bp2000
Amp1
1000
400
Eco'Kl Kpn I
420
Bam HI
440 460
Hinc II 
Acc I 
Sail Sph I
agtgaattCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGcgtaatcatggtcat
S a d Sma I 
Xma I
Xba I Pstl Hind III
Figure 2.1: Schematic diagram of pUC 19
The multiple cloning site is shown in full below the plasmid, giving all of the restriction 
endonuclease sites including the unique Eco R1 site into which the inserts are cloned.
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2.1.7 Animal husbandry
Male Wistar albino rats, obtained from the University of Surrey breeders were used as a source 
of major organs for use in experiments to characterise the RLM6 cDNA. The rats (140-180g) 
were housed in cages with sawdust (RS Services Ltd) bedding, being allowed water, and 
except where stated, chow (LAD2)û<2 libitum. A 12hr light/dark cycle was in operation at 22°C 
Experiments conducted with hormones (insulin and testosterone) were performed at the 
University of Connecticut with male and female CD rats (7 weeks of age), purchased from 
Charles River Breeding Laboratories (Wilmington,MA). The animals were housed in 
suspended metal cages and maintained on a 12hr light/dark cycle, with standard chow and 
water available ad libitum.
2.1.8 Animal treatments
Animals were made diabetic with a single tail vein or i.p. injection of streptozotocin (65mg/kg), 
control rats were given an equal volume of the dosing vehicle (50mM sodium citrate, pH 4.5). 
The development of diabetes in the streptozotocin treated group was confirmed by positive 
urine glucose dip test values of 1,000 or higher (Bili Lab Stix, Ames, Inc), the lack of 
significant weight gain and serum glucose determination.
To study the time course of insulin reversal diabetic animals were dosed daily with 
human insulin (NPH Isophane, Squibb). Dosing regimes are indicated in the results sections.
Daily testosterone treatments were performed for a 2 week period as described by 
Thummel and Schenkman, (1990) at a dose level of j250|J.g/rat. This dosing protocol resulted in 
testosterone plasma levels within the normal physiological range of around 3-4ng/ml (Favreau 
et al, 1987). Fasted animals received no food for 48hr but water was provided ad libitum.
Bile duct ligation and division or sham operation were performed by Dr. S. Singh 
(Robens Institute, University of Surrey), via an upper midline incision under intraperitoneal
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p entobarbital anaesthesia (75mg/l OOg body weight). The extrapancreatic part of the common 
bile duct was mobilised and divided between silk ligatures. In the sham operation, a silk 
ligature was placed around the common bile duct and then removed. The abdominal muscles 
and skin were closed by single layers of continuous silk.
2.2 GENERAL NUCLEIC ACID PROCEDURES
2.2.1 Sterilization
For all nucleic acid procedures, solutions, glassware and plasdcware were sterilised for 20min 
at 120°C in a Rodwell series 32, automatic autoclave, unless otherwise indicated in order to 
destroy nucleases.
2.2.2 Phenol extraction
All phenol prior to use was redistilled to remove any impurities. An equal volume of TE 
(lOmM Tris.HCl pH 8.0, ImM EDTA) -saturated phenol was added to the aqueous solution 
containing either DNA or RNA and mixed thoroughly. The emulsion (volumes greater than 
2ml) was centrifuged at 12,900g (4°C) for a minimum of 10min (this was longer if a large 
amount of protein precipitate was expected at the interface). For smaller volumes (<2ml), 
samples were spun at 16,000g (15min) at 4°C in a microfuge. The top aqueous phase was 
extracted in this manner until the white (protein) interface disappeared. In certain procedures 
(as indicated) the initial phenol extraction was followed by a 1:1 phenol/chloroform extraction 
and then a chloroform extraction, to remove residual phenol.
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2.2.3 Ethanol precipitation
The DNA or RNA was precipitated from the aqueous solution, by the addition of 0.5 volume 
7.5M ammonium acetate or 0.1 volume of 3M sodium acetate, pH 5.2 and 2 volumes of 100% 
ethanol. If the DNA or RNA concentration was high the mixture was left at -70°C for 30min, 
lower concentrations were precipitated overnight at -20°C. The precipitated nucleic acids were 
pelleted by centrifugation at ! 16,000g : (4°C) for 15min in a microfuge. The supernatants 
were discarded and the pellet dried in a Univap centrifugal evaporator (Uniscience Ltd.) under 
vacuum. The dried pellets were resuspended in an appropriate volume of water or TE.
2.2.4 Visualisation of DNA or RNA
To visualise either DNA/RNA in agarose gels, the fluorescent dye ethidium bromide was 
routinely used. The gels were immersed in water containing 0.5pg/ml ethidium bromide for 
approximately 20min, destained in water alone for a similar period and the nucleic acid bands 
visualised by UV-irradiation (Sharp et al, 1973). This is possible as irradiation absorbed by 
the bound dye at 300nm is re-emited at 590nm in the red/orange region of the visible 
spectrum.
2.2.5 Photography and autoradiography
A permanent record of ethidium bromide stained gels was made by photographing the UV- 
irradiated gel with a polaroid land speed MP-4 camera and type 55 positive/negative film. The 
film was exposed for approximately 15sec with an aperture of f4.5 and an orange filter.
Autoradiography was used to visualise on film, radioactive molecules hybridised to 
nitrocellulose filters. For all procedures Kodak X-Omat AR 5 high speed film was used. For 
Northerns, Southerns and dot blots where 32P was the incorporated nucleotide, filters were
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wrapped in Saran wrap and placed in cassettes containing Croner lightening plus intensifying 
screens. The films were exposed at -70°C and developed automatically in a Fujii RGII Medical 
Film Processor. The RG developer and RG fixer were purchased from Wardray products Ltd. 
For 35S sequencing gels no intensifying screen was used (because this isotope, a weak |3 
emitter is absorbed by the film) and the film exposed overnight at room temperature.
2.2.6 Agarose gel electrophoresis
DNA: The standard protocol as described by Maniatis et al, (1982) was routinely employed. 
All gels were electrophoresed in E-Buffer (40mM Tris.acetate, 20mM sodium acetate, lOmM 
EDTA pH 8.0). Preparative 1.0 % (w/v) LMP-agarose gels were run in the cold room (4-8°C) 
at 100mA whereas analytical agarose gel electrophoresis was performed at room temperature 
and 150mA. The majority of the work was carried out using the Pharmacia GNA-100 
submarine apparatus, however for preparative gels and Southern blots, the BRL H5 submarine 
gel apparatus was used. The marker dye for electrophoresis comprised of 10% (w/v) 
bromophenol blue in 50% (w/v) sucrose.
RNA: RNA was electrophoresed in formaldehyde denaturing gels as originally described by 
Lehrach et al, (1977) and modified by Maniatis et al, (1982). All gels were run in 1 x running 
buffer (0.4M Mops pH 7.0, lOmM sodium acetate, ImM EDTA pH 8.0). The marker dye mix 
contained 4% (w/v) bromophenol blue, 4% (w/v) xylene cyanol and lOmM EDTA pH 8.0 in 
50% (v/v) glycerol. The 1.2% (w/v) agarose gels were run at 150mA, until the more rapidly 
migrating bromophenol blue marker had moved 3/4 of the way down the gel.
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2.2.7 DNA extraction from preparative LMP-agarose gels
DNA was electrophoresed as described in section 2.2.6, after which the gels were stained with 
ethidium bromide and the DNA bands of interest excised with a scalpel on the UV light box. 
The agarose was placed into a preweighed Falcon tube, its weight was determined and an equal 
volume of water was added. The gel was melted at 90°C in the minimum amount of time and 
allowed to equilibriate to 37°C. The DNA was extracted by the addition of ice cold phenol as 
described in section 2.2.2. However before the DNA was precipitated (see section 2.2.3) the 
volume was reduced to approximately lOOfil by butan-2-ol extraction as described by Maniatis 
et al, (1982).
2.3 ENZYMOLOGY AND PROTEIN PROCEDURES
2.3.1 Protein determination
The protein content of microsomal preparations were determined by a modified method of 
Lowry et al, (1951). The standard curve was generated using duplicate dilutions (range 
between 0-40}ig) of bovine serum albumin and test samples were diluted 1 in 50. The protein 
standards, samples and blanks (0.5ml) were mixed with 2ml of protein buffer (2% (w/v) 
sodium carbonate in 0.1 M sodium hydroxide, 1% (w/v) hydrated copper sulphate, 2% (w/v) 
sodium potassium tartrate) and allowed to stand for 10min. Folin-Ciocalteau reagent was 
diluted 1:1 with distilled water and 0.25ml was added to the solution which was then vortexed 
immediately. After a 30min incubation period at room temperature the absorbance was read at 
750nm on a Cecil 292 UV spectrophotometer.
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2.3.2 Isolation of hepatic and renal microsomes
The microsomal subcellular fraction was prepared by ultracentrifugation using a modification 
of the method of Omura and Sato, (1964). Livers were excised and contaminating blood 
removed by perfusion (0.9% (w/v) saline). The kidneys were decapsulated and both tissues 
immersed in 0.25M sucrose. This step and all subsequent steps were performed on ice or at 
4°C. A 25% (w/v) liver homogenate was made using 3-4 strokes on a Potter Elvehjem 
homogeniser. A 15% (w/v) kidney homogenate was made using a polytron (half speed, 
15sec). The homogenates were spun for 10min at 13,800g, the pellets discarded and the 
supernatants re-centrifuged at 150,000g for 60min in a Beckman L7-65 ultracentrifuge. The 
resultant microsomal pellet was resuspended in a glycerol buffer (50mM potassium phosphate 
pH 7.25, 20% (v/v) glycerol), to give a protein concentration of approximately 20mg/ml for 
liver and 5mg/ml for the kidney. The microsomes were stored at -70°C.
2.3.3 Microsomal cytochrome P450 content
Total liver cytochrome P450 content was determined spectrophotometrically by a method 
described by Omura and Sato, (1964). Resuspended microsomal samples (0.5ml) were diluted 
to 3ml with glycerol buffer, reduced with a few grains of sodium dithionite and vortexed. The 
sample was then divided between two plastic cuvettes and the baseline recorded between 400- 
500nm using a Kontron-Uvikon 860 spectrophotometer. Carbon monoxide was gassed (40 
bubbles at approximately 1 a second) through the sample cuvette only and the spectrum
| scanned (3 times) until there was no further absorbance development at 450nm. The
| cytochrome P450 concentration was determined using the difference millimolar extinction 
coefficient (450-490) of 9 lmM“ 1 cm" 1.
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2.3.4 Immunoblotting (Western Blotting)
This technique as originally described by Towbin et al, (1979) was performed essentially by 
the method of Burnette, (1981). However horseradish peroxidase (HRP)-labelled antibodies 
(see section 2.4.2) were used and dilutions and incubation times were optimised at each stage. 
The microsomal proteins were separated on a 10% (w/v) polyaciylamide gel and transferred to 
a 0.45pm nitrocellulose sheet (Schleicher and Schuell). Electrophoretic transfer was achieved 
overnight at 20 volts (constant voltage). Development of the blot was stopped with thorough 
rinsing in distilled water. The following cocktail of proteins (Sigma) were used as standards 
to size proteins of interest:
2.3.5 Serum acetone and glucose determination
Blood was collected in sealable vials from the neck of decapitated, insulin treated diabetic male 
rats, at 0, 6, 12, 24, 48, 72hr and 2 weeks. It was allowed to clot (10-15min) and centrifuged 
at 2,500 rpm for 10min to separate the serum. Acetone determination was kindly performed by 
Dr. K. Thummel (University of Connecticut) using a Varian model 3700 gas chromatograph 
equipped with a 6ft x 2mm glass column packed with 0.2% (w/v) CW1500 on 80/100 mesh 
Carbopack (Supelco). The injection temperature was 160°C with an oven temperature of
cc-Macroglobulin
P-Galactosidase
(Mr=180,000)
(Mr=l 16,000)
(Mr=84,000)
(Mr=58,000)
(Mr=48,500)
(Mr=36,500)
(Mr=26,600)
Fructose-6-phospate kinase
Pyruvate kinase 
Fumarase
Lactate dehydrogenase 
Triosephosphate isomerase
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70°C. A standard curve of acetone was run before each assay and serum samples were stored 
at -70°C, prior to analysis.
Glucose was quantified using the glucose oxidase kit (Sigma) essentially as described 
by the manufacturers, monitoring the absorbance at 450nm.
2.3.6 Arachidonic acid metabolism and metabolite detection
The metabolism of arachidonic acid was performed in essence as described by Capedevila et al,
(1985) by Mr S. Huang at the University of Surrey. The reaction products were separated by 
reverse phase high-performance liquid chromatography (HPLC, Waters Model 510) on an 
Ultrasphere ODS C l8 column (250mm x 4.6mm, Beckman). The elution profile of the 
radioactive metabolites was monitored using a Berthold LB503 HPLC radioactive detector
(Lab-Impex, Twickenham U.K.) interfaced with a Commodore PET (series 4000). Rates of 
| metabolite formation were calculated from the reverse phase chromatograms.
2.3.7 Hepatocyte and Kupffer cell isolation
Hepatocytes and Kupffer cells were isolated from the same Wistar rat (200-250g) by the 
following protocol (developed at the Robens institute, University of Surrey by Dr. S. Singh). 
The animals were anaesthetised with a subcutaneous injection of fentanyl and fluanisone 
(0.015ml/100mg body weight), the abdomen opened by a cruciate incision and the skin and 
muscle flaps were reflected. The portal vein was cannulated with an 18 gauge cannula and the 
caudate lobe was excised as close to its origin as possible. This tissue was used for hepatocyte 
isolation and the rest of the liver for Kupffer cells, both procedures from here progressed 
simultaneously.
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Hepatocytes: The caudate lobe was placed onto a wire mesh and perfused with calcium free 
buffer (142mM NaCl, 4.37mM KC1, 1.24mM KH2PO4 , 24mM NaHBOg, 0.62mM 
MgS04.7H20, 0.62mM MgCl2.6H20 and a few grains of phenol red) using a needle inserted 
into the open cut vessel. A flow rate of 25ml/min was established and maintained for 20min, 
after which the tissue was perfused with 0.05% collagenase for a further lOmin. The tissue 
was then disaggregated in PBS-A (reconstituted from tablets, Flow Laboratories), filtered and 
washed twice by centrifugation at 50g for Imin. The cells viability was checked with trypan 
blue, counted and then plated. All solutions were gassed with a 95%02/5%C02 mixture.
Kupffer cells: Initially the cells were perfused in calcium free buffer at a flow rate of 12ml/min 
for 15min. All solutions were at 37°C and gassed with a 95%02/5% CO2 mixture. Following 
this, 0.05% collagenase was perfused at 8ml/min for 5-10min. The liver was then carefully 
removed and disaggregated in 0.2% Pronase E. This digest was incubated with continuous 
shaking at 37°C for one hour, killing the hepatocytes. The mixture was filtered (125pm nylon 
cloth) and washed 3-4 times by centrifugation with PBS-A. The final re suspension was in 
Hanks balanced salt solution (HBSS) and this was then layered onto a preformed Percoll 
gradient (a mixture of 3 x HBSS with Percoll at a ratio of 3:1 centrifuged at 30,000g for Ihr). 
This was centrifuged at 800g for 45min. The Kupffer cells were harvested and washed again 
prior to plating. At this stage the hepatocytes had been in culture for 2-3hr, they were washed 
with warmed PBS-A and the medium containing the Kupffer cells added. The cells were then 
left for a 24hr period prior to the addition of conditioned medium.
2.3.8 Isolation of hepatocyte and Kupffer cell microsomes
Microsomes were prepared from hepatocytes and Kupffer cells essentially by the method 
described by Eliasson et al, (1988). The cells were harvested with a cell scraper into 2ml of ice 
cold PBS-A and placed into Eppendorf tubes. The cells were then subjected to 3 liquid
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nitrogen freeze thaw cycles, followed by sonication (20, Isec bursts per ml of cells). The
resulting lysates were then centrifuged at 16,000g at 4°C in a microfuge and the
supernatants were recentrifuged at 150,000g for 60min (4°C). The microsomal pellet, a thin 
brown disc of material was resuspended in 100- 150jil of glycerol buffer.
2.4 PROCEDURES WITH X gtll
There are two distinct life cycles in the growth of lambda phage , lytic and lysogenic, both of 
which I have exploited in these studies. Briefly, lysogenic growth is established when X 
repressor (C1 gene product) binds the operators (Ol and Or ) that control the two early 
promoters PL and PR and the phage DNA is inserted into the host genome. In the absence of 
this repression the phage enters the lytic cycle in which it reproduces until approximately 100 
progeny are formed and the host cell is lysed.
2 .4.1 Assay of phage titre (Xgtll libraries and recombinants)
To ascertain the correct number of phage for screening a library it is necessary to serially dilute 
the phage stock. This was routinely performed over the range lO'^-lO'1® in SM buffer (0.1M 
NaCl, 0.1M MgS04.7H20, 0.05M Tris.HCl pH 7.5, 0.01% (v/v) gelatin). lOpl was taken 
from each dilution and adsorbed to 200pl of Y1090 (overnight culture). The bacteria/phage 
mixture was incubated at 37°C for 10-15min, added to 3ml of top agar (7g/L"l bacto-agar in L- 
broth media) (kept at 47°C) and poured immediately onto a prewarmed (37°C) L-agar 
(Maniatis et al, 1982) plate (petri dish, 90mm diameter). The dish was gently rotated until the 
top agar evenly coated the L-agar and allowed to set. The plates were inverted and left at 37°C 
overnight, the titre was calculated by counting the plaques and expressed as plaque forming 
units per ml (pfu/ml) of the undiluted phage suspension.
56
2.4.2 Immunological screening of Xgtll recombinant libraries
To clone a low abundance mRNA from a given library (i.e to have a 99% probability of 
obtaining a given clone in a given mRNA population), it is necessary to plate out and screen 
between 100,000-200,000 plaques (Clarke and Carbon, 1976). The rat liver cDNA library 
used here has been described in section 2.1.4. Xgtll is special, because it has an altered C1 
gene (C^857) which renders the C  ^repressor heat labile at 42°C. Essentially the method of 
Hunyh et al, (1985) was followed and the schematic diagram shown in Figure 2.3 outlines the 
protocol. In practice 1.7ml of Y1090 (overnight culture) was mixed with 50p.l of a 10"4 
dilution of the rat Xgtl 1 cDNA library (titre=3 x 107 pfu/ml) and incubated at 37°C for 10min. 
The bacteria/phage suspension was added to 27ml of top agar, dried, inverted and incubated at 
42°C until the phage plaques just became visible (usually 3-4hr). The plate was removed to 
room temperature and a nitrocellulose filter, which had been pre-soaked in lOmM IPTG (a p- 
galactosidase inducer) was carefully overlaid. The plate was incubated for a further 2.5-3hr at 
37°C , thereby allowing the proteins encoded by the inserts, under the promotion of the P~ 
galactosidase gene, to be expressed. The position of the filter was marked (so the correct 
orientation could be identified at a later stage) and transferred into 50ml of TEST (50mM 
Tris.HCl pH 8.0, 150mM NaCl and 50|il/100ml Tween 20). The plate was sealed and stored
at 4°C until required.
The filter was washed in TEST (10min) to remove any unbound protein, placed into 
fresh medium containing 1% (w/v) BSA and left overnight at 4°C. The following steps were 
then performed:
i) Filter incubated for Ihr (room temperature) with primary antibody (lOqg/ml) to 
RLM6 (see section 2.1.3) in TBST/BSA.
ii) Filter washed 3 times (5min each) in TEST.
iii) Filter incubated for 1.5hr (room temperature) with streptavidin-biotinylated anti­
rabbit IgG (1:700 dilution).
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iv) Repeat step ii) as above.
v) Filter incubated for Ihr (room temperature) with streptavidin-biotinylated enzyme 
(HRP) complex (1:700 dilution).
vi) Filter washed 3 times (5min each) in TBS (50mM Tris.HCl pH 8.0, 150mM
NaCl).
vii) Filter developed by the addition of the enzyme substrate (4-chloro-naphthol).
The substrate was prepared by dissolving 30mg of 4-chloro-naphthol in 8ml of methanol and 
diluting to 50ml with TBS. 20jil of hydrogen peroxide was added just prior to use. At each 
stage the filter was gently agitated on a Luckham rotary shaker. All times given for the 
antibody incubations are minimum times. Both the primary and secondary antibodies were 
stored at 4°C after use and reused in later experiments.
2.4.3 Plaque purification
Positive recombinant cDNA clones were identified by the appearance of purple spots on the 
filters after incubation, as described in section 2.4.2. The corresponding plaques were excised 
from the top agar and placed into 0.5ml of SM buffer. This was stood at 4°C overnight, 
enabling the phage to diffuse out of the gel. The cDNA clones of interest were further purified 
by repeated rounds (usually 2-3) of plating and immunoscreening until individual positives 
could be cleanly picked.
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Figure 2.3: Immunological screening of a X gtll cDNA library
2.4.4 Isolation of recombinant phage DNA
Phage from the positive cDNA clones were grown on agar plates as described in section 2.4.2, 
to confluent lysis. The phage were eluted from the agar overnight at 4°C with 5ml of SM 
buffer. This buffer was transferred to a 14ml polypropylene tube and spun at 8,240g for 
lOmin at 4°C in an MSE high speed 18 centrifuge. Each supernatant was divided into 0.7ml 
aliquots and placed into Eppendorf tubes (Scotlab). RNAse A (5mg/ml) and DNAse I 
(5mg/ml) were added and the tubes incubated for 30min at 37°C to destroy E. coli nucleases, 
0.7ml of 20% (w/v) polyethylene glycol (PEG)/2.5M NaCl was added and the mixture left on 
ice for Ihr. The precipitated phage were collected by centrifugation at 16,000g for Imin 
(room temperature) and the supernatants removed to fresh tubes. To the tubes, 0.5ml of 10% 
(w/v) SDS and 0.5ml of 0.5M EDTA pH 8.0 were added and the mixture incubated at 68°C 
for 5min to break open the phage particles and release the DNA. Phage DNA was isolated by 
phenol extraction and ethanol precipitation as described in sections 2.2.2 and 2.2.3 
respectively.
2.4.5 Large scale preparation of recombinant phage DNA
Recombinant phage DNA was prepared in bulk using a method adapted from that of Kaslow,
(1986). A cleared lysate of phage was prepared by mixing 10ml of an overnight culture of 
Y1090 with lOOpl of high (108 pfu/ml) titre phage at 37°C for 10min. This was added to 
450ml of L-Broth + lOmM MgS04 and the culture was incubated with shaking at 42°C for 
approximately 4hr (until lysis had occurred). A few drops of chloroform were added to kill 
any remaining bacteria and the culture was cooled on ice for 5min. Debris was removed by 
centrifugation at 10,000g for 10min. To the supernatant, DNAse I was added to give a final 
concentration of 10qg/ml and incubated at 37°C for 30min, to degrade bacterial chromosomal 
DNA. 150ml of 1.5% (w/v) SDS, 0.3M Tris.HCl pH 9.0, 0.15M EDTA was then added and
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the mixture heated to 70°C to dissociate the phage particles and inactivate the DNAse I. The E. 
coli and phage proteins and the E. coli DNA fragments were precipitated from this mixture 
after incubation on ice (15-30min) in the presence of 110ml 8M potassium acetate. The 
precipitate was pelleted by centrifugation at 6000g for 15min at 4°C. The supernatant was 
retained and the phage DNA was precipitated by the addition of 0.6 volume of isopropanol. 
After standing for 15min at room temperature the DNA was pelleted by centrifugation at 
13,800g for 20min. The supernatant was discarded and the pellet resuspended in l-2ml of 
sterile water. RNAse A was added to 50fig/ml, and the mixture was incubated at 37°C for 
30min (this treatment degraded any residual bacterial RNA). This was followed by a further 
incubation with Proteinase K (200p.g/ml) under the same conditions as above. Phenol 
extractions were then performed as described in section 2.2.2 and the DNA precipitated with 
ethanol (section 2.2.3). The final DNA pellet was resuspended in 200p,l of water and its 
concentration was determined (lA260=50|ig/ml)
2.4.6 Generation of X gtll lysogens
The formation of Xgtll lysogens, provides a method to express large amounts of foreign 
proteins, in a bacterial environment. This allows a means to characterise a given clone, 
isolated from a cDNA library, using antibodies raised to the protein of interest, thereby giving a 
good indication that the cDNA you believe to have isolated codes for the protein to which the 
antibody (in this case RLM6) was raised.
Y1089 is the E. coli host of choice for lysogen formation, since like Y1090 it has the 
lac repressor and the Ion protease, but in addition it has a mutation (hflA150) that enhances the 
frequency of phage lysogeny.
A single Y1089 colony was picked from an L-broth agar/0.2% (w/v) maltose plate and 
grown in liquid culture o/n at 37°C (bacteria grown in the presence of maltose adsorb 
bacteriophage X more efficiently, as the sugar induces the maltose operon, which contains the
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gene {lamb) coding for the X receptor). The Y1089 cells were then infected with the 
recombinant phage at a multiplicity of 5, for 20min at 32°C. The cells at different dilutions 
were then plated onto L-broth plates and incubated at 32°C overnight (at this temperature the 
temperature-sensitive phage repressor is functional). Colonies were tested for temperature 
sensitivity by replica plating the same colony onto two different plates, incubating one at 42°C 
and the other at 32°C. Clones that grew at the lower temperature were assumed to be 
lysogens.
2.4.7 Crude lysate formation from X gtll recombinant lysogens
A single colony of recombinant lysogen was grown to an absorbance of approximately 0.5 (600nm) 
at 32°C in 100ml of L-broth media. The temperature of the culture was then increased rapidly 
to 42°C-450C and shaken (G25 shaker, New Brunswick Scientific Co. Inc.) with good 
aeration for 20min. IPTG (lOmM) was added and the culture incubated at 37°C for a further 
60min. Cells were harvested in a Beckman J2-21 centrifuge at room temperature at 3,400g 
(5min) and resuspended in 1/30 of the original culture volume in 50mM Tris.HCl pH 8.0. The 
resuspended cells were frozen in liquid nitrogen and stored at -70°C. Thawing of the cells 
resulted in complete lysis and provided the crude lysate. Western blot analysis as described in 
section 2.3.4 was used to identify the [3-galactosidase cytochrome P450 fusion protein.
2.5 SUBCLONING IN PLASMID VECTORS
2.5.1 Small scale plasmid DNA preparation
A rapid extraction of plasmid DNA from bacterial cells was used in a quick method to screen 
recombinant subclones. The protocol applied was based on the original procedure of Holmes 
and Quigley, (1981). From a 10ml overnight culture grown in TYN/AMP (10g tryptone, 10g
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yeast extract, 5g NaCl diluted to 1000ml with distilled water +150jig/ml ampicillin), 1.4ml was | 
; microfuged at top speed for 15-30sec (to pellet the cells). The supernatant was discarded and l 
the pellet resuspended in 100p-l of STET (0.1M sucrose, lOmM Tris.HCl pH 8.0, ImM EDTA 
pH 8.0, 5% (v/v) Triton X-100). To this lOjil of a freshly prepared lysozyme solution 
(10mg/ml) was added and the tube left on ice for 10min. The tube was then boiled (90sec) and 
centrifuged at 9880g for 15min at 4°C in a microfuge. The supernatant (50-lOOpl) was 
carefully removed and the plasmid DNA purified using Geneclean (Stratech Scientific Ltd). 
Geneclean was preferred over phenol in this case since the DNA is obtained free of 
contaminating RNA and salt. In essence 2.5 volumes of sodium iodide was added to the DNA 
sample and G l a s s m i l k ^ M  solution was added (approximately Ijil glassmilk to each Ifig of 
DNA using a minimum volume of 5jil). The solution was mixed and left at room temperature 
for 5min. During this time the DNA was adsorbed onto the silica matrix in the glassmilk 
matrix. The glassmilk was pelleted by centrifugation at top speed in a microfuge (5sec). The 
supernatant was removed and the glassmilk washed by resuspending in 500|il of ice cold 
NEV/TM solution (a sodium chloride/ethanol wash) and recentrifuging for 5sec. The washing 
procedure was repeated twice more and the pellet finally resuspended in sterile water (the same 
amount of water was added as there was glassmilk initially used). The mixture was incubated 
at 50°C for 3min to release the DNA from the matrix and centrifuged at top speed in the 
microfuge (30sec). The resulting supernatant contained the purified DNA.
2.5.2 Large scale plasmid DNA preparation
Plasmid DNA was prepared in bulk using a procedure based on the SDS-lysis method 
described by Maniatis et al, (1982). Routinely 200ml of culture was grown overnight, the cells 
were harvested and resuspended in 3.5ml of 25% (w/v) sucrose in 50mM Tris.HCl pH 8.0. 
Lysozyme (0.5ml of 20mg/ml) was added and left on ice for 10min, to this 3.5ml of 0.25M 
EDTA, pH 8.0 was added and incubated further on ice (5min). The cells were lysed by the
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addition of 5ml of BrijDoc (1% (w/v) Brij 58, 0.4% (w/v) sodium deoxycholate in TE, pH 
8.0) and gentle repetitive pipetting. After another 30min on ice, the suspension was 
centrifuged at 31,000g (4°C) for 45min. To every 5ml of supernatant, 4.75g of caesium 
chloride (CsCl) and 150fil of 1.5% (w/v) ethidium bromide were added. The mixture was 
loaded into Beckman polyallomer quickseal tubes (16 x 76mm) and light liquid paraffin was 
used to fill the tubes, thereby creating a 1/2 gradient of CsCl. The tubes were spun at 
200,000g overnight at 12°C and the lower closed circular plasmid DNA was removed by side 
puncture using a 20-G needle under UV light. The ethidium bromide was removed by 
sequential CsCl-saturated isopropanol extractions until the upper isopropanol layer was clear. 
The DNA was precipitated in 200|il aliquots with 3M sodium acetate pH 5.2 (50pl) and 
isopropanol (500pl) for 30min at room temperature in a total volume of 1ml. For sequencing 
studies, the pellet was ethanol precipitated a further 2-3 times as described in section 2.2.3.
2.5.3 Subcloning
The plasmid cloning vector pUC 19 (see figure 11) was chosen for subcloning because it 
contains a large number of restriction enzyme sites in the multiple cloning site and 
transformants are selectable by ampicillin resistance. An additional advantage is that the 
cloning site is situated within the plasmid p-galactosidase gene. Thus p -gal'E . coli 
transformed with native plasmid give blue, p-gal+, colonies on X-gal plates, whereas 
recombinant plasmids give white, p-gal", colonies. In addition sequencing can be performed 
directly on pUC 19 from both ends of the DNA insert, as the universal primer and reverse 
primer ( S e q u e n a s e ^ M  catalogue, 1988) binding regions are present at either side of the 
multiple cloning site.
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Isolation of cDNA insert: To subclone the phage cDNA insert prepared in section 2.4.4, the 
recombinant bacteriophage was cut with the restriction enzyme Eco RI (see section 2.1.6). 
This released the cDNA from the two arms of the bacteriophage and the mixture was separated 
on a 1% (w/v) low melting point gel. The rat cDNA insert was recovered by phenol extraction 
as described in section 2.2.7.
Preparation of cut plasmid: The plasmid vector pUC 19 was prepared as described in section 
2.5.2. 30|ig was routinely digested with the enzyme Eco RI which linearised the plasmid 
(lOOng was electrophoresed on 1% agarose gels to confirm this). The enzyme was removed 
from the remainder of the digest by phenol extraction (see section 2.2.2) and the linear plasmid 
recovered by precipitation with ethanol (see section 2.2.3). The precipitated DNA was 
resuspended in a volume of distilled water to give an approximate final concentration of lOng 
Eco RI cut pUC 19 per jil of water.
Ligation: lOng of cut plasmid DNA was mixed with either the purified cut recombinant phage 
or purified cDNA insert to give varying molar DNA ratios (usually 1:1 or 1:3 respectively). 
The mixture was heated to 65°C for 2min, cooled on ice, which ensured that all "sticky ends" 
were available for the formation of recombinant molecules and 2pI of 5 x ligase buffer, Ipl of 
T4 DNA ligase (BRL) and sterile water were added and the ligation was allowed to proceed at 
14°C overnight. The ligation buffer was provided with the enzyme and gave reaction 
conditions of 66mM Tris.HCl pH 7.6, 6.6mM MgCl2, lOmM DTT and 0.1-ImM ATP. 
Ligation mixes were kept at 0°C until required (but not longer than 24hr). Controls of lOng 
uncut plasmid (to check competency of cells), of no plasmid (to check selection of cells) and of 
lOng cut plasmid without insert (to check efficiency of ligation) were included in all 
experiments.
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2.5.4 Introduction of recombinant plasmid DNA into bacterial cells
Preparation of competent cells: To identify the plasmids containing inserts, competent E. coli 
TB1 cells were prepared by a modification of the magnesium chloride/calcium chloride method 
originally described by Cohen et al, (1972). This procedure renders the bacterial cells capable 
of taking up DNA and was accomplished as follows: TB1 cells (35ml) were grown to log 
phase (OD650nm=0-5) in TYN and left to stand on ice for 5-10min, all subsequent steps were 
performed on ice. The cells were concentrated by centrifugation (3440g for 10min), 
resuspended gently in 1/2 volume of cold CaCla and left for Ihr. The cells were then pelleted 
(as above), resuspended in 2ml of C ad 2 solution and left overnight on ice (this increases cell 
competency).
Transformation of competent cells: The competent cells (200gl) were then transformed with 
5p.l of the ligation mixture (see section 2.5.3), for 15-30min at 37°C. The cells were heat 
shocked in a 42°C water bath for 2min and 0.8ml of prewarmed TYN was added. The cells 
were incubated at 37°C for Ihr with shaking and lOOjul was plated out on TYN/X-gal/AMP 
(TYN agar containing 150{ig/ml ampicillin and 40|ig/ml X-gal) plates. The plates when dry, 
were incubated overnight at 37°C.
Selection of transformed cells: pUC 19 contains the lac Z gene coding for the p-galactosidase 
gene, therefore insertion of a DNA fragment into the multiple cloning site of the plasmid causes 
the inactivation of this gene. The chromogenic substrate X-gal is cleaved by p-galactosidase 
releasing a blue indolyl derivative, this is why it is used as a marker for the presence of the p- 
galactosidase gene product. TB1 cells are constitutive for p-galactosidase induction but 
express a mutant p-galactosidase and so are not be able to cleave X-gal. However if they are 
transformed by a plasmid containing an active lac Z gene, this complements the deficiency 
resulting in blue colonies, when grown on X-gal plates. Therefore by growing transformed
bacteria on TYN/AMP/X-gal plates any white colonies that appear should be recombinant, in 
experiments these were picked and small scale plasmid preparations were carried out (see 
section 2.5.1).
2.5.5 Plasmid DNA sequencing
Based on the original dideoxy sequencing strategy of Sanger et al, (1977), RLM6 inserts were 
sequenced using a modification of the protocol first reported by Chen and Seeburg, (1985). 
Double stranded DNA sequencing was favoured because of its simplicity and the convenience 
of not having to subclone the insert into M l3. The Sequenase™ version 2.0 sequenase kit 
(United States Biochemical Corporation) was used primarily as it possessed a genetically 
engineered form of T7 DNA polymerase. This enzyme has several properties which make it 
more suitable for sequencing over the Klenow polymerase (Pol 1). For example it is more 
efficient and is less impeded by secondary structure (GC rich regions). In addition to the 
Sequenase™ kit, template DNA was denatured by alkali essentially as described by Zhang et 
a/, (1988).
Apparatus: The sequencing apparatus for gel electrophoresis was manufactured in the 
departmental workshop at the University of Surrey and routinely accommodated glass plates 
with the dimensions of 58 x 20 x 0.5cm. The plates were always scrubbed with Decon™ and 
hot water, rinsed with distilled water and allowed to dry. After every 4-5 runs the gel side of 
the front plate was resiliconised with 10ml of dimethyl dichlorosilane. The gel spacers 
(0.4mm) were put in place and the plates sealed using S YLGLAS™ waterproof tape.
Template preparation: CsCl purified plasmid DNA (l-2qg) was denatured for 5min at room 
temperature with NaOH (to 0.2M) and EDTA (to 0.2mM), in a total volume of 20|il. The 
mixture was neutralised by the addition of 2|il of 2M ammonium acetate (pH 4.6) and the DNA
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precipitated with ethanol (60jil) as described in section 2.2.3. The DNA was pelleted in a 
microfuge, washed with 80% (v/v) ethanol, repelleted and dried.
Annealing, labelling and termination: The instructions as laid out in the Sequenase™ manual 
were followed for the annealing, labelling and termination stages of the reaction. However 
when the template was annealed to the primer at 65°C (3-5min) it was allowed to cool at room 
temperature for 30-40min.
Electrophoresis: 6% (w/v) polyacrylamide gels were prepared according to the method of 
Sanger and Coulson, (1978). 11.25ml of 38% acrylamide/2% bisacrylamide and 7.5ml of 10 
x TBE (see below) were added to 3l.5g of urea. Distilled water was added to 75ml and the 
urea dissolved by heating at 37°C. Just prior to pouring, 420|il of freshly prepared 10% (w/v) 
ammonium persulphate and 75jil of Temed were added to the acrylamide-urea solution and the 
gel was allowed to polymerise. When not used immediately, they were wrapped in Cling film 
and stored at 4°C overnight. Just prior to loading the samples (3jil) on to the gels, they were 
heated to 75°C for 2min. Sharkstooth combs with 5.7mm point to point spacing (BRL) were 
routinely used and the samples were loaded with a Drummond sequencing pipette (Drummond 
Scientific Co.). The apparatus was run at 50W constant power for the desired length of time. 
The same sample dye described in section 2.2.6 was used as indicator of how the 
electrophoresis was progressing. The gel was run in a Tris-Borate buffer (TBE) which 
contained 0.89M Tris.HCl, 0.89M Borate and 0.02M EDTA.
Autoradiography: After gel electrophoresis the apparatus was disassembled and the plates 
prised apart, leaving the gel on either the back or front plate. After noting the orientation of the 
gel it was fixed in 10% (v/v) methanol/10% (v/v) glacial acetic acid (20min) and rinsed with 
water (this procedure removes the urea which can interfere with the autoradiography). The gel 
was peeled off of the glass plate onto a wet piece of Whatman 3MM paper and dried at 80°C
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for 60min in a gel diyer (Model 4823 slab gel dryer, Biorad). Autoradiography was performed 
as described in section 2.2.5.
2.5.6 Synthesis of oligonucleotides
Oligonucleotides (20mers) were synthesized on an applied biosystems Model 381A DNA 
synthesizer in the Microbiology Department at the University of Surrey. To cleave the 
oligonucleotide from the column support, 1ml of neat 880 ammonia was drawn up through the 
column using a disposable 2.5ml syringe. A second syringe was inserted into the opposite end 
and the ammonia was slowly passed through the column (3-4 times). The solution was left in 
contact with the column at room temperature for 45min and the process repeated as above. 
After a further 45min, the solution was drawn into one syringe and sealed in a screw cap tube. 
At this stage the oligo had been liberated and the cyanoethyl group protecting the phosphate 
removed. The tube was incubated at 55°C overnight (this removed the benzoyl and isobutyryl 
groups present on the exocyclic amines during synthesis, in order to prevent side reactions 
taking place), and cooled on ice. The solution was then transferred to Eppendorf tubes and the 
oligonucleotides precipitated with ammonium acetate and ethanol (see section 2.2.3). The 
concentration was calculated spectrophotometrically using the equation A26O l=20|lg/ml.
2.6 PREPARATION OF TISSUE NUCLEIC ACIDS
2.6.1 Isolation of RNA
Total RNA: Total RNA was extracted from both hepatic and extrahepatic tissues by a 
modification of the method first described by Cathala et al, (1983). Tissues on some occasions 
(these will be stated) were used fresh but more usually had been frozen in liquid nitrogen and 
stored at -70°C. For the frozen tissue prior to homogenisation it was ground up in liquid
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nitrogen with a pestle and mortar. To 1 g of tissue 8ml of RNA lysis buffer (5M guanidinium 
isothiocyanate, 50mM Tris.HCl pH 8.0, lOmM EDTA pH 8.0) and 0.5ml of undiluted p- 
mercaptoethanol was added. The mixture was homogenised using a polytron (Kinematica 
GmbH, Switzerland) and allowed to stand for 20min at room temperature to ensure complete 
dispersion. To this homogenate, 50ml of 4M LiCl was added and left at 4°C for approximately 
20hr. The precipitate formed was pelleted at ll,000g for 90min (4°C) and the supernatant 
discarded. The pellet was rinsed with 30ml of 3M LiCl and recentrifuged for 30min as above. 
The resultant pellet was resuspended in 5ml TE/0.1% (w/v) SDS and the RNA extracted with 
phenol and ethanol (see section 2.2.2 and 2.2.3 respectively). The RNA pellets were dried and 
resuspended in an appropriate amount of water. The concentration of RNA in the samples 
were determined using the equation A26O l=40|ig/ml.
Polvsomal RNA: 1ml of the polysomes isolated in section 2.6.2 was diluted 1:1 with 0.1M 
sodium acetate. SDS was added to give a final concentration of 0.5% (w/v) and the mixture 
was vortexed for 5-lOsec. The polysomal RNA was extracted with 2ml of phenol/chloroform 
(see section 2.2.2), however the bottom layer was removed and replaced with 2ml of 
chloroform alone. This was repeated until any flocculence at the interface had been cleared. 
The RNA was precipitated with ethanol (see section 2.2.3).
2.6.2 Precipitation of polysomes with magnesium salts
The technique of precipitating ribosomes with Mg2+ as originally reported by Takanami, 
(1960) was performed using the modification described by Palmiter, (1974). All procedures 
were performed on ice. Tissue (2g) was scissor minced and homogenised in 18ml of buffer A 
(250mM Tris.HCl, 250mM NaCl, 50mM MgCl2, Img/ml Heparin, 2% (v/v) Triton X-100), 
with 3-4 strokes of a loose fitting pestle using a Potter Elvehjem homogeniser. The 
homogenate was spun at 31,000g (5min) and the supernatant decanted to a clean tube. An
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equal volume of buffer B was added, mixed and left on ice for 110min. Aliquots of 20ml were 
carefully layered onto 10ml pads of 0.2M sucrose/PBM (25mM Tris.HCl, 25mM NaCl, 
lOOmM MgCl2 pH 7.5) and the tubes were recentrifuged at the same speed for 10min. The 
supernatants were removed by aspiration and the walls of the tube wiped dry with tissue. The 
pellet was then resuspended in 8ml of resuspension buffer (2mM EGTA, 20mM MgCla, 2mM 
DTT, 50mM Tris.HCl pH 8.0, 300mM NaCl). To measure the concentration of polysomes, 
4ql was dissolved in tepid 0.5% (w/v) SDS (1ml) and the A measured at 260nm (' A'260 
l=20|ig/ml).
2.6.3 Genomic DNA isolation
Genomic DNA for use in Southern blots was prepared from liver that had been frozen in liquid 
nitrogen. The sample was ground with a pestle and mortar and the powdered tissue suspended 
in 1.2ml of DNA digestion buffer (lOOmM NaCl, lOmM Tris.HCl pH 8.0, 25mM EDTA pH 
8.0, 0.5% (w/v) SDS, 0.1 mg/ml Proteinase K) (per lOOmg of tissue). The samples were 
incubated with shaking at 50°C overnight in tightly capped tubes. The DNA was extracted 
with phenol/chloroform (see section 2.2.2) and precipitated with 7.5M ammonium acetate and 
ethanol (see section 2.2.3). In this method the DNA immediately formed a stringy precipitate 
and was recovered by centrifugation (this brief precipitation in ethanol reduced RNA 
contamination). DNA was resuspended in TE buffer and stored at 4°C. The concentration of 
DNA was determined from the equation A26O l=50jig/ml.
2.6.4 Northern (RNA) blots
RNA was isolated as described in section 2.6.1 and unless otherwise stated 20p.g of total RNA 
was loaded routinely onto 1.2% (w/v) agarose/formaldehyde gels (Rave et al, 1979). The 
samples were heated to 65°C for 15min to denature the RNA and cooled on ice just prior to
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electrophoresis. Agarose gel electrophoresis was performed as described in section 2.2.6 and 
the gel stained with ethidium bromide. After electrophoresis the size separated RNA was 
transferred from the agarose gel to 0.45pm nitrocellulose sheets essentially as in section 2.6.6.
A 10 x standard saline citrate solution (lOxSSC) was used for the capillary transfer of RNA to 
nitrocellulose. A IxSSC solution contains 150mM NaCl and 15mM sodium citrate. The 
nitrocellulose was air dried (5 - 10min), baked at 80°C in a conventional (non-vacuum) oven 
(2hr) and stored in Cling film at room temperature. The efficiency of transfer of RNA to the
nitrocellulose was quantified by visualising the ethidium bromide stained RNA under UV light 
(Denis et al, 1988).
2.6.5 RNA dot blots
As originally described by Lehrach et al, (1977), total or polysomal RNA was denatured with 
formaldehyde, before being bound to nitrocellulose filters. RNA was diluted appropriately and 
made up to lOOpl with sterile distilled water. The RNA was denatured by the addition of 
300pl of a 1:1 18.5% formaldehyde/10 x SSC solution and subsequent incubation at 65°C for 
15min. Nitrocellulose filters were presoaked in water for 5min and then 10 x SSC for 5min 
just before the Dot blot apparatus was assembled (Hybri Dot™ 96-well filtration manifold, 
BRL). The elution speed was adjusted by applying a vacuum so that 400pl took approximately 
5min to pass through the apparatus. After the samples had loaded, the wells were washed with 
400pl of 10 x SSC. The RNA was fixed to the filter by baking as described in section 2.6.4.
2.6.6 Southern (genomic) DNA blots
Aliquots of genomic DNA, as isolated by the method described in section 2.6.2, were digested 
overnight with the restriction endonucleases Eco RI, Pst I, Bam HI or Hind III and the 
fragments separated on a 0.8% (w/v) agarose gel (see section 2.2.6). After visualisation with
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ethidium bromide, the gel was photographed and shaken gently in 0.25M HC1 for 10min. This 
treatment depurinates the DNA, breaking it down into smaller pieces which enables large DNA 
fragments to efficiently transfer to nitrocellulose. The gel was then rinsed in distilled water and 
shaken (2 x 20min) in denaturing solution (1.5M NaCl, 0.5M NaOH) at room temperature. 
The denaturing solution was decanted and replaced with neutralising solution (3M NaCl, 0.5M 
Tris.HCl pH 7.5) and shaken for a further 30min. The DNA fragments were then transferred 
from the gel to a 0.4mm nitrocellulose membrane by capillary action as described in the original 
procedure (Southern et al, 1975) using 20 x SSC. The filter was then treated as described in 
section 2.6.4.
2.6.7 Radioactive labelling of cloned cDNA
RLM6 cDNA insert fragments isolated from pUC 19 as in section 2.5.3 were routinely labelled 
using the random priming method of Feinberg and Vogelstein (1983,1984). The Multiprime 
DNA Labelling Kit was purchased from Amersham and the manufacturers protocol followed. 
The radioactive label used in all DNA labelling experiments was [a-32P]-dCTP (see section 
2 . 1.2).
The Multiprime DNA labelling technique, which employs random sequence 
hexanucleotides to prime DNA synthesis was preferred over Nick translation (Rigby et al, 
1977) because of its economy and safety aspects i.e smaller amounts of both input DNA and 
radioactive label were required.
2.6.8 Hybridisation and filter washing
Hybridization: Unless otherwise stated, the conditions for hybridisation of radioactive probes 
to nucleic acids bound to nitrocellulose were as follows:Filters were prewetted in 5 x SSC and 
prehybridised overnight at 42°C in prehyb/Hyb solution [usually a 100ml stock solution was
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prepared containing 50ml deionised formamide, 25ml of 20 x SSC, 10ml of 50 x Denhardts, 
10ml of 25mM sodium phosphate and just prior to use 1ml of sonicated salmon sperm DNA 
(IQmg/ml) which had been boiled for 5min]. This was carried out for the majority of 
experiments in sandwich boxes and more recently in a Hybaid™ oven. The probe (see section 
2.6.8) was boiled for 5min, cooled on ice (5min) and added to the Prehyb/Hyb solution After 
thorough mixing the filter was left to hybridise at 42°C overnight.
An exception to this was for Southern blots where the Prehyb/Hyb solution was 
replaced with fresh Prehyb/Hyb containing 10% (w/v) dextran sulphate.
Washing: Washing conditions for the filters after hybridisation, varied according to the type of 
experiment being conducted. But unless otherwise stated high stringency washes were 
conducted as follows:
i) 2 x 15min, room temperature in 3 x SSC/0.1% (w/v) SDS.
ii) 1 x 30min, 42<>C in 1 x SSC/0.1% (w/v) SDS.
iii) 1 x 30min, 55°C in 0.5 x SSC/0.1% (w/v) SDS.
Occasionally when the background radioactive signal remained high, the salt concentration was 
lowered to 0.1 x SSC and the temperature raised to 60°C for a further 30min.
2.7 IN VITRO TRANSLATION AND IMMUNOPRECIPITATION
Polyribosomes (lOjig), prepared as in section 2.6.2, were translated in vitro using a rabbit 
reticulocyte lysate kit (Dupont NEN Research Products) by a modification of the method 
reported by Hardwick et al, (1985). However conditions were optimised to give a maximal 
yield of translation products, resulting in a Ihr reaction period and an incubation temperature of 
26°C. Translation of yeast mRNA served as a positive control. Small aliquots (Ipl) of 
translation products were spotted onto Whatman Number 1 Biter papers, dried and precipitated 
with ice cold 7% (w/v) TCA (10-15min). The filter was dried and the radioactivity (i.e total
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incorporation) was determined in a liquid scintillation counter using Aquasol as scintillant. 
When 10p.l of L-[35S]-methionine was used, the total incorporation of radioactivity into 
translation products was about 2.0 x 106 cpm in a 50|il translation mix.
The remaining incubation mixture was boiled for 4min with 4% (w/v) SDS and then 
diluted with immunoprécipitation buffer (1% (v/v) Nonidet P-40, 0.15M NaCl, 2mM EDTA, 
0.5% (v/v) Aprotonin, lOmM Tris.HCl pH 7.4) such that the final SDS concentration was 
0.3% (w/v). Translation products were immunoprecipitated essentially as described by 
Anderson and Blobel, (1983) using 50pg of RLM6 antibody (IgG fraction) (Favreau et al, 
1987). The mixture was briefly vortexed and incubated at 4°C overnight. The 
immunoprecipitates were recovered by adding a 1:1 suspension of protein-A-sepharose CL-4B 
(Sigma) followed by rocking end to end for 45min (Ames aliquot mixer). The suspension was 
microfuged at full speed for Imin and the pellet washed with 3 x 1ml of immunoprécipitation 
buffer. Pellets were finally resuspended in 70jil of sample buffer containing 50mM phosphate 
and 25% (w/v) glycerol, boiled for 2min, spun down and the supernatant saved. This was 
repeated twice more to fully elute the antigen and antibody from immunoprecipitin. The 
supernatants were pooled and electrophoresed on a 9% SDS-PAGE gel (see section 2.3.4). 
The gels were stained and fixed in 10% (v/v) glacial acetic acid, 50% (v/v) methanol, 40% 
water and 0.25% (w/v) coomassie blue for 3hr and then destained in 15 % (v/v) isopropanol, 
10% (v/v) glacial acetic acid and 75% water. The gels were finally rinsed in water alone (2 x 
2hr) and then saturated with 1M sodium salicylate (Chamberlain, 1979). The gel was dried 
onto Whatman 3MM paper at 60°C for Ihr and exposed to film for fluography (see section
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The methods to isolate a diabetes-inducible P450'tgene'v (encoding the protein RLM6) have been 
based on methods not too dissimilar from those first used by Fujii-Kuriyama et al, (1981), 
when they isolated the very first cytochrome P450 cDNA. However in my case a 
monospecific antibody, raised against RLM6 was used to probe a Xgtll rat liver cDNA library.
3.1 WESTERN BLOT OF CONTROL LIVER MICROSOMES
To check that the primary antibody and the antibody detection system (see section 2.3.4) was 
functioning normally and to confirm that the RLM6 IgG was monospecific in its reaction with 
the Wistar albino rat colony at Surrey, I performed a Western blot on uninduced rat liver 
microsomes. The microsomes were isolated as described in section 2.3.2 and the blot 
performed as detailed in section 2.3.4. The results, shown in Figure 3.1 show an intense, 
single staining band. Unfortunately pure RLM6 protein was unavailable and therefore could 
not be used as a standard but the protein band observed exhibited the correct molecular weight 
! (approximately 53,500) for this P450 (Favreau et al, 1987).
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Figure 3.1. W estern blot analysis of control ra t liver microsomes using a 
polyclonal anti-RLM6 antibody
Microsomal protein (10|ig) was electrophoretically separated on a 10% SDS polyacrylamide 
gel, blotted onto nitrocellulose and probed with the rat anti-RLM6  IgG. Molecular weight 
standards are also shown
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3.1.1 Isolation of recombinant rat cDNA clones using the polyclonal anti- 
RLM6  antibody
The Xgtl 1 rat liver cDNA library was screened using the method detailed in section 2.4.2. 
From an initial screening of approximately 100,000 plaques, 6 positive clones were identified 
and isolated. Three of these clones which reacted most strongly with the antibody were further 
purified by another 2-3 rounds of screening. Phage stocks of the three recombinant purified 
clones were prepared as described in section 2.4.4 .
However, with the antibody detection system employed (see section 2.4.2) it is 
possible that some biotinylated ZT.co/z. or rat proteins expressed in the infected cells may be 
detected. Thus a false positive could be generated by the streptavidin-HRP complex reacting 
directly with the biotinylated protein. To show that the plaque purified recombinant cDNA 
clones were specific to RLM6 the following experiment was conducted. The recombinant 
phage were plated out as described in section 2.4.3, however when the filters were lifted from 
the bacterial lawn it was cut in two, with one of the halves exposed to the primary antibody and 
the other to TBST/BSA. After completing the remaining steps of the screening procedure, it 
was found that only the filter incubated with the primary antibody showed a positive signal 
(data not shown). This confirmed that the clones isolated were not false positives. A 
photograph of one of the final rounds of screening incubated with the primary antibody is 
shown in Figure 3.1.1.
3.1.2 Determination of the size of the three recombinant phage cDNA inserts
Phage DNA was prepared from the three recombinant plaque-purified clones as described in 
section 2.4.4. The cDNA inserts were released from Xgtll (see figure 2.2), by
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Figure 3.1.1 Isolation of recombinant phage plaques by immunoscreening with 
the anti-RLM6 IgG (3rd round of screening-all plaques positive)
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digesting the phage DNA with the restriction enzyme Eco RI and the digested material (15fig) 
was run on a 1% agarose gel. Figure 3.1.2 shows a photograph of the ethidium bromide 
stained gel and it clearly demonstrates that the cDNA inserts had been released. To determine 
the molecular weight of the individual cDNAs a graph was plotted of the migration of the X 
Hind m  digested DNA fragments from the origin, against their known molecular weight (semi­
log plot) (Figure 3.1.3). The molecular weight of the inserts were then interpolated from this 
standard graph and the results are tabulated in Table 3.1.
X Hind HI fragments Mobility (mm from origin) Size (Kbp)
A 10 23.31
B 11.1 9.48
C 12.3 6.56
D 13.8 4.36
E 18.1 2.32
F 19.2 2.02
G 34.5 0.56
Rat clone 1 25 1.1
Rat clone 2 25.6 1.05
Rat clone 3 28.5 0.85
Table 3.1: Determination of the size of the rat RLM6 cDNA inserts
The largest of the cDNA inserts isolated (Table 3.1) was approximately 1.1Kb and it was this 
particular insert that I concentrated on for further characterisation. I termed this cDNA insert 
RLM6-1 and will refer to this in the remainder of this results chapter.
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Figure 3.1.2: Digestion of plaque purified recombinant phage DNA with Eco RI
Phage DNA (15|ig) was digested overnight with the restriction endonuclease Eco RI and 
separated on a 1% agarose gel. Lanes 1 and 8  : X Hind III molecular weight markers (see 
Figure 3.3 for molecular weight details). Lanes 2, 4 and 6 : undigested phage DNA. Lanes 3, 
5 and 7: Eco RI digested phage DNA.
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Figure 3.1.3. Semi-log plot of the distance travelled by the X H in d  III  DNA 
fragments against their size
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3.2 ISOLATION AND CHARACTERISATION OF A X gtll RECOMBINANT 
(X RLM6-1) LYSOGEN
To further characterise the coding potential of cDNA RLM6-1 and to confirm that a cDNA 
corresponding to a diabetes-inducible gene had been isolated, a lysogen was prepared using 
RLM6-1 as detailed in section 2.4.6. In an initial experiment, 80 phage infected bacterial 
(Y1089) colonies were tested for temperature sensitive growth at 42°C and 32°C. The results 
of this showed that 30 out of the 80 colonies grew at the lower temperature giving a lysogenic 
frequency of 38%. Of these 30, one was picked at random and a crude bacterial lysate was 
prepared as detailed in section 2.4.7. A crude lysate was also prepared from a colony that did 
not grow at 32°C and used as a non-lysogenic control for this experiment. Figure 3.2 shows 
the results of a western blot performed on these crude lysates and it can be seen that the 
antibody to RLM6 recognises a protein band which has migrated to just above the p- 
galactosidase molecular weight marker. This is as one would expect because the protein 
produced by the lysogen is a fusion protein of P-galactosidase and part of the protein encoded 
by the cDNA insert. In lanes 2 and 3 a single band is not observed as one would expect using 
the monospecific antibody, but this is probably due either to overloading of the crude lysate 
I sample or to protein degradation. The different band intensities seen in Figure 3.2 may be a
consequence of the particulate nature of the bacterial crude lysate.
3.3 SUBCLONING OF THE RLM6-1 cDNA INSERT INTO THE PLASMID 
VECTOR pUC 19
To proceed with the characterisation I subcloned the RLM6-1 insert from the bacteriophage 
Xgtll to the plasmid pUC 19 as described in section 2.5.3. pUC 19 is a much smaller vector 
(2.6Kb) than Xgtll (43Kb). Thus with an insert to plasmid DNA ratio of 1:2 one is able to 
recover a substantial amount of insert DNA from a single plasmid DNA preparation. Two 
approaches were attempted in order to subclone the RLM6-1 cDNA insert. In the first instance,
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Figure 3.2 Western blot analysis of Y1089 bacterial crude lysates (RLM6-1 
lysogen)
Crude protein extract was separated on a 10% SDS polyacrylamide gel, blotted onto 
nitrocellulose and probed with anti-RLM6  IgG. Lane 1: E.coli Y 1089 (100p.g) infected with 
Xgtl 1 bacteriophage without RLM6-1 insert. Lanes 2-4: E.coli Y1089 (150,100,50p.g 
respectively) infected with recombinant (RLM6-1) Xgtll bacteriophage. Gal: Indicates the 
position of the p-galactosidase protein molecular weight marker.
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shotgun cloning was attempted, where the whole preparation (i.e Eco RI digested Xgtll and 
insert) was included in the ligations. Secondly and more successfully the 1.1Kb fragment 
was purified from a low melting point agarose gel (section 2.1.7) and directly ligated into pUC 
19. ,
3.3.1 Preparation of plasmid DNA and recombinant phage (X RLM6-1) DNA 
for subcloning
Plasmid pUC 19 DNA was prepared in bulk as described in section 2.5.2. The A26O/A28O 
absorbance ratio (a measure of purity) was routinely measured at 1.8-2.0 indicating that the 
plasmid DNA was of high purity. For subcloning, 15pg was digested overnight with the 
enzyme Eco RI and to confirm that the plasmid had been linearised, approximately 2jig was 
run on a 1% agarose gel. The enzyme was then removed from the remainder of the digest by 
phenol extraction followed by ethanol precipitation (see sections 2.2.2 and 2.2.3 respectively). 
A 20% loss of DNA accompanied this purification procedure (data not shown) and was taken 
. into account in subsequent calculations. The resulting pellet was resuspended in 1ml of water . 
to give an approximate final concentration of lOng Eco RI cut pUC 19 per pi of water.
Recombinant X RLM6-1 phage was prepared by the large scale method described in 
section 2.4.5. For shotgun cloning, 12p.g of RLM6-1 DNA was digested with Eco RI and a 
proportion (1/10 of the digest) was electrophoresed in 1% agarose to check that the insert had 
been released from the vector (Xgtll) arms. The remaining DNA was purified from the 
enzyme using phenol as above and the resulting DNA pellet resuspended in water to give a 
final concentration of 80ng/pl.
For direct cloning the insert was purified from the vector (Xgtl 1) using low melting 
point agarose gels (section 2.2.7). The insert DNA was diluted with water to give a final 
concentration of 35ng/pl
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3.3.2 Results of subcloning experiments
All attempts to shotgun clone the RLM6-1 insert into pUC 19 failed. I used a number of 
different ratios of pUC 19 : Xgtll/RLM6-1 DNA. Ratios of 1:1 and 3:1 actually gave a few 
white colonies, but when plasmid DNA was extracted from these colonies and subjected to Eco 
RI digestion, no insert was present (data not shown). This sometimes happens during the 
ligation process. Some nicking of the DNA around the Eco RI site in the vector can occur, 
rendering the (3-galactosidase gene non-functional and hence causing the appearance of a white 
colony.
Attempts to subclone RLM6-1 using the purified insert alone, were more successful. I 
calculated the DNA molar ratios using the following information:
DÜC 19
size 2.686Kb
molar ratio (approx) 1
Different amounts of plasmid to insert DNA were ligated and transformed into competent cells 
(see sections 2.5.3 and 2.5.4). The results of the first successful subcloning experiment are 
tabulated in Table 3.2.
All of the white colonies from plates 6, 10, 15, 16 and 17 were isolated and plasmid 
DNA was prepared (see section 2.5.1). When the plasmid DNA was cut with Eco RI only two 
of the suspected recombinant clones (from plate 15) gave a positive result. Figure 3.3 shows a 
photograph of one of these positive clones which has been digested with the restriction 
endonuclease Eco RI. It clearly demonstrates that in recombinant plasmid pRLM6-l the 
RLM6-1 insert is present within the vector pUC 19. In addition it is interesting to note from 
Table 3.2 that most of the white colonies were found on plates 15 and 16, indicating that the
Insert
1.1Kb
2
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Plate DNA Enzyme Molar Ratio Whites Blues
1 * NoDNA 0 0
2 * pUC 19 (lOrig) 1 200+
3 *pUC 19 (lOng) Eco RI 0 0
4 pUC 19 (lOng) Eco RI 2 32
5 pUC 19 (10ng)+RLM6-l (lOOng) Eco RI 1:20 0 1
6 pUC 19 (10ng)+RLM6-l (40ng) Eco RI 1:8 1 48
7 pUC 19 (10ng)+RLM6-l (lOng) Eco RI 1:2 0 46
8 *pUC 19 (30ng) 3 500+
9 *pUC 19 (30ng) Eco RI 0 0
10 pUC 19 (30ng)+RLM6-l (lOOng) Eco RI 1:3 2 230
11 pUC 19 (30ng)+RLM6-l (40ng) Eco RI 1:2.5 0 150
12 pUC 19 (30ng)+RLM6-l (lOng) Eco RI 1:0.6 0 48
13 *pUC 19 (50ng) 1 600
14 *pUC 19 (50ng) Eco RI 0 0
15 pUC 19 (50ng)+RLM6-l (lOOng) Eco RI 1:4 4 300
16 pUC 19 (50ng)+RLM6-l (40ng) Eco RI 1:1.6 3 200
17 pUC 19 (50ng)+RLM6-l (lOng) Eco RI 1:0.4 1 150
Table 3.2 Cloning strategy and results of direct subcloning of the RLM6-1 insert 
into pUC 19
* = No ligase included
Eco RI = Indicates that the plasmid had been linearised before ligation
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Figure 3.3 Digestion of recombinant plasmid DNA with Eco RI
Plasmid DNA was digested overnight with the restriction enzyme indicated and then separated 
on a 1 % agarose gel.
Lane 1: X Hind III molecular weight markers 
2: pUC 19 (200ng)
3: Uncut pUC 19 (3|ig)
4: Recombinant pRLM6 - l (3p.g)
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DNA ratios used were favourable for ligation. However it should also be pointed out that the 
plasmid DNA concentration was higher (50ng) in these ligations. The reason for the low white 
colony counts on the other plates was probably due to not enough pUC 19 DNA and that the 
wrong molar ratios were used.
3.3.3 Isolation of purified RLM6-1 insert
To further characterise the RLM6-1 cDNA at the gene level, and to see how it was modulated 
under different pathophysiological conditions, it was necessary to purify enough of the insert 
so that it could be used for radioactive labelling (thus as a molecular probe). Routinely, 
approximately 30|ig of purified pRLM6-l plasmid DNA (section 2.5.2) was digested 
overnight with Eco RI and run on a 1% low melting point agarose gel. The separated insert 
was purified by the method described in section 2.2.7 and a yield of approximately 10-12fig 
was recovered. Figure 3.3.1 shows a photograph of an ethidium bromide stained agarose gel 
which clearly shows the purified RLM6-1 insert at approximately 1.1Kb.
3.4 RESTRICTION ENZYME MAPPING OF THE RECOMBINANT PLASMID 
pRLM6 - l
Single enzyme digests {Bam HI, Eco RV, Pst I, Stu I and Ava I) were used to map the RLM6- 
1 insert. These enzymes were chosen because they either cut pUC 19 once {Bam HI, Pst I and 
Ava I) or not at all {Stu I and Eco RV). In addition I also analysed the published P450 HE1 
cDNA sequence (Song et al, 1986) using Microgenie™ software and found that these 
particular enzymes cut at specified positions along the whole length of the P450 HEl cDNA 
(Figure 3.4). If RLM6 and P450 HEl were similar then they might share some restriction 
endonuclease sites in common.
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Figure 3.3.1: Agarose gel electrophoresis of purified RLM6-1 insert probe
Lane 1: X Hind 111 DNA markers (as described in Figure 3.3)
2: 250ng purified RLM6-1 insert
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On digestion all of the enzymes cut the plasmid DNA except Stu I. Eco RV linearised the 
plasmid giving a single band at approximately 3.8Kb which indicated that it had cut the insert 
in only one position. Pst I gave two fragments of approximately 3.5Kb and 85bp which 
indicated that it had cut the insert once and also in the multiple cloning site of the plasmid 
(Figure 2.1). Ava I also gave two fragments, of approximately 3.1Kb and 700bp in length as 
did Bam HI, 2.8Kb and 800bp. These results when compared to the restriction maps of both 
pUC 19 and P450 HEl strongly suggested that an Eco RV, Bam HI, Ava I and Pst I site (see 
Figure 3.4) were conserved between the two genes.
3.5 SEQUENCING OF THE RLM6 cDNA INSERT IN THE PLASMID 
pRLM 6-l
3.5.1 Sequencing with the universal and reverse primers
Plasmid DNA sequencing was performed using the Sequenase procedures described in section 
2.5.5. However initial attempts proved unsuccessful since after autoradiography the gels 
showed bands of radioactivity present in a line across all 4 tracks. This indicated that either the 
plasmid DNA was not pure enough or that it had not been completely denatured. To correct 
this problem, I reprecipitated the plasmid DNA with ethanol without addition of salt (see 
section 2.2.3) and employed the method of Zhang et al, (1988) to denature the plasmid DNA 
(section 2.5.5). Sequencing gels were then run for varying lengths of time (either "short gels" 
for 2hr or "long gels" for 6-8hr) using both the universal and reverse primers in order to 
maximise the number of bases that could be resolved. Routinely, approximately 250bp were 
read in both directions for each sequencing reaction. The sequencing strategy used in this 
study is shown in Figure 3.5.
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/
Figure 3.4.1: Restriction endonuclease mapping of pRLM6-l
Single restriction enzyme digests were performed on pRLM6-l (3pg) as per the manufacturers 
instructions. The digests were run in a 1.2% agarose gel. Lane 1:1 Hind III molecular weight 
markers (see Figure 3.3 for details). Lane 2: Pst I. Lane 3: Ava I. Lane 3: Bam HI. Lane 4: 
Eco RV. Lane 6: Stu I. Lane 7: uncut pRLM6-1 (200ng).
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On a few occasions, some nucleotides could not be resolved due to compression 
artifacts. To overcome this problem a nucleotide analog (dITP) of dGTP was used in the 
sequencing reaction . dITP functions, by forming a weaker secondary structure with the DNA 
which allows it to be fully denatured (GC rich regions) during electrophoresis, thereby 
eliminating DNA compressions.
To obtain the first nucleotide of the RLM6-1 cDNA insert and thus to sequence close to 
the universal primer a few of the parameters detailed in section 2.5.5 were changed. The 
labelling mix which contained the cold nucleotides d l'IP, dCTP, and dGTP was diluted 1:15 
instead of 1:5 (see Sequenase™ manual) and the labelling and termination reactions were 
shortened from 5min-3min. These optimised conditions enabled the first nucleotide to be 
successfully resolved.
3.5.2 Further sequencing of the pRLM6 - l  cDNA insert using internal 
oligonucleotide primers
To continue the sequencing of the pRLM6-l cDNA insert two 20mer oligonucleotides 
homologous to the newly determined sequence were synthesised and purified as detailed in 
section 2.6.4.
1) CATTGCGGATATCCTCTTCA: to continue sequencing in the same strand as
the universal primer.
2) TTTAAACTTCTCTGGATCTG: to continue sequencing in the same strand as
the reverse primer.
Both oligonucleotides were diluted to a concentration of 5ng/|il and l|il was used for the 
sequencing reactions. Results were obtained at the first attempt and the remaining
9 6
undetermined sequence was resolved. All sequencing gels were run at least 3-4 times to 
confirm the sequence data.
3.5.3 Analysis of DNA sequence data
Nucleotide sequence data, compiled from the information described in sections 3.5.1 and 3.5.2 
was analysed and processed on an Olivetti M24 computer with the aid of the Microgenie™ 
software package. This revealed that the RLM6-1 cDNA contained an open reading frame of 
1092 nucleotides (Figure 3.5.1). When this sequence was compared to the published sequence 
of P450IIE1 (Song et al, 1986) it was found to be identical to bases 310-1402.
An interesting feature to emerge from the deduced nucleotide sequence of the RLM6-1 
cDNA was that it actually encompassed a Stu I recognition site, which I had originally thought 
from the restriction map (see Figure 3.4) was not present in the RLM6-1 sequence. I therefore 
repeated the Stu I enzyme digest with fresh enzyme known to cut other DNA (results not 
shown). However I obtained the same negative result as was described in section 3.4. I 
pursued this further and discovered that the Stu I recognition site (AGGCCT) is one of the few 
sites that is sensitive to dcrn méthylation. That is the bacterial host has the capability to 
methylate the internal cytosine residues of the Stu I recognition sequence rendering it non- 
susceptible to enzyme digestion. To overcome this I would have had to transform the 
recombinant plasmid into a dcm '  E.coli strain such as E.coli B.
3.6 FURTHER CHARACTERISATION OF THE RLM6  CLONE
3.6.1 Northern blot analysis
To ascertain the size of the complete mRNA encoding the protein RLM6, total RNA was 
isolated from diabetic and non-diabetic male rat livers (see section 2.6.5) and subjected to
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Figure 3.5.1: Nucleotide and deduced amino acid sequence for the RLM6-1 
cDNA
The RLM6 -1 sequence was determined by the dideoxy chain termination method as described 
in section 2.5.5. The deduced amino acid sequence is given in the single letter nomenclature 
below the nucleotide sequence.
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Northern blot analysis as detailed in section 2.6.5. The A26O/28O ratio of the RNA used was 
between 1.85 and 2.0, indicating it was of high purity. Following electrophoresis, the 
ethidium bromide stained gel, when placed under UV illumination showed two distinct bands 
in each individual lane (data not shown). The higher band corresponded to the 28S ribosomal 
RNA subunit and the lower band to the 18S ribosomal RNA subunit. The bands were narrow 
and little to no smearing was observed, indicating that the RNA had not been denatured during 
isolation. The visual inspection of the RNA under UV illumination also confirmed that the 
same amount of RNA had been loaded in each track. The autoradiograph from this experiment 
is shown in Figure 3.6. The blot shows a number of interesting points:
i) The size of the RNA is approximately 1.7Kb.
ii) RLM6 mRNA is increased several fold in diabetic animals compared to control
levels.
hi) There appears to be a single mRNA species of RLM6.
3.6.2 Southern blot analysis
As a further confirmation that RLM6 and HEl were the same gene and not very closely related 
members of a subfamily, genomic DNA was isolated from rat liver as detailed in section 2.6.2 
and subjected to Southern blot analysis (see section 2.6.6). Agarose gel electrophoresis of the 
DNA prior to restriction enzyme digestion indicated that high molecular weight genomic DNA 
had been isolated, with negligible degradation to smaller fragments (data not shown). 
Overnight, single digestions with the restriction enzymes Bam HI, Eco RI, Hind III and Pst I 
followed by gel electrophoresis yielded DNA that appeared as a smear on an agarose gel, 
indicating that DNA fragments of many sizes had been generated (data not shown). The 
digested material was transferred to nitrocellulose (see section 2.6.6) and hybridised with the 
32p-labelled RLM6-1 cDNA. A simple pattern of hybridisation was observed in each lane 
(Figure 3.6.1), not inconsistent with the presence of only one RLM6 family member in the rat.
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Figure 3.6: Northern blot analysis of total RNA isolated from control and 
diabetic rats
Total RNA (20{ig) isolated from control (Lane 1) and 2 week diabetic male rats (Lane 2) was 
denatured and electrophoresed on a formaldehyde-containing 1 .2 % (w/v) agarose gel, blotted 
onto nitrocellulose and hybridised with 3 2 P - l a b e l l e d  RLM6-1 cDNA. The filters were washed 
at high stringency (55°C and 0.1 x SSC) as described in section 2.6.8. Ribosomal RNA 
migration is shown (28S rRNA = 5Kb, 18S = 2Kb).
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Figure 3.6.1: Southern blot analysis of rat genomic DNA
Genomic DNA (30|ig) from a male Wistar rat was digested overnight with the enzymes 
shown, fractionated by electrophoresis in a 1 % agarose gel and blotted onto nitrocellulose. 
The filter was probed with 3 2 P-labelled RLM6-1 cDNA and washed (60°C and 0.1 x SSC) as 
indicated in Materials and Methods (section 2.6.8). X Hind III molecular weight markers are 
shown in the right hand side of the gel.
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3.7 THE EFFECTS OF DIABETES AND FASTING ON RLM6 mRNA LEVELS
3.7.1 Dot blot analysis
Dot blot analysis was performed with total RNA isolated from control and diabetic (4 day 
streptozotocin treatment) male rats as described in section 2.6.7. In a separate experiment, the 
same dot blot analysis was performed but this time on RNA isolated from control and fasted 
(48hr) male rats. RNA was quantitated by spectrophotometric readings at 260 and 280nm. 
The ratio A260/280 provides an estimate of the purity of nucleic acids. Pure RNA should have 
an A260/280 of about 2.0. Proteins have a peak at 280nm due to the contribution of aromatic 
amino acid residues and thus protein-contaminated samples of RNA will have a 260/280 ratio 
lower than 2.0. The A260/280 ratios of RNA used in this experiment were approximately 1.9 
indicating that the RNA samples were reasonably pure with little protein contamination. Using 
the RNA isolation procedure described in section 2.6.1, the RNA yield from a gram of frozen 
tissue was approximately 2.0mg. 50ng of RLM6-1 insert was labelled with 32P using the 
Multiprime DNA labelling kit and hybridised to the nitrocellulose filter as described in Materials 
and Methods. The results of the autoradiograph are shown in Figure 3.7, and clearly 
demonstrates that RLM6 mRNA levels are significantly increased not only by the 
pathophysiological state of diabetes but also in the normal rat by nutritional changes which alter 
the hepatic metabolic flux. It addition, it is worth noting that even in the control animals there 
is a basal level of RLM6 gene expression.
3.8 TISSUE DISTRIBUTION OF RLM6 mRNA
In section 3.7,1 demonstrated that RLM6 mRNA is expressed at a basal constitutive level in 
uninduced male rat livers. To characterise the expression of this gene in extrahepatic tissues, 
total RNA was extracted from the testis, kidney, small intestine and lung (as detailed in section
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Figure 3.7: Dot blot analysis of total RNA isolated from control, diabetic and 
fasted male rats
1 and lOpg of total RNA from control, diabetic and fasted male rats were applied directly onto 
nitrocellulose with a Hybridot filtration device, hybridised with the 3 2 P-labelled RLM6-1 probe 
and visualised by autoradiography. The filters were washed at high stringency (55°C and 0.1 
x SSC) as described in section 2.6.8. In this experiment and other dot blots such as Figures 
4.3 and 4.5 the actin probe was unavailable (see NOTE page 122) also only the RNA from one 
animal has been spotted in this blot, however identical blots from different animals were 
obtained but are not presented here.
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2.6.1) from a male control rat and subjected to Northern blot analysis (section 2.6.5).
The radioactive probe was made in exactly the same way as detailed in section 3.5.1 
and the autoradiograph of the hybridised filter is shown in Figure 3.8. In addition to the 
constitutive level of to the liver RNA, there was hybridisation to mRNA sequences in the 
kidney at approximately 10% of the level found in the liver. No mRNA sequences 
corresponding to RLM6 were detected in the testis, lung or small intestine RNA.
3.9 DETECTION OF RLM6  ORTHOLOGS IN DIFFERENT SPECIES
The antibody raised to RLM6 (see section 2.1.3) and the RLM6-1 cDNA (section 3.3.3) were 
used as probes to detect orthologous proteins and mRNA in liver samples from different 
species. The aim was to examine the basal level of P450 HEl expression in species of 
importance to the toxicologist.
3.9.1 Detection of protein sequences orthologous to RLM6  in human, dog and 
ferret
Humans: This work was carried out in Dr. J.B. Schenkman's laboratory at the University of 
Connecticut. Human liver microsomes, isolated from 10 different patients (identified as 1-10) 
were prepared and their protein concentrations determined by the methods described in sections
2.3.1 and 2.3.2 respectively. Complete patient histories were not known but patients 3 and 8 
were suspected alcoholics. A Western blot was performed on these microsomes the results of 
which are shown in Figure 3.9 and it shows a number of interesting points:
i) A single band is recognised in the human microsomes with the rat antibody.
ii) The human protein migrates at a slightly higher molecular weight (approximately Mr 
= 54,000) than the rat protein Mr =53,500).
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Figure 3.8 Northern blot of total RNA extracted from hepatic and extrahepatic 
tissues
Total RNA (20|ig) isolated from lung (Lane 1), kidney (Lane 2), liver (Lane 3), testis (Lane 4) 
and small intestine (Lane 5) was denatured and electrophoresed on a 1.2% (w/v) agarose gel 
containing formaldehyde, blotted onto nitrocellulose and hybridised with 3 2 P-labelled RLM6 -1 
cDNA. Only the hybridising region of the autoradiograph is shown.
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iii) There is a wide interindividual variation in the orthologous RLM6 protein levels 
expressed in humans.
The data shown in Figure 3.9 was quantitated using laser densitometry and is 
presented in Table 3.3. This data confirms that indeed the levels of RLM6 in humans are not 
constant and show quite a marked interindividual variation.
Ferret and Dog: (This was work performed in conjunction with Miss S Roffey and Mr J. 
Shavila, Department of biochemistry, University of Surrey). Microsomes from two control 
male dogs and three male ferrets were prepared as described in Methods and Materials. Figure
3.9.1 shows the Western blot analysis of dog microsomes and Figure 3.9.2 the blot performed 
with ferret microsomes. Rat liver microsomes isolated from uninduced, diabetic and insulin 
reversed diabetic animals were used as controls for the ferret experiment and uninduced rat 
liver microsomes for the dog Western blot. A notable feature which distinguishes these blots 
from the human blot (see Figure 3.9) is that the protein recognised by the rat RLM6 antibody in 
both the dog and ferret is of a lower molecular weight whereas in the human the protein was 
slightly larger than the rat protein.
3.9.2 Detection of mRNA sequences orthologous to RLM6  in marmoset, 
guinea pig and five different rat strains
This work was carried out in conjunction with Dr. J. Makowska (Department of Biochemistry, 
University of Surrey) who isolated total RNA from the livers of control marmosets, guinea 
pigs and 5 strains of rat. Dot blot analysis was performed on these RNA samples and the 
nitrocellulose filter was probed with 32P-labelled RLM6-1 cDNA . The washing procedure for 
the filters was as described in Materials and Methods (section 2.6.8) but the high stringency 
wash at 60°C was omitted. The results of this experiment as shown in the autoradiograph in
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Figure 3.9: Western blot of human liver microsomes using polyclonal anti-RLM6 
IgG
Microsomal protein (lOfig) and pure RLM6  protein (2 pmol) was electrophoretically separated 
on a 10% SDS-polyacrylamide gel, blotted onto to nitrocellulose and probed with the rat anti- 
RLM6  IgG. Lanes 1 and 12 : Pure RLM6  protein. Lanes 2-11 : Human microsomal samples 
(individuals 1 - 1 0 ).
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Lane Identification Area %
1 RLM6 2904
2 1 1177 38.5
3 2 1763 58
4 3 3033 1 0 0
5 4 1274 45
6 5 2275 75
7 6 2817 92
8 7 2240 74
9 8 2308 76
1 0 9 2460 81
1 1 1 0 1905 63
1 2 RLM6
Table 3.3: Quantitation of the human western blot data (Figure 3.9) by laser 
densitom etry.
The data in column 3 (Area) has arbitary units. To demonstrate the interindividual variation in 
cytochrome P450 ILEl content. Patient 3 (Lane 4) was taken to represent a maximum value (i.e 
100%)
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Figure 3.9.1: Western blot of dog liver microsomes using polyclonal anti-RLM6 
IgG
Microsomal protein (lOfig) was electrophoretically separated on a 10% SDS-polyacrylamide 
gel blotted onto nitrocellulose and probed with the rat anti-RLM6  IgG. Lane 1+2: uninduced 
dog microsomes. Lane 3: Control rat liver microsomes
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Figure 3.9.2: W estern blot of ferret liver microsomes using polyclonal anti- 
RLM6 IgG
The blot was performed as detailed in Figure 3.8.1. Lanes 1-3: Ferret microsomes (10p,g). 
Lane 4: Insulin treated diabetic rat liver microsomes (lOpg). Lane 5: Diabetic rat liver 
microsomes (lOjag). Lane 6 : Control rat microsomes (lOjag).
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Figure 3.9.3 clearly shows that P450 HEl-related sequences are recognised in these species. 
However the levels of RNA detected in the rat strains, do not appear to correlate directly with 
the amounts of RNA that were loaded and this is probably due to either inaccuracies in the 
measurement of total RNA or in the application of the samples to the Hybridot™ wells. To 
check this conclusively one would have to strip the P450 HEl probe off of the filter and re­
probe with an actin probe. As actin is a "housekeeping" protein it is assumed that the quantities 
of actin mRNA will remain constant per p.g of RNA and therefore an actin probe can be 
employed as a control to ensure that the amounts of RNA loaded onto the filter are the same.
3.10 DISCUSSION
In 1987 when I started my studies very little was known at the molecular level as to how 
individual P450 genes were modulated in the pathophysiological condition of diabetes. 
Therefore it was my intention to isolate and characterise the gene encoding diabetes inducible 
P450 RLM6 protein (Favreau et al, 1987), using antibody screening of a cDNA libraiy.
The specificity of the starting antibody was examined by Western blotting. This 
technique also provides information on the electrophoretic migration (Mr) of the antigen and the 
number of related but electrophoretically distinct antigens in a sample. The Western blot 
shown in Figure 3.1 showed a single staining band in agreement with the previous data of 
Favreau et al, (1987) and thus enabled me to use the RLM6 antibody to screen the Xgtll rat 
liver cDNA library. The initial round of immunoscreening resulted in the isolation of six 
; recombinant clones, three of which contained inserts ranging in size from 0.85-1.1Kb. Since 
previous reports had suggested that most cytochrome P450 cDNAs were approximately 2Kb in 
length (Hardwick et al, 1983, Friedberg et al, 1986 and Johnson et al, 1987), it was clear that I 
had probably not isolated a full length cDNA for RLM6. However I proceeded to characterise 
the largest of the cDNA inserts which I termed RLM6-1.
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Figure 3.9.3: Dot blot analysis of total RNA isolated from the liver of
marmoset, guinea pig and five different species of rat
0.1, 1, 5, 10 and 20 fig of total RNA from control liver of the species shown was applied 
directly on to nitrocellulose with a Hybridot filtration device, hybridised with the 2^ P-labelled 
RLM6-1 probe and visualised by autoradiography. The filters were washed at moderate 
stringency (55°C in 0.5 x SSC) as described in section 2.6.8.
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At this time (1987) it had been reported that the RLM6 protein was similar in a number 
of characteristics to the ethanol-inducible cytochrome P450 DEL Both isozymes efficiently 
metabolised aniline and were identical in at least their first 20 NH% terminal amino acids (Ryan 
et al, 1985 and Favreau et al, 1987). However these reports did not conclusively prove that 
RLM6 and DEI were identical proteins, or indeed that they were encoded by the same gene, 
and it was the restriction mapping data (Figure 3.4) and nucleotide sequence of the RLM6-1 
cDNA (Figure 3.6) which gave the strongest indication that the two genes were almost 
certainly identical. Indeed one would have expected that if the two proteins were very similar 
but encoded by different genes then there would have been some nucleotide differences 
between them, as has been reported for other very closely related cytochromes, which have
greater than 90% niRNA sequence identity, fbr example in the rat, the phenobarbital-inducible
genes IIB1 and IIB2 (Suwa gf a/, 1985), the pregnenolone 16a carbonitrile-induced genes 
m A l and mA2 (Gonzalez gf a/, 1986) and in the rabbit HC4 and HC5 (Johnson gf a/, 1987). 
Just recently Khani gf a/, (1988) have reported the appearance of two closely related P450 HEl
cDNA sequences in the rabbit, and in this case, there are only a few nucleotide differences 
between the genes, but they are spread evenly along the length of the gene. Therefore even 
although the RLM6-1 cDNA was not full length (approximately 70%) it was 100% identical to 
part of the P450 UE1 sequence and this is good evidence that they are probably the same gene.
Further evidence of the identity of RLM6 and P450 HEl comes from Southern blot 
analysis of rat genomic DNA. Use of either the P450 HEl probe (Song et al, 1986) or my 
RLM6-1 probe (Figure 3.5.2) gives a simple pattern of hybridisation with the restriction 
endonucleases (Bam HI, Pst I, Eco RI and Hind III) and leads to the conclusion that there is 
probably only one genomic sequence corresponding to these cDNAs in the rat. It should be 
noted that the hybridisation pattern for genomic DNA in my Southern blots using the RLM6-1 
cDNA probe is different from that reported by Song et al, (1986), because different size cDNA 
probes and different rat strains were used in the two studies.
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The Northern blot and dot blot analysis (Figures 3.6 and 3.7 respectively) performed in 
this study also agrees with the proposal that P450 HEl and RLM6 are the same gene. Shortly 
after I had shown that RLM6 mRNA levels were significantly increased in both diabetic and 
fasted animals over control levels, similar reports appeared in the literature for P450 HEl, 
(Song et al, 1987 and Hong et al, 1987), confirming my findings. All of the data mentioned so 
far leads to the conclusion that RLM6 and P450 HEl are the same protein, encoded by the 
same gene. For the remainder of this chapter and in the other results chapters I will now refer 
to RLM6 as P450 HEl.
The expression of P450 HEl mRNA level, has not been extensively studied in rat 
extrahepatic tissues. Ooi et al (1990) have detected the presence of putative DNA-protein 
transcriptional complexes of the P450 HEl promoter in the brain, but the majority of work in 
extrahepatic tissues has only reported the immunodetectable level of P450 HEl (section 1.3). 
In this study I have shown on Northern blot analysis that RLM6 mRNA is detected only in the 
kidney of control animals. Previously Thomas et al, (1987) examined both control and 
isoniazid treated male Long Evans rats and measured (by competitive ELISA) the extrahepatic 
cytochrome P450 HEl content in the kidney, lung and testis. They found that the kidney from 
control animals was the only extrahepatic tissue that contained a detectable level of cytochrome 
P450 HEl as indicated by Western blots . However P450 HEl expression was observed on 
Western blots in the lung, kidney and testis from isoniazid-treated male rats. In addition, the 
kidney P450 HEl content from control rats was significantly lower than that in the liver, which 
agrees with the mRNA data that I have presented. There would seem therefore to be a close 
correlation between the levels of HEl mRNA and protein in the extrahepatic tissues from 
control animals. However it would be interesting from the point of view of P450 HEl 
regulation, to repeat the Northern blot in my study with animals that have been treated with 
isoniazid or ethanol, to confirm that mRNA levels are also induced. This experiment has been 
conducted in the rabbit (Porter et al, 1989) where P450 HEl mRNA were detected in the 
kidney and nasal mucosa (at approximately 10% of the level found in the liver) and in the lung
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(at approximately 5% of the level found in the liver). The gene was not expressed in testis or 
the small intestine and when rabbits were treated with imidazole or acetone there was no 
significant corresponding increase in P450 IIE1 mRNA in either the kidney or liver, even 
although protein levels were significantly increased.
The use of antibodies to detect and isolate specific P450 counterparts in other animal 
strains and species has been widely used (Kloepper-Sams et al, 1987 and Wrighton et al, 
1987). I have employed the rat antibody to P450 HEl to examine humans, dogs and ferrets.
A strong specific recognition by the polyclonal antibody to P450 HEl of a single protein band 
was observed in the human and dog microsomal samples, indicating the presence of a P450 
HEl counterpart. In the ferret the signal was much weaker but still a single protein band was 
observed, suggesting that the polyclonal antibody was recognising an epitope common to both 
proteins.
The Western blot of the human microsomes (Figure 3.8) is of particular interest as it
shows that P450 HEl is constitutively expressed in all livers that were studied. This is in
agreement with the results of the literature. For instance Wrighton et a/, (1986) found P450
HEl in 19 out of 20 livers from kidney transplantation donors, Yoo et al, (1988) reported the
presence of this isozyme in all 16 human liver samples examined and Raucy et al, (1987) found
this isozyme in all 9 livers tested. In the 10 human microsomal samples studied here a wide
interindividual variation of P450 HEl levels was observed, coupled with the range of
compounds metabolised by this enzyme, it is of some importance to understand the causes of
such variations. In Figure 3.8 the highest levels of P450 HEl were found in patient 3, a
suspected alcoholic and it would therefore seem likely that ethanol plays a role in modulating
(Wrighton et al, 1986)
P450 HEl levels in humans/as it does in rats (aohg et al, 1986). The larger molecular weight 
of human P450 HEl (shown in Figure 3.8) has been reported previously (Wrighton et al, 
1987, Lasker et al, 1987 and Ekstrom et al, 1989). To my knowledge there have been no : 
reports of a P450 HEl counterpart in the dog or ferret to date. This is an important 
observation as both species are non-rodents which are used by pharmaceutical companies to
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test new drug formulations. Therefore it is useful to know which P450s are constitutively 
expressed in these animals as it could have an effect on how the drugs are metabolised.
I have also shown here that P450 IIE1 is constitutively expressed in laboratory rats. 
This constitutive expression of cytochrome P450 HEl is important since it is involved in the 
metabolism of exogenous compounds of physiological and toxicological relevance such as 
paracetamol, nitrosamines and ethanol (see Figures 1.5 and 1.6).
The detection of homologous gene sequences to P450 HEl in the marmoset, guinea 
pig and the different rat strains shown in Figure 3.8.3 is also indicative of a close structural 
homology of P450 HEl counterparts in these animal species. A dot blot analysis was also 
performed on total RNA isolated from the digestive gland of the common Mussel (Mytilis 
edulis), but even at low stringency (the final wash was 55°C in 1 x SSC/0.1% (w/v) SDS for 
45min) there was no detectable signal observed on autoradiography (data not shown). These 
results support the idea that P450 HEl like the whole P450II gene family has evolved from a 
relatively recent set of gene duplication events (Gonzalez, 1989). It is thought that the reason 
for the increase in the numbers of P450 genes during the past several hundred million years 
and in particular the P450 H family was the emergence of aquatic vertebrates onto land and the 
consequent change in their diet where they had to cope with plant toxins (Nelson and Strobel, 
1987). Taking this into account, it is not surprising that a mRNA signal for P450 HEl was not 
picked up using a rat probe in the mussel.
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In the last chapter I demonstrated that RLM6 and P450 HEl are probably the same protein 
encoded by the same gene. Song et al, (1986) have suggested that this gene is regulated by 
two different post-transcriptional mechanisms, namely mRNA stabilisation (Song et al, 1986) 
and protein stabilisation (Eliasson et al, 1988), depending on the inducing stimulus (see Figure 
1.7). However this has not been confirmed by other workers and I therefore decided to 
examine the regulation of P450 HEl mRNA levels by hormones.
4.1 EFFECT OF INSULIN ON THE DIABETIC MALE RAT
4.1.1 Modulation of body weight and serum glucose
In an initial study (experiment 1), seven, Charles River male rats (7 weeks old) were given a 
single dose (65mg/kg) of streptozotocin as described in section 2.1.8. Diabetes was allowed to 
develop for 10 weeks, after which time the animals were supplemented with insulin over a time 
course of 72hr. The insulin dosing regime was 1 Unit of human insulin at 7am, 1 Unit at 
12.00pm and 3 Units at 5.00pm. Animals were sacrificed at 6, 12, 24, 48 and 72hr after the 
first insulin dose. Control (non-insulin treated) rats (diabetic and non-diabetic) were sacrificed 
at Ohr just before the first insulin dose. Total RNA was prepared from the liver at the indicated
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ANIMAL Body weight 
(g)
Serum glucose 
(mg/dl)
RNA purity
A260/280
Control 548 161 1.50
Diabetic 285 ND 1.49
Diabetic + Insulin (6hr) 230 ND 1.44
Diabetic + Insulin (12hr) 287 699 1.40
Diabetic + Insulin (24hr) 272 889 1.50
Diabetic + Insulin (48hr) 290 949 1.53
Diabetic + Insulin (72hr) 207 937 1.66
Table 4.1 Experiment 1, body weight, serum glucose concentration and RNA 
purity (A260/280 ratios)
ND = not determined
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time intervals and upon sacrifice, blood was collected and serum prepared as detailed in 
section 2.3.5. The difference in body weight (Table 4.1) between the control (non-diabetic) 
and diabetic animals was striking (approximately double) indicating that the animals were 
diabetic. In spite of polyphagia (increased appetite), observed in diabetic animals the disease is 
associated with weight loss. This is because the majority of peripheral tissues cannot utilise the 
high circulating levels of glucose and thus, to maintain energy supplies, proteins and fats are 
metabolised. On insulin treatment, the animals did begin to significantly gain more weight 
(data not shown) which was also indicative that insulin was reversing the metabolic effects of 
diabetes. Insulin increases the uptake of glucose into the peripheral tissues, thus inhibiting the 
metabolism of protein and fats, preventing weight loss.
Blood samples which were used for glucose determination were collected at 7am (24 
and 48hr) and 7pm (12 and 72hr). However the serum glucose concentration of the insulin 
treated diabetic animals seemed to contradict their gain in body weight, with very high values 
compared to the control (Table 4.1).
It was assumed that possibly the insulin dosing regime was not as effective as it could 
be in controling serum glucose concentrations and therefore the experiment was repeated and a 
different dosing regime was employed. In this study (experiment 2), two rats were sacrificed 
at each time point (as in Table 4.1) and in addition another 3 animals were given insulin for a 2 
week period. At the commencement of insulin treatment, the animals had been diabetic for 12 
weeks. The insulin dosing regime was as follows: 1 Unit at 7am, lUnit at 12.00pm and 6 
Units at 5.00pm. Serum glucose concentrations for the 2 week insulin reversed animals were 
determined on blood collected 4hr after the morning insulin injection. In this latter group of 
animals the levels of blood glucose were considerably lower than that observed over the time 
course (Table 4.2). The reason for this and the results seen in experiment 1 is probably 
reflected in the time of blood collection, for, in both experiments over the time course, animals 
were sacrificed at times when the effects of the insulin dose were either wearing off (7am) or 
before the insulin could take its full effect (7pm).
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Animal Body weight 
(g)
Serum glucose 
(mg/dl)
RNA purity
(A260/280)
Diabetic + Insulin (6hr-A) 228 484 1.50
Diabetic + Insulin (6hr-B) 264 650 1.77
Diabetic + Insulin (12hr A) 280 530 1.70
Diabetic + Insulin (12hr-B) 377 367 1.83
Diabetic + Insulin (24hr-A) 336 789 1.62
Diabetic + Insulin (24hr-B) 299 736 1.63
Diabetic + Insulin (48hr-A) 342 794 1.49
Diabetic + Insulin (48hr-B) 230 865 1.80
Diabetic + Insulin (72hr-A) 363 702 1.78
Diabetic + Insulin (72hr-B) 254 755 1.48
Diabetic + Insulin 2wk-l 262 704 1.45
Diabetic + Insulin 2wk-2 333 147 1.41
Diabetic + Insulin 2wk-3 275 118 1.50
Table 4.2: Experiment 2, body weight, serum glucose concentration and RNA 
purity (A260/280 ratios)
; The wide variation in serum glucose concentrations observed here and in Table 4.4 probably
i
reflects the variation in the efficiency of the sub cutaneous injection.
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NOTE: The use of actin probe in this experiment clearly indicates that problems can arise in the 
loading of mRNA for the dot blots. This may be due to the measurement of purified RNA 
concentration or subsequent degradation to mono or oligonucleotides that pass through the 
filter. Thus as mentioned previously experiments where actin probing has not been used 
atypical alterations in RLM6 levels should be treated with caution.
4.1.2 Insulin modulation of cytochrome P450 IIE1 mRNA
Dot blot analysis was performed on total RNA, which had been isolated from individual 
animals in experiments 1 and 2, the filter was probed with 32P-labelled RLM6-1 probe and the 
results of the autoradiograph shown in Figure 4.1. The nitrocellulose filter was stripped of the 
radioactive RLM6-1 probe by three-four sequential washes in distilled water at 95°C (30min).
Filters were checked for radioactivity (<3cps) initially with a Geiger counter and then by 
autoradiography over a 3 day period to verify that all/most radioactive probe had been removed 
(data not shown). The filter was then re-probed with 32P-labelled actin cDNA and the results 
of this blot are also shown in Figure 4.1. P450IIE1 mRNA levels decrease rapidly in the 
initial 12hr of insulin treatment followed by a gradual decrease over the remainder of the 14 day 
: period to levels just below that seen in control animals. The actin data in general showed that 
; in experiment 1 (12 and 24hr) more than 5fig of RNA was loaded also in other wells there 
j appears to be less than 5|ig loaded. However the results (Figure 4.1) do confirm that RLM6 
| mRNA levels are decreased within 6hr of insulin treatment.
4.1.3 Effect of insulin on serum acetone levels
In parallel with the analysis of changes in P450 HEl mRNA levels, serum acetone 
concentrations were determined from blood serum, that had been collected from the same 
animals used in experiments 1 and 2, by the methods described in section 2.3.5. As shown in 
Table 4.3, streptozotocin-induced diabetes elevated the serum acetone concentrations 58.6 fold 
over the control value. These elevated levels dropped rapidly after 6-12hr of insulin treatment, 
returning to approximately control levels following 14 days of continuous insulin treatment. 
Thus, the rise in P450 HEl mRNA level in the diabetic state, and its reversal by insulin noted 
previously, is accompanied by similar changes in serum acetone concentrations.
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Figure 4.1 Effect of insulin on RLM6 mRNA level in diabetic rat liver
RNA (5|ig) was applied directly on to nitrocellulose with a hybridot filtration device, 
hybridised with the 3 2 P-labelled RLM6-1 cDNA probe and visualised by autoradiography.
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TREATMENT SERUM ACETONE 
(mM)
Control 0.07 ± 0.03
Diabetic 4.10 ±2.26
Diabetic + Insulin (6hr) 5.94 (n=2)
Diabetic + Insulin (12hr) 0.49 ± 0.35
Diabetic + Insulin (24hr) 0.59 ±0.10
Diabetic + Insulin (48hr) 0.75 ± 0.36
Diabetic + Insulin (72hr) 0.87 ± 0.49
Diabetic + Insulin (2 week) 0.28 ±0.19
Table 4.3: Serum acetone concentrations during insulin reversal of diabetic rats
The results are expressed as mean ± S.D. from 3 rats (experiments 1 and 2) in each group 
unless otherwise stated
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4.2 EFFECTS OF STREPTOZOTOCIN-INDUCED DIABETES AND INSULIN 
REVERSAL IN FEMALE RATS
Previous work has concentrated on the male rat Here I present results to examine cytochrome 
P450 HE 1 modulation in the female rat.
4.2.1 Changes in body weight and serum glucose
Twelve female Charles River, CD rats (eight weeks old) were grouped into the following 
groups, 4 controls (C1-C4), 4 diabetics (D1-D4) and 4 insulin-reversed diabetics (D+Ii- D+I4). 
Diabetes was induced with a single (i.v) tail vein injection of streptozotocin (65mg/kg) and 
allowed to develop for 4 weeks. At 2 weeks post dose, insulin dosing was started on the 
animals designated D+I1-D+I4. The daily dosing schedule was 1 Unit at 8.00am and 4 Units 
at 5.00pm and was continued over a 14 day period. The body weights of the diabetic animals 
did not increase significantly when compared to the control animals (Table 4.4). In addition, it 
was only after insulin was administered to the diabetic rats (D+I1-D+I4) that they began to gain 
weight and this was reflected in their weights at death compared with the diabetic animals. As 
with the male rats, this was a good indication that the animals were diabetic and also that the 
insulin was having the desired metabolic effect. Animals in all treatment groups were killed by 
decapitation 4hr after the a.m. insulin dose on the 14th day. Blood was collected from the neck 
and serum was prepared as detailed in section 2.3.5. Diabetic serum was observed to be 
cloudy in all four samples (D1-D4), indicating the presence of triglycerides and chylomicrons, 
whereas the control and insulin treated groups had clear sera. This result together with the 
doubling of the serum glucose concentration in diabetic animals (Table 4.4) was confirmatory 
evidence to the weight gain/loss (Table 4.4) that the animals were indeed diabetic and that the 
insulin dosing regime was effective.
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A)
Animal Starting weight
(s)
End weight 
(g)
Body weight 
gain (g)
Serum glucose 
(mg/dl)
Control (Ci) 203 264 61 152
Control (C2) 191 249 58 150
Control (C3) 191 252 61 170
Control (C4) 193 253 60 175
Diabetic (Di) 189 196 7 499
Diabetic (D2) 199 207 8 512
Diabetic (D3) 203 205 2 539
Diabetic (D4) 203 207 4 569
Diab+Ins (D+Ii) 200 222 22 593
Diab+Ins (D+I2) 204 242 38 109
Diab+Ins (D+I3) 200 235 35 77
Diab+Ins (D+I4) 205 235 30 94
B)
Animal Body weight gain (g) Serum glucose (mg/dl)
Control 60 ± 1 161 ±12
Diabetic 5 ±3*** 529 ± 31***
Diabetic + Insulin 31+ 7*** 218 ±250
Table 4.4: Body weight gain/loss ratio and serum glucose concentration in 
control, diabetic and insulin-treated diabetic female rats
A) Data on the individual animals. B) Values are the mean ± S.D of the four individual 
animals, shown in Table 4.4A, using the students t-test, P values for results significantly 
different from control data at ***P<0.001.
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4.2.2 Isolation of microsomes, determination of P450 specific content and 
Western blot analysis
Microsomes were prepared from each of the three groups [Control (C), Diabetic (D) and 
Diabetic + Insulin (D+I)] by the methods described in section 2.3.2 and the protein 
concentration and specific P450 content determined (see sections 2.3.1 and 2.3.3 respectively). 
The results are tabulated in table 4.5. It can be seen that there is an approximate 90% increase 
in the P450 specific content of diabetic microsomes over control values (PcO.OOl, using 
students t-test). Insulin treatment reversed this induction of P450 specific content to levels 
comparable to those observed in the control female rats.
Microsomes, isolated as above, were pooled from all four animals in each group and 
Western blot analyses performed. The results (Figure 4.2), mimicked the specific content 
levels observed in Table 4.5, with a significant increase in P450 HEl protein levels in diabetic 
liver microsomes and with insulin once again reversing this induction. The appearance of a 
smear above the IIE1 band and a lower Mr band is probably due to over development of the 
Western blot. Some lower Mr bands can also be seen in other overdeveloped blots such as 
Figure 4.6. Whilst it is possible that the antibody may pick up other non-specific peptides an 
alternative explanation is that the additional bands are specific degradation products of TIFT
4.2.3 Isolation of total liver RNA
Total RNA was prepared as described in section 2.6.1, from 0.5g segments of tissue using the 
same animals as in the previous experiment (section 4.3.1). Dot blot analysis was carried out 
and the autoradiograph of this blot is shown in Figure 4.3. RNA was prepared from one 
animal in each group (control, diabetic and diabetic plus insulin) and had A26O/28O RNA ratios 
of 1.31, 1.32 and 1.36 respectively. These values were quite low suggesting that there was 
some protein contamination. Unfortunately in this particular experiment there was not enough 
material to re-precipitate the RNA therefore it was not possible to purify it further.
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A)
Animal Total cytochrome P450 
specific content (nmol/mg)
Control (Ci) 0.68
Control (C2) 0.59
Control (C3) 0.68
Control (C4) 0.69
Diabetic (Di) 1.31
Diabetic (D2) 1.20
Diabetic (D3) 1.34
Diabetic (D4) 1.19
Diabetic 4-Insulin (D4-I1) 0.75
Diabetic 4-Insulin (D4-I2) 0.66
Diabetic 4- Insulin (D4-I3) 0.56
Diabetic 4- Insulin (D4-I4) 0.68
B)
Animal Total cytochrome P450 specific content (nmol/mg)
Control 0.66 ±0.04
Diabetic 1.26 ±0.07***
Diabetic 4- Insulin 0.66 ± 0.08
Table 4.5: Cytochrome P450 changes following streptozotocin-induced diabetes 
and insulin reversal of diabetes in female rat liver microsomes
A) Data on individual animals. B) Values are the mean ± S.D. of the four individual animals 
shown in table 4.5 A, using the students t-test P value for results significantly different from 
control data at ***P<0.001.
128
Lane 1 2 3
Figure 4.2: Western blot of female rat liver microsomes using polyclonal anti- 
RLM6 IgG
Microsomal proteins (lOpg) were electrophoretically separated on a 10% SDS-polyacrylamide 
gel blotted onto nitrocellulose and probed with the rat anti-RLM6  IgG. Lane 1 : control. Lane 
2: diabetic and Lane 3: diabetic plus insulin.
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I control diabetic
diabetic+insulin
Figure 4.3: Dot blot analysis of total RNA isolated from control, diabetic and 
diabetic plus insulin treated female rats
5 jig of total RNA from control, diabetic and diabetic plus insulin treated female rats were 
applied directly onto nitrocellulose with a Hybridot filtration device, hybridised with the 32p_ 
labelled RLM6-1 probe and visualised by autoradiography. The data presented shows just one 
concentration, however various concentrations were loaded on the original blot (data not 
shown).
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The cytochrome P450 HEl mRNA levels mirrored the observed protein changes with a 
noticeable increase in the diabetic animal and a reversal of this induction by insulin, thus 
confirming that the modulation of DEI by insulin in the female is also at the mRNA level.
4.3 EFFECT OF TESTOSTERONE ON CYTOCHROME P450 IIE1 IN THE 
DIABETIC MALE RAT
Streptozotocin-induced diabetes is accompanied by a substantial drop in serum testosterone 
levels in the rat (Murray et al, 1981). It was of interest therefore to examine the influence of 
testosterone treatment on the regulation of P450 IIE1 expression in the diabetic male rat and 
comparison to that observed with insulin treated rats
4.3.1 Effect of testosterone on cytochrome P450 HE I mRNA levels
Total RNA and polysomal RNA were prepared from the livers of four control, diabetic, 
diabetic plus testosterone and diabetic plus insulin male rats as detailed in section 2.6.1. 
Diabetes was induced and allowed to develop over 12 weeks as described in section 4.1. At 10 
weeks, the testosterone and insulin treatments were commenced for 14 days, the details of 
which are given in section 2.18 and 4.1 respectively. Dot blot analysis was performed on both 
total and polysomal RNA in two separate experiments, and the resulting autoradiographs, after 
probing the nitrocellulose filter with 32P-labelled RLM6-1 are shown in Figures 4.4 and 4.5 
respectively. There is a clear indication from both blots that testosterone treatment of diabetic 
animals results in a partial reversal of the diabetes-induced elevation of P450 HEl mRNA but 
one does not see the almost full reversal observed in the insulin treated group (Figure 4.5). 
The dot blot of total RNA was stripped of the ELM6-1 probe and re-probed with 32P-labelled 
actin cDNA. This demonstrated that the amounts of RNA loaded in each well were similar.
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D+T #
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Figure 4.4: Dot blot analysis of total RNA isolated from control, diabetic and 
diabetic plus testosterone treated male rats
Total RNA from control (C), diabetic (D) or diabetic plus testosterone (D+T) treated male rats 
were pooled from 4 animals and dot blot analysis (5jig RNA loaded) was carried out with the 
RLM6-1 cDNA probe (left hand panel), or actin cDNA probe (right hand panel).
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Figure 4.5: Dot blot analysis of polysomal RNA isolated from control, diabetic, 
diabetic plus testosterone and diabetic plus insulin treated male rats
Polysomal RNA from control (C), diabetic (D), diabetic plus testosterone (D+T) and diabetic 
plus insulin (D+I) treated rats were pooled from 4 animals. Dot blot analysis (10, 5 and Ipg 
RNA loaded) was performed with the RLM6-1 cDNA probe.
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and thus the decrease in P450 HEl mRNA levels observed in the testosterone treated group 
was specific.
4.3.2 M odulation of cytochrome P450 IIE1 levels by testosterone in the 
diabetic rat
Microsomes were prepared from the same livers as described above (section 4.4.1) and a 
Western blot was performed. The results shown in Figure 4.6 are similar to those observed 
with the RNA dot blots (figures 4.4 and 4.5), where, an increase in P450 IIE1 protein in 
diabetes and its reversal to control levels by insulin was observed. In addition, the testosterone 
treated diabetic animals showed a decrease in P450IIE1 level as was seen with the RNA data 
(Figures 4.4.and 4.8). As was observed with Figure 4.2 the blot was overdeveloped and the 
lower Mr bands are most likely degradation products of cytochrome P450 HEl.
4.3.3 M easurem ent of cytochrome P450 H E l mRNA levels by in vitro 
translation and immunoprécipitation
In order to confirm the dot blot analysis shown in Figure 4.5, I decided to use in vitro 
translation followed by immunoprécipitation of the translated products (using polyclonal anti- 
RLM6 IgG), to re-examine the effects of testosterone on P450IIE1 mRNA levels in diabetic 
animals. This was felt necessary in order to gain further insight as to whether the observed 
decrease in HEl mRNA correlated directly with the decrease in protein synthesis.
Optimisation of RNA translational activity in the rabbit reticulocyte system: The main criteria 
for any translation system are low levels of endogenous mRNA, the requirement for low 
concentrations of radiolabelled amino acid and efficient and reproducible translation of added
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Lane 1 2  3 4
Figure 4.6 W estern blot analysis of microsomes derived from testosterone 
treated diabetic animals using polyclonal anti-RLM6 IgG
The blot was performed as detailed in the legend to Figure 4.2. Microsomes were derived 
from the following treatments: Lane 1: control. Lane 2: diabetic. Lane 3: diabetic plus 
testosterone. Lane 4: diabetic plus insulin.
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mRNA. The system used in this study was a commercially available kit supplied by NEN 
Research Products (see section 2.7). An important criterion for the successful translation of any 
RNA is the salt concentration. In all translations performed, the concentration of magnesium 
and potassium ions used were as recommended by the manufacturer. However the effect of 
RNA concentration, temperature and incubation time were investigated on in vitro synthesis 
using both total and polysomal RNA. In early pilot studies, where RNA preparations were 
used which had an A26O/28O ratio of less than 1.8 a marked inhibition of translation was 
observed as the amount of RNA was increased (data not shown). This was probably due to 
the presence of small amounts of residual ethanol remaining from the RNA isolation procedure. 
Ethanol is a known inhibitor of the in vitro translation system (NEN translation kit catalogue). 
In subsequent experiments with polysomal RNA (A26O/28O ratios >1.8) which had been 
properly dried and resuspended in distilled water, a linear increase in translational activity was 
observed, with increasing amounts of polysomal RNA (Figure 4.7A), and 10p,g was used in 
all subsequent translations. Using this constant amount of RNA (10|ig) a time course for the 
reaction over 60min was performed. The results of the kinetic curve are shown in Figure 4.7B 
which shows a linear increase in translational activity up to about 50min . Accordingly, all 
translations were carried out for 60min to achieve maximum translation.
The in vitro translation experiments were performed at 26°C and not at 37°C as 
recommended by the manufacturers, as a higher incorporation of TCA precipitable counts 
was obtained at this lower temperature (data not shown). Although the initial reaction rate is 
faster at 37°C there is a greater tendency for the translational system to shut down earlier, 
resulting in the synthesis of only low molecular weight polypeptides. In addition, if the RNA 
preparation had been contaminated in any way by ribonucleases or proteases, incubation at 
25°C reduces the extent of degradation.
In every translation experiment, controls were run in parallel with the tests, and 
included a negative control (-RNA) and a positive control (yeast RNA, supplied with the kit). 
The "blank" (-RNA) routinely produced some labelled protein but this was to be expected due
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NOTE: Although 60min incubation period was non-linear. I decided to further use this time 
period to maximise incorporation. It should be noted that the 60min time point is nearly linear 
and would not drastically alter subsequent conclusions.
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Figure 4.7: The effect of liver RNA concentration and incubation time on total in  
vitro protein synthesis
The data points in both graphs represent single determinations. A: Effect of RNA 
concentration. B: progress curve.
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to residual endogenous message which had not been destroyed completely by the nuclease 
treatment of the lysate. The translated yeast RNA produced comparable counts per minute/fil 
as reported by the kit manufacturers (data not shown).
In vitro translation of polvsomal RNA: Polysomal RNA which had been isolated in the dot 
blot experiment shown in Figure 4.5; was translated in vitro using the optimised conditions 
described above; the translation mixture was scaled up to 58|il and the total TCA precipitable 
counts were determined (data not shown). There was no significant difference in the efficiency 
of incorporation of radioactivity into total TCA-precipitable products using equivalent amounts 
of polysomal RNA from the different experimental groups, indicating that the diabetic 
condition did not affect the total translational efficiency of the system.
Quantitation of the translated products by immunoprécipitation: The immunoprécipitation 
protocol used involves two main steps. First, specific antibody is added to a detergent- 
treated cell lysate containing the synthesised radiolabelled antigen. Next, the complex of 
labelled antigen and antibody is bound to a second agent that provides sufficient mass to 
facilitate precipitation. In this study, monospecific polyclonal anti-RLM6 IgG was the specific 
antibody employed and protein A-sepharose CL-4B was the second agent. The second agent 
usually is anti-immunoglobulin antibody directed against the primary antibody but the use of 
protein A has a number of advantages. It has a high binding specificity to the Fc regions of 
many IgG subclasses and it behaves like an immunosorbent, possessing a high adsorbtion 
capacity and rapid binding, which permit the specific recovery of antigen from cell lysate 
simply by centrifugation.
Figure 4.8 shows the resulting fluorogram of the immunoprecipitated in vitro 
translation products from control, diabetic, diabetic plus testosterone and diabetic plus insulin 
treated male rats. The translation products were immunoprecipitated with 0.9|ig IgG/jil
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Figure 4.8: Effect of diabetes, insulin-reversal and testosterone on P450 IIE1 
mRNA-directed protein synthesis
Liver polysomal RNA (lOpg) was used to program a rabbit reticulocyte protein synthesising 
system and 2 x 106 cpm from each translation mix was immunoprecipitated with RLM6 
antibody (0.9(1g/|il reaction mix) and protein A-sepharose CL-4B (1:1 suspension). The 
immunoprecipitates were run on SDS-PAGE and visualised by fluorography. Polysomal RNA 
was derived from either control (Lane 1), diabetic (Lane 2), diabetic plus insulin (Lane 3) and
diabetic plus testosterone (Lane 4) treated male rats. Since the immunoprécipitation method 
used (Andersson and Blobel, 1983) results in almost complete antigen precipitation the 
amounts of IIE1 precipitated can be taken as a direct measure of translatable HEl polysomal 
RNA.
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reaction mixture using the method detailed in section 2.7. The Fluorogram showed a single 
band in all four tracks with a molecular weight of about 53k, this is comparable to the known 
molecular weight of P450 HEl of 53.5k (Favreau a/, 1987). The observed difference in 
molecular weight (0.5k) is probably due to the running of the molecular weight markers. 
Given the known specificity of the polyclonal antibody preparation, namely that it does not 
recognise any other microsomal proteins besides P450 HEl near this molecular weight it is 
concluded that the band represents labelling of rat HEl protein. Figure 4.8 also shows that 
diabetes induces the amount of P450 HEl translatable mRNA which can be significantly 
reversed by both testosterone treatment and insulin treatments. These results are in agreement 
with those obtained in section 4.4.
4.4 DISCUSSION
Expression of the majority of both eukaryotic and prokaryotic genes is regulated primarily at 
the level of mRNA transcription. However the phenomenon of regulation via mRNA turnover 
has also been recognised for some time (for a review, see Brawerman, 1987).
With respect to the superfamily of cytochrome P450 genes, most genes are regulated at 
the transcriptional level. However cytochrome P450 HEl mRNA appears to exhibit mRNA 
stabilisation, at least in the diabetic rat (Song et al, 1987). This cytochrome is by no means 
unique in this respect, as Boggaram et al, (1989) have recently shown, that treatment of bovine 
adrenocortical cells in primary culture with adrenocorticotrophic hormone results in the 
accumulation of cholesterol side chain cleavage P450 mRNA, resulting in a five fold increase 
in the half life. This effect is also thought to be involved in the regulation of cytochrome P450 
IHAl by dexamethasone (Watkins et al, 1986) and P450IA2 by TCCD (Kimura et al, 1986).
In the case of all genes where hormonal regulation by mRNA stabilisation has been 
observed, features of the mRNA that influence stability remain largely undetermined, as is the 
case for P450 HEl mRNA. Previous data have suggested that for some genes hormones do 
exert their effect via mRNA turnover. For example, oestrogens have a dramatic effect on the
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stability of vitellogenin mRNA in Xenopus liver (Brock and Shapiro, 1983). Vitellogenin 
mRNA was shown to be degraded with a half life of 480hr in oestrogen-treated cells compared 
to a half life of 16hr in untreated cells. In another series of experiments, it was observed that 
the relative amounts of type 1 procollagen mRNA in the rat was significantly influenced in 
response to exogenous treatment with glucocorticoids and growth factors. The synthetic 
glucocorticoid dexamethasone was shown to destabilise type 1 procollagen mRNA (Raghow et 
al, 1986), whereas transforming growth factor (3 stabilised type 1 procollagen mRNA 
(Raghow et al, 1987).
In this study, I have examined the influence of insulin and testosterone on P450 HEl 
mRNA levels. From Figure 4.1 it is clear that insulin treatment of diabetic rats results in a 
rapid (within 12hr) return of P450 HEl mRNA levels to just above that observed in the control 
animal, with a full reversal after 2 weeks of treatment.
However the question arises as to whether insulin has a direct or indirect effect on P450 
HEl mRNA levels, for one must also consider that as well as a decrease in insulin 
concentration other hormones are also perturbed in diabetes. For example, the circulating 
levels of plasma testosterone (Murray et al, 1981) and thyroid hormone (Chopra et al, 1981) 
are significantly lowered in addition to a diminution in the daily pulsatile growth hormone 
rhythm (Tannenbaum, 1981). In this study I have presented evidence which suggests that 
testosterone partially reverses the induction of P450 HEl mRNA observed in the diabetic state 
(Figures 4.4, 4.5 and 4.8), but not to the same extent as insulin treatment. It therefore seems 
likely that insulin is not acting directly to control P450 HEl mRNA level but may act by 
reversing the hormonal imbalances that are observed in the diabetic animal. This would explain 
the effect testosterone has on P450 HEl, but the data also suggest that testosterone is not the 
only factor involved in this complicated regulatory system as only a partial reversal is seen, 
indicating that other factors (possibly other hormones) may be involved. For example, one 
cannot rule out the possibility of a mechanistic role for growth hormone which has been shown 
to suppress P450 HEl mRNA levels (Williams and Simonet, 1988 and Yamazoe et al, 1989).
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However in both of the aforementioned studies, hypophysectomised animals were used, which 
entails the surgical removal of the pituitary gland and in doing so, alters other, additional 
hormone levels than that observed in the diabetic animal model (see Table 1.2). Therefore, 
although there is a possibility of growth hormone altering the level of cytochrome P450 HEl 
mRNA, one must view this in the light of other hormonal changes. Polysomal RNA was also 
examined, as previous data had suggested that the translation process affects the decay of many 
mRNA species. For example in bacteria, inhibitors of protein synthesis that affect polymerase 
chain elongation lead to increased mRNA stability (Imamoto, 1973). The results presented 
here (Figures 4.4 and 4.5) indicate that probably P450 IIE1 mRNA is not affected by 
polyribosomes.
Testosterone treatment would also appear to decrease slightly the immunodetectable 
level of P450 HEl (see Figure 4.6) but not to the same extent as that seen with mRNA levels. 
This is not a surprising result if testosterone doesn't alter the ketone body levels. For as I have 
already discussed, if ketone body levels remain high in testosterone-treated diabetic rats, then 
the turnover of the protein would be decreased due to the stabilisation of the protein, even 
though the mRNA for this cytochrome is decreasing the effect might not be seen at the protein 
level. Whereas insulin does alter the status of fat metabolism and decreases the levels of ketone 
bodies, thus returning the level of P450 HEl to that seen in the control animal.
The decrease in P450 HEl mRNA observed in Figure 4.1 is paralleled by a drop in 
circulating blood acetone levels (Table 4.3). Recently, Kaloyianni and Freedland, (1990) 
conducted a study in isolated hepatocytes, where they demonstrated that insulin significantly 
decreased ketogenesis after 8hr of insulin treatment (1.33 Units of insulin 8hr before cell 
isolation). This is in agreement with my in vivo data. : ?
I The involvement of ketone bodies in P450 HEl regulation has been postulated for
. some time. Cassazza et al, (1984) observed that P450 HEl catalysed the oxidation of acetone 
to acetol and then to methyl glyoxal. This pathway can lead to the ultimate synthesis of glucose 
and may be an emergency gluconeogenesis pathway during diabetes and fasting. Both diabetes
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and fasting result in increased lipid metabolism which increases ketone body levels including 
acetone, as shown in Table 4.3. It has also been established that excessive ethanol 
consumption also increases the concentration of ketone bodies (LeFevre et al, 1970), a clinical 
situation which also leads to an induction of P450 DEI. In the light of recent research (Eliasson 
I  et al, 1990), there is little doubt that ketone bodies act as ligands to stabilise the P450 HEl 
protein against phosphorylation and ultimately degradation. Mechanistically, it is known that 
the elevation of P450 DEI mRNA level in diabetes and fasting (Hong et al, 1987, and Dong et 
al, 1988) must be caused by factors other than acetone.
A further point of interest from my studies is that cytochrome P450 HEl unlike other 
constitutive P450s such as IIC11, IIC12, IIA1 and IIIA1/A2 (Thummel and Schenkman, 
1990) was altered by diabetes to a similar degree in both male and female rats (Figures 4.2 and 
4.6 respectively). Given the distinctly different patterns of growth hormone (see Figure 1.10) 
between the two sexes, it suggests that growth hormone does not play a role in P450 HEl 
regulation, but provides further backing for the role of ketone bodies in stabilising the protein, 
as metabolic ketosis is found in diabetic animals of both sexes. However it would be 
interesting to know whether testosterone has a similar effect on the level of female P450 HEl 
mRNA. It could be that oestrogen plays the role of testosterone in the female rat with respect 
to P450 HEl regulation. Further experimentation is required to confirm this idea.
However like insulin, it is difficult to say from these experiments exactly where 
testosterone is having its effect in regulating cytochrome P450 HEl mRNA. Experimentation 
in cell culture may provide an answer where one could look at the effects that cycloheximide 
treatment has on the testosterone mediated decrease in P450 HEl mRNA levels. 
Cycloheximide abolishes protein synthesis and this would give information as to whether a 
trans-acting factor was involved in P450 HEl mRNA regulation. Conceivably, protein(s) that 
may be involved in mRNA turnover either directly (e.g an exo or endonucleases) or indirectly 
(by regulating the degradative process either by binding to the mRNA or the nuclease) could be 
regulated by testosterone, or some other hormones that are altered in the diabetic state.
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CHAPTER 5
THE EFFECTS OF BILE DUCT LIGATION ON CONSTITUTIVE 
CYTOCHROME P450 EXPRESSION
It has been known for some time that drug metabolism, as measured by drug elimination 
(Renton, 1986), is modulated not only by pathophysiological states such as diabetes, but also 
by infective agents such as viruses, bacteria and parasites. In rodents, bacterial infections are 
also associated with an impaired ability to metabolise drugs {in vivo), in addition to a depletion 
in total hepatic P450 content and a decreased microsomal metabolism of drug substrates 
(Renton, 1976 and Batra et al, 1987). A common feature of infection disorders which is 
thought to play a major role in the modulation of liver isozymes is endotoxaemia. These effects 
can be mimicked by administration of a single dose of endotoxin, the bacterial 
(lipopolysaccharide) molecule that initiates the febrile and acute phase responses typical of 
bacterial infection (Bissel et al, 1976 and Gorodischer et al, 1975).
However, although the effects of infection on total hepatic microsomal P450 content 
and drug metabolising activities are well documented, there is a lack of information regarding 
the effects of endotoxaemia on the expression of individual P450 genes. In this study I have 
examined the effects of endotoxin both in vivo and in vitro on the expression of both protein 
and mRNA derived from the rat cytochrome P450 HEl and P450 IVA1 genes. However it 
must be bom in mind that the effects observed might equally well be due to changes in 
metabolic status, e.g ketosis, induced by the infection itself or to associated cachexia.
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5.1 EFFECTS OF BILE DUCT LIGATION ON CYTOCHROME P450
HEl AND P450 IVA1 mRNA LEVELS
In order to study the effects of endotoxaemia on liver P450s the bile duct was ligated using the 
surgical procedure described in section 2.1.8. Sham operated animals were used as controls. 
In the sham operation a ligature was placed around the bile duct, removed and the abdomen 
was closed. By obstructing the bile duct in this way it mimics the condition of cholestasis 
(obstructive jaundice) which occurs in humans and causes endotoxaemia by promoting the 
absorbtion of increased quantities of lipopolysaccharide (LPS) from gram negative bacteria in 
the gut (Bailey, 1976). The reason for this is that intraluminal bile acids which normally block 
the uptake of endotoxin are absent and the clearance of endotoxin by Kupffer cells is also 
impaired (Gaeta et al, 1989).
In an initial study, total hepatic RNA was isolated 3 weeks after the initial surgery from 
seven bile duct ligated animals and five controls. Dot blot analysis was then performed as 
detailed previously. The nitrocellulose filter was first probed with 32P-labelled RLM6-1 cDNA 
the results of which are shown in Figure 5.1. The RLM6-1 probe was then stripped from the 
filter as described in section 4.1 and reprobed with 32P-labelled actin cDNA (Figure 5.1). The 
autoradiograph obtained with the actin probe indicated that equal amounts of RNA had been 
loaded in each well and therefore the marked suppression of P450 IIE1 mRNA level seen in 
each of the bile duct ligated animals was genuine. However it can also be seen that there is 
some inter-individual variation with 2 of the animals in the bile duct ligated group having a 
slightly higher P450 HEl mRNA level.
This initial study prompted a further investigation to examine the immunodetectable 
levels of P450 apoprotein as well as mRNA. In this experiment a further five controls and six 
bile duct ligated animals were used, the majority of the liver was used for microsome isolation 
but a portion (0.5-Ig) was kept for RNA extraction (the results of the immunoblots are 
discussed in the next section). In this experiment only a small amount of RNA was produced,
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Figure 5.1: Dot blot analysis of total RNA isolated from sham-control and bile 
duct ligated male rats
Total RNA (lOjig) from 7 bile duct ligated (1) and 5 control (2) male rats were applied directly 
on to nitrocellulose with a Hybridot filtration device, hybridisation was carried out with the 
RLM6-1 cDNA probe (left hand panel) or actin cDNA probe (right hand panel).
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which was of a sufficient quality to use in the slot blot analysis. The filter was probed with 
3 2 P-labelled P450 IVA1 cDNA but unfortunately when the film was developed there was 
considerable background radiation, which masked the hybridisation to the total RNA, making 
any sensible interpretation impossible (data not shown).
5.2 EFFECTS OF BILE DUCT LIGATION ON CYTOCHROM E P450 IIE1 
AND P450 IVA1 PROTEIN LEVELS
Animals were killed 3 weeks after bile duct ligation, microsomes were isolated and the total 
cytochrome P450 specific content was determined from five controls and six bile duct ligated 
animals. The results are shown in Table 5.1. Surprisingly the P450 specific content in the 
control group was unusually low (normally 0.8-1.0). This may be accounted for by a large 
P420 peak, which was found in these samples when the P450 levels were scanned on a 
Uvikon 860 spectrophotometer (data not shown). All microsomal preparations were treated 
equally, thus, if the mean value from the individual animals in both groups is calculated the 
specific P450 content for untreated animals is 0.254+0.029 (expressed ± SD) and for the test 
group 0.164 ± 0.028, representing a significant loss (35%) in the specific content of 
cytochrome P450 (P<0.001, using students t-test), in bile duct ligated animals.
Western blot analysis performed on the microsomes isolated above, with anti P450 
IIE1 IgG indicated that there was some inter-individual variation both within and between the 
control and bile duct ligated groups. Although the band intensities were similar in both groups 
it appeared as if the bile duct ligated animals had a slightly higher immunodetectable level of 
P450 HEl (Figure 5.2). This result is apparently in disagreement with mRNA data shown in 
Figure 5.1. However as discussed later (section 5.4) similar effects have been observed with 
other P450s. Western blot Analysis using the same microsomes, but with anti IVA1 IgG, 
showed a marked suppression in immunodetectable cytochrome P450 IVA1 levels (Figure
5.3). However the antibody to cytochrome P450 IVA1 is not monospecific, but recognises 
two bands of similar molecular weight. The lower molecular weight protein band has similar 
electrophoretic properties to purified cytochrome P450 FVAl (Sharma et al, 1988).
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Animal Total cytochrome P450 
specific content (nmol/mg)
Ci 0.24
c2 0.29
C3 0.28
C4 0.24
C5 0.22
Ti 0.13
t2 0.16
t 3 0.13
t4 0.16
t 5 0.18
t6 0.21
Table 5.1: Changes in cytochrome P450 specific content following bile duct
ligation
Key C1-C5 = Control animals
T1-T6 = Bile duct ligated animals
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Figure 5.2: Western blot analysis of male rat liver microsomes using anti-RLM6 
IgG
Microsomal protein (10p,g) was electrophoretically separated on a 10% SDS-PAGE, blotted 
onto nitrocellulose and probed with the rat anti-RLM6  IgG. Lanes a-e: control microsomes, 
Lanes f-k: bile duct ligated microsomes.
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Figure 5.3: Western blot analysis of rat liver microsomes using anti-IVAl IgG
The blot was performed as detailed in the legend to Figure 5.1. Lanes a-f: bile duct ligated 
microsomes (lOjig). Lanes g-k: control microsomes (10|ig).
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It is not clear presently what the upper band corresponds to but may represent a closely related 
family member such as P450IVA2 or 3 (Kimura et al, 1989). It is clear from this blot (Figure
5.3) that the lower P450IVA1 band was decreased.
The animals used in this study were pair fed and over the 3 week duration of this 
experiment a significant statistical change in body weight was not observed, between the 
control and bile duct ligated animals (data not shown).
5.3 EFFECTS OF ENDOTOXIN AND KUPFFER CELLS ON CYTOCHROME 
P450 PROTEIN LEVELS IN CULTURED HEPATOCYTES
In order to determine whether the effect observed in vivo was due to endotoxaemia or other 
biochemical and/or pathological effects associated with obstructive jaundice, a further study 
was performed. The effect of endotoxin on isolated hepatocytes and hepatocyte/Kupffer cell 
co-cultures was investigated.
Hepatocytes and Kupffer cells were isolated by the procedures described in section 
2.3.8. The Kupffer cell yield was 6-8 x 106/g of liver with a viability always greater than 
95% as ascertained by Trypan blue exclusion. The hepatocyte yield was 1 x 107/g of liver 
tissue and the viability greater than 80%. 2.5 x 10  ^Cells were seeded in 25ml Falcon tissue 
culture flasks for hepatocytes and 2.5 x 107 cells/25ml flask for Kupffer cells. In the 
experiments where co-cultures were used, the hepatocytes were isolated, seeded and allowed to 
attach while the Kupffer cell isolation was progressing (2-3hr). The medium was then 
carefully removed and the prepared Kupffer cells from the same liver added. After a 24hr 
recovery period, lpg/ml of E.coli Oil B4 (phenol extracted) lipopolysaccharide was added 
in a medium to the test cultures and endotoxin free culture medium to the control cultures. 
Microsomes were prepared after a further 24hr incubation. The protein yield was typically 
120|ig/flask. The Kupffer cell microsomal pellet was considerably smaller than the
hepatocytes or co-culture and this was reflected in a substantially lower protein yield
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(approximately 12-18jig/flask). Latex bead phagocytosis, peroxidase staining and electron 
microscopy revealed that at 24hr the cells were essentially only Kupffer cells and hepatocytes.
Immunodetectable levels of P450 IIE1 or IVA1 were not observed in untreated or 
endotoxin treated Kupffer cells on Western blot analysis (data not shown). However Western 
blots using anti-RLM6  IgG (Figure 5.4) and anti-IVAl IgG (Figure 5.5) showed that P450 
HEl levels (Figure 5.4) were increased in LPS treated hepatocytes and P450 IVA1 protein 
levels were largely unaffected (Figure 5.5) in hepatocytes ± LPS. But the presence of Kupffer 
cells in the presence or absence appeared to decrease the amount of immunodetectable protein 
for both P450s as compared to hepatocyte cultures alone. The lower Mr weight band seen in 
Figure 5.5 is most likely a degradation product of cytochrome P450 IVA1, it does not have a 
high enough Mr to be another cytochrome P450.
5.4 DISCUSSION
In this preliminary investigation I have presented data from both in vivo and in vitro 
experiments, suggesting that endotoxaemia affects the constitutive expression of P450 HEl and 
P450IVA1. It has previously been shown (S. Singh, personnal communication) that bile duct 
ligation leads to a direct increase in circulatory levels of endotoxin, it may thus be postulated 
that these effects are due to endotoxin. Although other explanations are possible (see below).
In the experimental model of biliary obstruction used in this study, there was a 
marked suppression in P450 HEl mRNA (Figure 5.1) but a corresponding change in protein 
was not observed (Figure 5.2). A similar effect on the levels of P450 HC11 mRNA and 
protein in endotoxin treated animals (Morgan, 1989) has been observed. A possible 
mechanism to explain this effect could be a decreased turnover of the P450 HEl apoprotein 
possibly due to ketosis or an increased rate of translation of the remaining P450 HEl mRNA. 
With respect to the former it is known from studies carried out in humans, that obstructive 
jaundice is associated frequently with cachexia (Greve et al, 1990) which may lead to changes 
in ketone levels. Although the animals in this experiment were pair fed and an overall change 
in body weight was not observed, if there were any perturbations such as increased ketone
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Figure 5.4: Effect of Kupffer cells and endotoxin (LPS) on hepatocyte P450 
IIE1 content
The Western blot was performed as detailed in the legend to Figure 5.1. Lane 1: co-culture and 
LPS, Lane 2: co-culture, Lane 3: hepatocytes and LPS and Lane 4: hepatocytes. lOjig of
protein was loaded in each lane. The apparent difference in the band intensity of track 3 
compared to track 4 may be due to the shape of the band in track 4 which is more elongated.
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Figure 5.5: Effect of Kupffer cells and endotoxin on hepatocyte P450 IVA1 
content
The Western blot was performed as detailed in Figure 5.1. Lane 1 : co-culture and LPS. Lane 
2: co-culture. Lane 3: Flepatocytes and LPS and Lane 4: hepatocytes. lOjig of protein was 
loaded in each lane.
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body production this may act to stabilise the P450IIE1 protein. Further work is required to 
test this hypothesis and to determine whether the decrease in P450 IIE1 mRNA is due to a 
decrease in P450IIE1 gene transcription or, for instance to increased mRNA degradation. The 
data presented here on the level of P450IIE1 apoprotein is not consistent with the findings of 
other authors who have measured P450IIE1 levels in endotoxaemic animals. Gorodischer et I 
al, (1976) observed a significant decrease in the activity of aniline hydroxylase (a known 
substrate of P450 HEl, Ryan et al, 1985), when female Holtzman rats were given 5mg/kg i.p 
dose of E.coli 026B6 lipopolysaccharide; and this finding was also confirmed by Sonawane et 
al, (1982). Recently Ishikawa et al, (1990) has demonstrated that when male ddY mice were 
given endotoxin (1 ,2  and 4 mg/kg) 24hr prior to a dose of acetaminophen (750mg/kg) the 
clinical chemistry profile and pathological alterations caused by acetaminophen were reduced in 
a dose-dependent manner, reflecting a decrease in acetaminophen-induced hepatic toxicity. 
Like aniline, acetaminophen is a substrate for cytochrome P450 HEl (Koop et al, 1982). One 
explanation of the discrepancy between my results and the above authors is that while there is 
no change in apoprotein levels there may have been a decrease in functional protein, possibly 
due to haem limitation.
The observation of diminished amounts of cytochrome P450 IVA1 (Figure 5.3) in 
obstructive jaundice has not previously been reported. It is difficult however to selectively 
assess the role of endotoxin in mediating cytochrome P450 loss in jaundiced rats, because of 
the multiple biochemical and pathological changes observed in the experimental biliary 
obstruction model. This problem can be overcome by using germ-free rats which have a very 
low endotoxin level in the bowel lumen and thus the effects of biliary obstruction can be looked 
at with little or no interference from endotoxins. But these animals are expensive to buy and 
keep, and difficult to handle. The level of Kupffer cell activation is also different in germ free 
animals (personal communication from Dr. S. Singh). Instead I looked at the effect of 
endotoxin in vitro using hepatocytes and Kupffer cells. Recently it has become evident that the 
changes in cytochrome P450 due to endotoxaemia are probably not due to the endotoxin per se, 
but mediated by potent cytokines released from macrophages (Laskin, 1989). For instance, 
Ghezzi et al, (1986) have demonstrated in mice that recombinant tumour necrosis factor (TNF)
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causes a marked depression of cytochrome P450. Other studies in mice (Bertini et al, 1989) 
suggest that it is not TNF which causes the direct suppression of P450 but interleukin-1 
((another LPS-induced monokine). In this latter study, interleukin-1 and not TNF or LPS i 
(depressed cytochrome P450 in cultured hepatocytes. This latter observation has also been
(confirmed by Shedlofsky et al, (1987). In my studies I have also found that endotoxin had no
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(effect on the levels of P450 HEl and P450 FVAl in cultured hepatocytes (Figures 5.4 and 5.5). 
i  While this might be due to a lack of direct interaction of bacterial lipopolysaccharide with the 
cell membrane to affect the levels of P450 HEl and FVAl it should be noted that hepatocytes in 
culture may have reduced numbers of LPS receptors and thus may not reflect the in vivo 
situation.
However because of the apparent influence of cytokines, which are released from 
Kupffer cells as described above and in section 1.6.2, in response to challenge by 
lipopolysaccharide my experiment was also designed to look at the influence of Kupffer cells, 
(both quiescent and endotoxin treated) on the levels of cytochrome P450 HEl and FVAl. The 
results shown in Figures 5.4 and 5.5 are a little surprising as it would appear that the Kupffer 
cells suppress the levels of cytochrome P450 HEl and FVAl independently of pretreating the 
cells with endotoxin. Other experiments have demonstrated a need for the Kupffer cells to be 
phagocytosing before a decrease in cytochrome P450 is observed (Peterson and Renton, 
1986). Although in their study Peterson and Renton used latex particles and not 
lipopolysaccharide and the hepatocytes were harvested after only 60min of incubation with the 
phagocytosing Kupffer cells and not 24hr. In trying to explain these results a protein dilution 
effect of the Kupffer cell microsomal protein was ruled out because the contribution 
(approximately 1/8 of the hepatocyte) was not sufficient to give the observed (visual 
inspection) immunodetectable differences (approximately 50%). However the question then 
arises as to whether the depression in cytochrome P450 is dependent on contact between the 
two cell types or a mediator like interleukin-1 that the Kupffer cells secrete.
It is clear from this preliminary data that the pathophysiological condition of 
endotoxaemia produced in bile duct ligated animals affects both mRNA and protein levels of 
two important constitutive cytochrome P450s, which may significantly alter susceptibility to
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drugs and toxic or carcinogenic foreign compounds. In addition, in vitro studies would 
suggest that Kupffer cells mediate this effect either directly (through cell contact) or indirectly 
(through the production of a mediator). This may have some direct clinical relevance in human 
patients, where the orthologous P450 for cytochrome P450 HEl has been identified and 
partially characterised, and P450 FVAl is thought to be present
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CHAPTER 6
ARACHmONIC ACID METABOLITE PROFILES 
IN DIABETIC LIVER AND KIDNEY MICROSOMES:
ROLES OF CYTOCHROME P450 IIE1 AND IVA1
The physiological role of cytochrome P45Q IIE1 has not been clearly defined. In chapter 1 
(section 1.4) I have indicated that a possible in vivo role for P450 IIE1 is to promote 
gluconeogenesis in times of need (diabetes and starvation) by metabolising acetone. However 
it may also play a role in normal liver function.
My examination of the effects of diabetes on arachidonic acid metabolites was prompted 
by reports that eicosanoid metabolism is unbalanced in diabetic animals (Harrison et al, 1978)
and patients (Lagarde et al, 1980), the most consistent feature of this imbalance being the 
increased production of thromboxane A% (TxA^) as indicated by the elevation of plasma 
thromboxane Bz (TxBz), which is the stable metabolite of TxA^. Prostacyclin metabolism 
however is unaffected by diabetes (Hui ef a l , 1989).
In spite of these frequent reports in the literature on the eicosanoid metabolism 
imbalance in diabetic animals, no explanation for this at the enzyme or molecular level has been 
given. However it has been well documented that TxA% synthase is a cytochrome P450 
(Ullrich and Haurand, 1983) and in this thesis I have demonstrated that cytochrome P450 HEl 
is induced by diabetes. Therefore arachidonic acid metabolism and cytochrome P450 HEl 
induction was examined under diabetic and control conditions. However it should be noted 
that arachidonic acid metabolism is normally associated with P450 FVA1. Therefore levels of 
this isozyme were examined in parallel with P450IIE1.
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6.1. PREPARATION OF DIABETIC LIVER AND KIDNEY MICROSOMES
Animals (n=3) were made diabetic by a single i.p injection of streptozotocin (65mg/kg) as 
detailed in section 2.1.8, and diabetes was allowed to develop over a 2 week period. Control 
animals (n=3) received only the saline vehicle. The body weights of all six animals were 
measured over the time period of the experiment and the results are shown in Figure 6.1. In 
the three animals receiving streptozotocin, an increase in body weight was not observed, 
indicating that the animals were diabetic. The initial decrease in body weight of the control 
group (in the first day) was due to water deprivation resulting from a non-functioning water 
bottle. This was corrected immediately and the animals gained weight as shown (Figure 6.1). 
Animals were killed on the 14th day after streptozotocin treatment, the liver and kidneys 
excised, weighed and microsomes were prepared as detailed previously. The protein and 
cytochrome P450 specific content of the microsomes from both organs were determined and 
the results are tabulated, along with the organ weights in Table 6.1. Statistical analysis 
(students t-test) revealed that there were no significant changes in either total cytochrome P450 
specific content or the ratio of organ to body weight in both the liver and kidney, with the 
exception of a slight decrease (P<0.05) in the liver/body weight ratio of the diabetic animal 
compared to the control group.
As a further check to confirm that the animals were diabetic and to ensure that indeed 
cytochrome P450 IIE1 levels were induced, Western blot analysis was performed on 
microsomes prepared from both the kidney and liver. The results are shown in Figure 6.2 and 
clearly shows that P450 HEl apoprotein content is induced in both organs, albeit to a much 
lesser extent in the kidney. The level of cytochrome P450 HEl in the kidney appears to agree 
well with mRNA levels observed in Chapter 3 (see Figure 3.8).
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A) Animal Organ/body weight 
ratio (%)
Total cytochrome P450 
Specific content (nmol/mg)
Control liver (1) 6.1 0.87
Control liver (2) 6.3 0.87
Control liver (3) 6.6 0.89
Diabetic liver (1) 5.7 0.84
Diabetic liver (2) 5.6 0.86
Diabetic liver (3) 5.8 1.14
Control kidney (1) 0.79 0.09
Control kidney (2) 1.0 0.10
Control kidney (3) 0.79 0.10
Diabetic kidney (1) 1.3 0.12
Diabetic kidney (2) 1.2 0.15
Diabetic kidney (3) 1.1 0.12
B) Animal Organ/Body weight ratio 
(%)
Total cytochrome P450 
Specific content (nmol/mg)
Control liver 6.3±0.25 0.8710.008
Diabetic liver 5.710.1* 0.9410.170
Control kidney 0.8610.12 0.09610.0072
Diabetic kidney 1.210.1 0.1310.01
Table 6.1: Organ to body weight ratio  and cytochrome P450 changes
accompanying diabetes in the liver and kidney
A) data on the individual animals. B) values are the mean ± S.D. of three individual animals, 
using students t-test, P values for results significantly different from control data at *P<0.05.
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Figure 6.2: Western blot analysis of liver and kidney microsomes from control 
and diabetic rats using a polyclonal anti-RLM6 antibody
Microsomal protein (lOf-ig) was electrophoretically separated on a 10% SDS polyacrylamide 
gel, blotted onto nitrocellulose and probed with the rat anti-RLM6 IgG. Lanes 1-3: diabetic 
kidney microsomes. Lanes 4-6: control kidney microsomes. Lanes 7-9: diabetic liver 
microsomes. Lanes 10-12: control liver microsomes.
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6.2 ROLE OF STREPTOZOTOCIN-INDUCED DIABETES ON HEPATIC AND 
RENAL ARACHIDONIC ACID METABOLISM: COMPARISON OF THE 
REVERSE PHASE HPLC METABOLITE PROFILES
The hepatic and renal microsomal arachidonic acid metabolite profiles shown in Figures 6.3 
and 6.4 were obtained by reverse phase HPLC analysis of the ethyl acetate extractable 
radiolabelled oxygenated products and unreacted substrate as outlined in section 2.3.6. Figure
6.3 shows the profile of metabolites formed during the NADPH dependent oxygenation of 
arachidonic acid by hepatic microsomal preparations and Figure 6.4 by renal microsomes. 
Figure 6.3A shows the metabolite profile of arachidonic acid catalysed by control rat liver 
microsomes. Three major groups of metabolites were identified according to their polarity. 
The arachidonic acid substrate (AA) was eluted at approximately 47min. The lowest polarity 
metabolites were eluted from fractions 184 (36.8min) to 197 (39.4min) and consisted of two 
major metabolite peaks, which when compared to the reported arachidonic acid metabolite 
profile (Capdevila et al, 1985) corresponded to the epoxyeicosatrienoic acids (EET). The 
second group, consisting of several small peaks eluting between fractions 166 (32min) and 175 
(35min) had a similar polarity to the monohydroxyeicosatetraenoic acids and were collectively 
labelled as HETE. The third group consisted of two peaks (PI and PII) which exhibited 
retention times of 30.4min and 31min respectively. Previous work (Capdevila et al, 1985) 
suggests that PI and PH are the 19-hydroxyarachidonic acid and 20-hydroxyarachidonic acid 
metabolites respectively. In the hepatic arachidonic acid metabolite profile derived from 
diabetic animals (Figure 6.3B), apart from a slight increase in peak II, there were no other 
significant changes from the control metabolite pattern, despite a significant induction in P450 
DEI protein (Figure 6.2). However one must consider that more radioactivity was injected on 
to the HPLC column for the diabetic liver microsomes, as judged by the breadth and topping 
off of the arachidonic acid peak (Figure 6.3B). This means that if the same cpm were injected 
on to the HPLC column then diabetes would result in a significant decrease in metabolite
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Figure 6.3: Reverse phase HPLC separation of arachidonic acid metabolites 
formed by rat hepatic microsomes
166
2000 CONTROL KIDNEY
AA
PH
g 1000 -
EET
HETE
10 30 40 50200
Time (min)
2000
DIABETIC KIDNEY
AA
pn
EET
HETE
0 10 20 30 40 50
Time (min)
Figure 6.4: Reverse phase HPLC separation of arachidonic acid metabolites 
formed by rat renal microsomes
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Legend for Figures 6.3 and 6.4:
Microsomal fractions (Img of protein/ml) were incubated for 10min at 37°C with [1-14C] 
arachidonic acid (0.25p.Ci/fimol) (0.5mM) in the presence of NADPH and O2. The reaction 
was terminated with lOOjil of HC1 and the metabolites extracted three times with 4ml of ethyl 
acetate. The combined extracts were dried under nitrogen and finally dissolved in 250|il of 
ethanol, lOOpl of which was injected onto the ODS Cig HPLC column. AA: arachidonic acid; 
EET: epoxyeicosatrienoic acid; HETE: hydroxyeicosatetraenoic acid.
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formation. This result suggested that cytochrome P450 HEl may not be able to efficiently use 
arachidonic acid as a substrate in the liver.
Figure 6.4 represents the reverse phase separation of metabolites formed by control and 
diabetic renal microsomes. Both the control and diabetic metabolite profiles exhibited similar 
patterns with corresponding retention times to those observed in the hepatic arachidonic acid 
metabolite profiles. The HETE and EET peaks were reduced from control and diabetic kidney 
microsomes compared to their hepatic counterparts, but were not different from each other. 
Peak II was increased in the diabetic kidney microsomes over control kidney. In addition both 
peak II in control and diabetic microsomes were increased over their counterparts in the liver 
revealing a difference in the metabolism of this substrate between the two organs.
6.3 DISCUSSION
The results presented in this study demonstrate, that in streptozotocin induced diabetes there is 
no significant change in total, carbon monoxide-discemable cytochrome P450 content in the 
liver or kidney, in male diabetic animals. In addition the arachidonic acid metabolite profile 
derived from streptozotocin-induced hepatic microsomal preparations resulted in a general 
suppression of all metabolites identified. A possible explanation for this observation may be
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Figure 6.5: Western blot analysis of liver and kidney microsomes from control 
and diabetic rats using a polyclonal anti-IVAl antibody.
Microsomal protein (10|J.g) was electrophoretically separated on a 10% SDS polyacrylamide 
gel, blotted onto nitrocellulose and probed with the rat anti-IVAl IgG. Lanes 1-3: diabetic 
kidney microsomes. Lanes 4-6 control kidney microsomes. Lanes 7-9: diabetic liver 
microsomes. Lanes 10-12: control liver microsomes.
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due to the suppression of those P450 isozymes that are responsible for arachidonic acid 
oxidation. The renal arachidonic acid metabolite profile was unchanged except for a significant
induction in peak H, in diabetic kidney microsomes. This increase in peak H is associated with 
the oxidation of arachidonic acid by cytochrome P450 IVA1 (Sharma et al, 1989). 
Considering that cytochrome P450 IIE1 is significantly induced in both organs following 
diabetes (Figure 6.2) these results suggest that arachidonic acid is not a substrate for
cytochrome P450 HEl in either the liver or kidney.
These data also confirm previous findings that cytochrome P450 IVA1 is induced by 
diabetes in the liver (Barnett et al, 1990) and show for the first time the induction of 
immunodetectable levels of P450IVA1 in the kidney.
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CHAPTER 7
DISCUSSION
The study of the role of altered physiological states and disease on the drug metabolising I
enzymes, has not been addressed at the level of individual cytochromes until recently (Favreau '
and Schenkman, 1987, Funae etal, 1988 and Morgan, 1990). Moreover, tittle is known at the
molecular level, as to how individual P450s are regulated under such conditions as diabetes, 
fasting and endotoxaemia.
This study was prompted by the reported similarity between ethanol-inducible
cytochrome P450 HEl and diabetes-inducible RLM6. Both isozymes are induced by diabetes
or fasting and both proteins are identical in their first 20 amino acid residues (Favreau et al,
1987 and Ryan et al, 1985). In addition, they have similar substrate specificity profiles.
Although the P450 HEl gene has been isolated and its regulation studied in the past four years
(Song «  a l , 1986, Song et al, 1989 and Yang et al, 1990), no such study has been reported
for RLM6. In this thesis I report on the isolation of P450 RLM6 cDNA, its characterisation
and studies on the mechanisms of regulation of this diabetes-inducible cytochrome P450. In
fact the DNA sequence of the RLM6 cDNA was not completed until late on in this study
therefore the question as to whether was identical to HEl remained open. Thus many of the !
experiments were performed to detemtine if indeed there were any differences between the two 
genes.
7.1 THE ISOLATION AND CHARACTERISATION OF THE DIABETES- 
INDUCIBLE GENE (RLM6)
The identity of the RLM6 partial cDNA sequence presented here to that of P450 DEI is strong 
evidence that diabetes-inducible RLM6 and ethanol-inducible P450 DEI are probably the same 
protein. Although the complete sequence for RLM6 was not determined in my studies, one 
would have expected there to be some nucleotide differences in the cDNAs if P450 HEl and 
RLM6 were distinct gene products, as has been reported for other closely related (>90% 
nucleotide homology) cytochrome P450 genes. Figure 7.1 illustrates this point by comparing 
closely related family members from the phenobarbital-induced gene family P450 DB.
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RAT
RABBIT
Figure 7.1 Comparison of rat and rabbit P450 IIB family members
The horizontal line labelled "RAT" represents a comparison of P450 IIB 1 and IIB2. The 
horizontal line labelled "RABBIT" represents a comparison of five closely related P450 IIB 
family members. The positions of amino acid differences between closely related P450 IIB 
family members, in the rat and rabbit are indicated by vertical lines.
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From Figure 7.1 it can be seen that in the rat, P450 FBI and IIB2 differ by only 14 amino acid 
substitutions, which although restricted to the carboxy terminal portion are spread out over 200 
amino acid residues (Suwa et al, 1985). In the rabbit, five sequences of similar identity (> 95 
% nucleotide homology) have been isolated. Amino acid differences among them total 24 : 
positions, but these are distributed over the entire sequence (Komori et al, 1988). In addition, 
recently it has been found that the alcohol-inducible P450 HE subfamily in the rabbit comprises 
of at least two genes (Khani et al, 1988) which are 97% identical. P450IIE1 and IIE2 have 32 
nucleotide differences, resulting in only 16 amino acid replacements, which occur like the 
related members of the P450 IIB family throughout the whole gene.
However in this study a polyclonal antibody (raised to the diabetes-inducible protein) 
was used to isolate the corresponding gene by immunoscreening a rat liver cDNA library. 
Therefore if two very similar, but different proteins existed, it would be highly likely that the 
RLM6 antibody would not be able to distinguish between them, especially given that the cDNA 
library used herein was constructed from a clofibrate-induced rat liver. However, further 
evidence in support of my sequence data which indicates the existence of only one gene in the 
rat liver P450 HE subfamily comes from Southern blot analysis of rat genomic DNA. Use of 
either the P450 HEl probe (Song et al, 1986) or my RLM6-1 probe (Figure 3.6.1) revealed a 
simple hybridisation pattern indicative of a single family member in this P450 gene family. 
Taken collectively I believe that these results confirm the identity of RLM6 to P450 DEI.
7.2 INDUCTION OF RLM6/IIE1 mRNA IN DIABETIC AND FASTED RATS
In chapter 3 ,1 report a significant increase in RLM6 mRNA level from either streptozotocin- 
induced diabetic male rats or rats fasted for 48hr (Figures 3.6 and 3.7). The Northern blot 
(Figure 3.6) indicated that RLM6 mRNA is the same size as P450 DEI mRNA and like P450 
DEI, its level is elevated during diabetes (Song et al, 1987). In addition, I have also shown 
through dot blot analysis that RLM6 mRNA is induced in fasted rats, a phenomenon also
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reported for P450 ILEl mRNA (Hong et al, 1987). There are two mechanisms that could 
account for this increase, namely, an increase in mRNA transcription or by an increase in 
mRNA stabilisation. Song et al, (1987), discounted the former of these suggestions by 
demonstrating (using nuclear run on transcriptional analysis) that the P450 DEI transcriptional 
rate was not enhanced in the diabetic rat. They proposed instead, that mRNA stabilisation was 
the major contributory factor for the observed increase in P450 HEl mRNA. Conclusive 
demonstration of mRNA stabilisation would require direct measurement of half-life, however, 
the low labelling efficiency of midabundance mRNAs preclude these experiments at this time. 
I felt that it was not necessary to repeat the nuclear run on experiments of Song et al, (1987) as 
the correct controls had been used and the data appeared conclusive. Instead I focussed my 
studies on the factors regulating P450 HEl mRNA stability.
Metabolic changes in the diabetic and fasted rat: There are a number of metabolic alterations 
that accompany insulin deficiency found in both diabetes and fasting and these are illustrated in 
Figure 7.2. The principal abnormality of fat metabolism is the acceleration of lipid catabolism, 
with increased formation of ketone bodies, and decreased synthesis of fatty acids and 
triglycerides. Recently, Barnett et al, (1988) have shown that ketone bodies are important in 
modulating levels of P450 HEl protein. These workers administered medium chain 
triacylglycerols to male rats, which induced a hyperketonaemic state and compared the effects 
on hepatic mixed-function oxidase activity to streptozotocin-induced changes. It was found 
that aniline hydroxylase activity increased similarly in both treatment groups. Indeed there is 
presently a wealth of evidence suggesting that ketone bodies regulate P450 HEl through a 
ligand-dependent protein stabilisation mechanism (Eliasson et al, 1988), although, definitive 
proof for the proposed cAMP-regulated degradation mechanism for P450 HEl (Eliasson et al.
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Figure 7.2 Effects of insulin deficiency in the diabetic and fasted rat
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1990) in vivo awaits confirmation. The role of ketone bodies in P450 IIE1 mRNA 
stabilisation, if any, is not known, however mechanistically it has been shown that the 
elevation of P450IIE1 mRNA in diabetes and fasting (Hong et al, 1987 and Dong et al, 1988) 
must be caused factors other than acetone.
It is not known what effect increased protein catabolism has on P450 IIE1 mRNA 
levels. Previous studies have indicated that rats fed on a low protein diet, show significant 
alterations in cytochrome P450 composition. For instance, Ameliazad et al, (1988) showed 
that the catalytic activities associated with cytochrome P450IIC12 were substantially decreased 
in rats fed on a low protein diet. Thus, further work is required to elucidate the role of dietary 
protein, if any, in regulating P450 HEl mRNA.
The other important factor that is changed by insulin deficiency is the decreased 
circulating levels of glucose. However this is thought not to play a role for the diabetes- 
induced increases in P450 HEl. For example, Barnett et al, (1988) have demonstrated an 
increase in aniline hydroxylase activity in rats treated with medium chain triacylglycerols. But 
alterations in the level of circulating glucose were not observed.
The condition of hypoinsulinaemia also exists in the lactating rat, which has a plasma 
insulin concentration approximately 50% lower than that of the non-lactating rat (Williamson, 
1980). Thus, it would be interesting to see if P450 HEl levels are modulated in this animal 
model as is seen in diabetes and fasting.
However, P450 HEl is almost certainly under additional homeostatic control as alluded 
to earlier, because firstly P450 HEl mRNA is not induced in acetone treated animals or by 
other small molecules like isoniazid and ethanol (Song et al, 1986) which contrasts with that 
seen in diabetic or fasted animals. Secondly, in newborn rats, P450 HEl appears to be. 
transcriptionally activated (Song et al, 1986). In addition, it has been found that when pituitary 
hormones are removed by hypophysectomy, P450 HEl mRNA levels are elevated (Williams 
and Simonet, 1988) but ketone body levels remain unchanged (Hong et al, 1990).
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7.3 MODULATION OF CYTOCHROME P450 RLM6/IIE1 BY HORMONES
Hormones are chemically diverse compounds that are secreted into the bloodstream by 
specialised endocrine cells. They are able to influence target cells far away from their original 
point of synthesis and can exert their effects in several ways:
1) By influencing the rate of synthesis of enzymes or other proteins
2) By affecting the rate of enzymatic catalysis
3) By altering the permeability of cell membranes
Figure 7.3 illustrates a number of important hormones that are thought to play a role in 
modulating drug metabolism in the rat (for a review see Waxman, 1988). Figure 7.4 
summarises the possible interaction of these hormones with the liver.
7.3.1 Modulation of RLM6/IIE1 by insulin and testosterone
In streptozotocin-induced diabetes, the loss of insulin through the destruction of pancreatic P 
cells is accompanied by decreases in testosterone (Murray et al, 1981) and thyroid hormone 
levels (Chopra et al, 1981). In addition, the pulsatile secretion of growth hormone is abolished 
(Tannenbaum et al, 1981). Similar hormonal changes are also found in the fasted rat (see 
section 1.5). Therefore in the light of the last section where I suggest that other factors are 
involved in P450 HEl modulation I decided to examine the influence of insulin and 
testosterone, two hormones whose levels are substantially altered in both diabetic and fasted 
rats.
In chapter 4 ,1 present data that shows that insulin completely reverses the induction of 
P450 HEl mRNA in a time-dependent manner (Figure 4.1) and that testosterone partially 
reverses HEl mRNA induction (Figure 4.4) in diabetic rats. However it is not clear from these 
studies whether insulin or testosterone decreases gene transcription or destabilises P450 HEl 
mRNA.
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Figure 7.3: Some examples of hormones
abbreviations; aa = amino acid
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Figure 7.3 (continued)
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Figure 7.4: Hormonal control of drug metabolism
The diagram has been modified from Gibson and Skett, (1986). Abbreviations not defined 
previously; T3, tri-iodothyronine: T4, thyroxine.
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Generally, steroidal hormones like testosterone, act directly at the level of gene 
transcription to increase or decrease protein levels via a receptor mediated process. This mode 
of regulation has been observed for some cytochrome P450 genes; for example, 
dexamethasone increases P450 IIIA1 mRNA levels (Simmons et al, 1988). A definitive 
answer as to whether transcription is affected is to perform nuclear run on analyses using 
nuclei isolated from insulin and testosterone treated diabetic animals.
As mentioned earlier and also detailed in section 1.3.1, P450 DEI mRNA is thought to 
be transcriptionally activated at birth, by specific 5' cytosine déméthylation. It would therefore 
be of interest to see what effects castration or ovariectomy has on the developmental regulation 
of P450 DEI in male and female rats . Waxman et al, (1989) have addressed this question and 
their studies have shown that both neonatal and adult castration significantly elevated P450 
DEI levels in adult male rats. Androgen replacement to these gonadectomised rats reversed the 
induction, particularly when the animal was exposed to androgen during the neonatal period as 
well as the adult period. Similarly, ovariectomy also increased P450 DEI mRNA levels in the 
female rat and these changes could be reversed upon oestrogen treatment.
If the effects of testosterone on P450 DEI observed in my studies and also by Waxman 
et al, (1989) are not to modulate gene transcription then the effect must be on mRNA stability. 
In recent years, an increasing number of P450 genes are thought to be regulated in part by 
mRNA stabilisation. For example, Boggaram et al, (1989) has shown that cholesterol side 
chain cleavage P450 mRNA accumulates in vitro when cells are treated with ACTH. Steroid 
hormone action is often associated not only with the primary response of switching on the gene 
of interest but with the activation of other genes producing a secondary response. Therefore 
testosterone may for example, modulate P450 DEI mRNA by inducing the genes encoding 
messenger-specific RNAases.
However only a partial reversal of P450 DEI mRNA induction by testosterone was 
observed in my studies, this suggests that either the testosterone dosing regime employed was 
not sufficient to elicit a full response or that other factors are involved.
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In recent times, considerable progress has been made in identifying a variety of mRNA 
decay processes, but there is little information as to how cellular factors affect the susceptibility 
of mRNA to degradation and how nucleases involved in the initial steps may be regulated. For 
instance, some mRNAs like those coding for histones accumulate to high levels during the 
period of DNA synthesis. The resulting mRNA stabilisation is mediated through the 3' 
terminal stem-loop structure on these mRNAs (Levine et al, 1987). It is has been suggested 
that the destabilisation of histone mRNA may occur by the action of ribosome-bound nucleases 
(Brawerman, 1989) that only become active when the cell is not undergoing DNA synthesis. 
This mode of mRNA regulation may be involved in P450 HEl regulation where the ribosomes 
become activated when the diabetic animals are treated with testosterone or insulin.
The transferrin receptor mRNA is destabilised when excess iron is present within the 
cells. This effect is thought to be mediated when a protein factor which binds to an iron- 
responsive structure in the 3' non-coding region of the mRNA is released by the presence of 
iron. Therefore it is conceivable that P450 HEl mRNA may be regulated by mediators that are 
induced by testosterone or insulin treatment which causes P450 HEl mRNA to be degraded 
(Brawerman, 1989).
Alternatively the decay of P450 HEl mRNA may occur by another type of signal that is 
not mediated through any structural element on the mRNA as appears to happen for tubulin 
mRNA (Yen gf a/, 1988).
An important fact shown in Figure 7.4 is that testosterone and oestrogen normally elicit 
their response through the hypothalamus by affecting a number of hormones, in particular, 
growth hormone (Jansson and Frohman, 1987). Indeed, in hypophysectomised animals a 
model similar to diabetes in that the pulsatile growth hormone rhythm in the male rat is 
abolished, leads to an increase in P450 HEl mRNA , and is reversed by growth hormone 
treatment (Williams and Simonet, 1988). This effect of growth hormone is particularly 
interesting as it appears to regulate P450 HEl mRNA independently of the secretion pattern, 
that is the level of cytochrome P450 HEl is reduced by continuous (Yamazoe et al, 1989) as
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well as intermittent administration of growth hormone (Williams and Simonet, 1988). This 
latter observation may well explain why P450 DEI is regulated similarly in male and female 
rats, especially if oestrogen and testosterone act by regulating growth hormone levels. This 
contrasts with other constitutive P450 isozymes which are dependent on the secretion pattern of 
growth hormone for their expression. For example, cytochrome P450 ECU requires the 
male-specific pulsatile pattern of growth hormone secretion for complete expression (Eden, 
1979) and P450IIC12 requires the female pattern (Kamataki et al, 1985).
Thyroid hormones, may also influence DEI regulation since it is known that T3/T4 have 
a direct effect on the liver through intracellular receptors. However current evidence suggests 
that these also may influence P450 DEI regulation, although current evidence suggests that T4, 
affects the regulation of NADPH-cytochrome P450 reductase (Waxman et al, 1989).
7.4 MODULATION OF P450 IIE1 BY ENDOTOXIN
In chapter 5 ,1 have demonstrated that following experimental bile duct ligation, there is a 
significant decrease in P450 DEI mRNA levels, compared to sham operated control male rats.
Many important changes, that might result in the alteration of P450 DEI mRNA level 
accompany biliary obstruction. I have suggested that the resulting endotoxaemia is the primary 
regulatory trigger for changes to P450 DEI, since previous data have implied a significant role 
for endotoxin in suppressing drug metabolising enzyme activities (Renton and Mannering, 
1976 and Yaffe and Sonawane, 1978) and individual cytochrome P450 isozymes (Morgan, 
1990). To fully establish this latter concept, experiments should be performed with germ free 
rats which have very low levels of endotoxin present in their gut lumen. Therefore one could 
then examine biliary obstruction with very little interference from endotoxin.
The endotoxaemic state is brought about by the increased uptake of endotoxin from the 
gut, due to the lack of intraluminal bile acids (Gaeta et al, 1989). This leads to the 
accumulation of bile acids in the systemic circulation. An alternative hypothesis therefore is
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that it may be this increase in bile acids, such as cholic acid (Figure 7.5), that affects P450 DEI 
levels.
COOH
'OHHCT
Figure 7.5: Cholic acid
It is interesting to note from Figure 7.5 that cholic acid has a similar structure to the steroidal 
hormones, therefore if it is involved in P450 DEI regulation, it might act in a similar way to 
that postulated for testosterone. Previously, cholestyramine a drug which acts by chelating bile 
acids in the gut and thus preventing their enterohepatic re-circulation, results in a 3-5 fold 
increase in cholesterol 7a-hydroxylase activity (Ogishima et al, 1987). This enzyme activity is 
catalysed by a unique form of P450 (Li et al, 1990).
Bile acids combine with lipids in the gut to form micelles, which are water-soluble 
complexes from which the lipids can be more easily absorbed. They reduce surface tension 
and in conjunction with phospholipids and monoglycerides, are responsible for the 
émulsification of fat preparatory to its digestion. Therefore, fat metabolism is altered in biliary 
obstruction as well, and this as discussed previously (section 5.4) might account for why P450 
DEI protein levels are not decreased.
There is also a severe malabsorption of fat soluble vitamins in endotoxaemia. Vitamins 
are essential for the synthesis of proteins and lipids, both of which are essential components of 
the drug metabolising system. Vitamin A and D are two fat soluble vitamins that are known to 
decrease cytochrome P450 levels. For example, Leo et al, (1986) has shown that vitamin A
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deficiency results in a decreased detoxification of N-nitrosodimethylamine, a known specific 
substrate of P450IIE1. Thus, vitamins may also modulate P450 HEl mRNA levels in biliary 
obstruction and further work is required to evaluate this possibility.
From my in vitro studies I have implicated the involvement of Kupffer cells in 
mediating P450 HEl and IVA1 protein levels. As discussed in section 5.4 this may involve 
mediators that are released from the Kupffer cell such as interleukin 1. Experiments which can 
and should be performed to elucidate the role of Kupffer cell mediators, if any, is to use the 
medium from cultured Kupffer cells ± endotoxin to replace the hepatocyte media and observe 
any changes in cytochrome P450 levels.
7.5 ENDOGENOUS CYTOCHROME P450S AND DRUG METABOLISM
The studies presented in this thesis show clearly that cytochrome P450 HEl is an adaptive 
enzyme responding to changes in homeostatic conditions in the animal, during both altered 
physiological and pathophysiological states.
Cytochrome P450 HEl is one of a number of so called "constitutive enzymes" which 
are present at basal levels in the uninduced animal. Collectively these constitutive P450s are 
responsible for maintaining the correct levels of many endogenous compounds such as bile 
acids, cholesterol and fatty acids (see Figure 1.2). Many constitutive forms of P450 are 
modulated under certain conditions however some of them are only altered by physiological 
mechanisms and not as a consequence of xenobiotic challenge (for a review see Schenkman et 
al, 1989). Cytochrome P450 HEl is one of the constitutive forms that responds to xenobiotic 
challenge, for example, its levels are increased when animals are given alcohol (Song et al, 
1986). What relevance therefore does the 3-5 fold induction of P450 HEl levels serve in 
diabetic, fasted or ethanol-induced animals and is this change significant for drug metabolism 
in man? Normally xenobiotic challenge results in a 50-100 fold increase in enzyme activity as is 
the case in the induction of P450 HB1 and IIB2 by phénobarbital (Remmer and Merker, 1963).
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One explanation might come from consideration of the relevant toxicity of the compounds involved 
in the induction process, to the animal in question. Clearly the amount of ethanol and 
phénobarbital that the liver can cope with is different. Indeed, other routes of metabolism other 
than the cytochrome P450s might be responsible for the metabolism of compounds like 
ethanol, when ingested in high concentrations, thus a large induction of the P450 is not 
observed. An alternative explanation is that more complex molecules act via specific gene 
regulatory receptor mechanisms, whereas the small (substrate) molecules act via endogenous 
secondary messenger systems which do not give such marked fluctuations in gene activity or 
enzyme levels.
Unlike most of the other rat constitutive enzymes, the orthologous human enzyme and 
gene for cytochrome P450 DEI has been isolated and characterised (Wrighton et al, 1986). In 
chapter 3 ,1 have also shown that the RLM6 antibody recognises a single human protein on 
western blot analysis (Figure 3.9). In addition, I have shown that its levels fluctuate widely 
between individuals and that in alcoholic patients there maybe increased levels. As is the case 
for the majority of P450s, cytochrome P450 HEl has many substrates (Figure 1.5), however 
many of these are metabolically activated producing hepatotoxic compounds. Ekstrom et al, 
(1989) has demonstrated that P450 DEI is responsible for the CCU-mediated hepatotoxicity in 
human liver. In addition, it has been demonstrated that acetaminophen is also bioactivated by 
P450 HEl in humans (Raucy et al, 1989).
Therefore in humans any factors that alter P450 HEl levels (even if its only 2-3 fold), 
such as, changes in nutritional status, pathophysiological states or indeed as initial studies 
suggest by alcohol and isoniazid (Wrighton et al, 1986 and Lasker et al, 1986), will affect how1 
specific drugs are metabolised and in some cases bioactivated by this isozyme. In this respect,1 
one should be particularly careful in the treatment of obese patients where recent data has 
shown that the obese rat is unusually susceptible to liver damage by several P450 IIE1 ' 
metabolically activated drugs that maybe more toxic in the obese human (Salazar et al, 1988). '
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In conclusion, it is now clear that constitutive drug metabolising enzymes are regulated 
by genetic, physiological and nutritional factors. The resulting inter-individual variation in 
these enzymes may be of great significance to drug metabolism in man.
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